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Epidemiology and aetiology of colorectal cancer 
 
Colorectal cancer (CRC) is one of the most common forms of cancer in Western societies and 
shows a 20-fold geographic variation in incidence worldwide (1). Despite recent advances in 
diagnosis and treatment, the mortality from CRC remains high. In The Netherlands, CRC is 
the second cause of death from malignant disease in women after breast cancer and the third 
cause of death in men after lung- and prostate cancer (2).  
 
It is now generally accepted that a time-dependent accumulation of multiple mutations in 
tumour suppressor genes (e.g. APC, p53, DCC), oncogenes (i.e. K-ras) and genes involved in 
DNA mismatch repair (e.g. MLH-1, MSH-2) results in the transformation of normal colonic 
epithelium into hyperproliferative tissue, adenoma, and finally eventually in carcinoma (3, 4). 
Accumulation of these mutations results in disturbance of the balanced epithelial cell 
turnover, as determined by rates of cell proliferation and apoptosis (4).  
 
Up to 10% of all CRC cases are due to hereditary factors of high penetrance; the most 
frequent being hereditary non-polyposis colorectal cancer (HNPCC) and familial 
adenomatous polyposis (FAP; refs. 5, 6). These syndromes may result in the development of 
tumours at a relatively early age. The other 90% of CRC, so called sporadic CRC, may be 
attributed to diet or lifestyle factors, eventually in combination with genetic factors of low 
penetrance. The incidence of sporadic CRC is strongly age-related, with the majority of cases 
diagnosed above 50 years of age. Ultimately, at the age of 75 years, up to 4.7% of men and 
3.2% of women will have developed CRC in The Netherlands (7).  
 
Though it is recognized that genetic factors are important determinants for the genesis of part 
of the CRC cases (8), epidemiological studies have revealed that the worldwide variation in 
CRC incidence is strongly related to differences in dietary habits and lifestyle factors (9). This 
is supported by migrant studies, which have shown that individuals migrating from low- to 
high-risk areas rapidly adopted the incidence rates of the high-risk areas (10, 11). Moreover, 
several epidemiological studies have shown that the consumption of a typical Western-style 
diet, which is characterized by high intake of red meat, (saturated) fat and alcohol, and a low 
intake of fresh vegetables, fruits and calcium is associated with a high risk for CRC (9, 12).  
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In addition, humans may be exposed daily to a large variety of toxic or even carcinogenic 
compounds, present in food (13, 14) or as a result of lifestyle habits such as smoking of 
cigarettes or drinking alcohol (15-17). However, humans also possess a highly efficient 
system of defence against such compounds, and an important role is reserved for the various 
detoxification enzymes (18). The levels and activities of these enzymes strongly vary between 
the various organs and between individuals (19-21). Variations between individuals may be 
due in part to the presence of genetic polymorphisms (genetic variations between individuals), 
which may contribute to the inter-individual differences in expression levels and enzyme 
activities of these enzymes (22-24). This might also influence the conversion rate of toxic or 
carcinogenic compounds in the gastrointestinal tract and consequently, may partly determine 
the levels of toxins and carcinogens in the colon. Therefore, polymorphisms in detoxification 
enzymes could contribute to individual susceptibility to CRC. In summary, tumour formation 
in the colon may result from interaction between external (environmental carcinogen 
exposure) and internal (genetic) factors. 
 
 
Detoxification enzymes 
 
Humans possess highly efficient defence systems against harmful compounds; one of these is 
the detoxification enzyme system (18).  The main purpose of the detoxification enzymes is to 
facilitate the elimination of potentially toxic or carcinogenic compounds from the body. This 
process usually involves the two-stage route of phase I and phase II reactions. Phase I 
reactions include oxidation, reduction, dealkylation or hydrolysis of chemical compounds and 
provide the molecules with hydroxyl- or amino-groups. This however, often leads to 
bioactivation of chemicals into more reactive compounds that even might be carcinogenic. 
Phase II reactions comprise conjugation of these chemical compounds with glucuronic acid, 
glutathione, sulphate, acetyl groups or amino acids. These cofactors react with functional 
groups that are either present or are introduced by the phase I reactions. In general, phase II 
reactions result in less biologically active compounds that are more water soluble, thereby 
facilitating their excretion via urine or bile. Phase I reactions are mainly catalyzed by a variety 
of cytochromes P450 monooxygenases (CYP; ref. 25) or epoxide hydrolases (EPHX; ref. 26), 
whereas glutathione S-transferases (GSTs; ref. 27) and UDP-glucuronosyltransferases (UGTs; 
ref. 28) play an important role in the phase II metabolism. However, many other 
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detoxification enzymes including alcohol dehydrogenases (ADH; ref. 29), NAD(P)H: quinone 
oxidoreductases (NQO; ref. 30) or paraoxonases (PON; ref. 31) have their own specific role 
in detoxification. 
 
 
Anticarcinogens and enzyme modulation 
 
In Western countries, environmental factors may account for up to 65% of the risk for CRC 
(32) and it has been estimated that ~50% of this risk is attributable to dietary factors (33). 
This makes CRC a potentially preventable disease to a large extent. Epidemiological studies 
have shown that regular consumption of vegetables and fruits may result in significant 
protection against cancer of the gastrointestinal tract (9, 12). In the face of these 
epidemiological associations, an impressive and still growing number of dietary non-nutritive 
constituents, which may inhibit mutagenesis or carcinogenesis, have been identified (34-37). 
Information on the anticarcinogenic potential of these dietary components mainly comes from 
studies on single crude dietary components (such as cruciferous vegetables, citrus fruits or 
garlic) and from studies on specific purified non-nutritive constituents of vegetables and fruits 
(such as glucosinolates, flavonoids, phenolic acids and organosulfides). Many of these dietary 
components have been shown to inhibit chemical-induced carcinogenesis in a variety of 
animal studies (14, 38-41) and therefore are called anticarcinogens or chemopreventive 
agents. According to the stage in the carcinogenic process at which they are effective,          
i.e. initiation, promotion and progression, they can be classified into different categories. 
Some anticarcinogens act as blocking agents by preventing carcinogens to be formed or to 
reach and react with critical targets. Others anticarcinogens act as suppressing agents by 
preventing the transformation of initiated cells, which have been previously exposed to 
carcinogens, into tumours (42). 
 
Though the exact mechanism(s) leading to the anticarcinogenic action of the potential 
anticarcinogenic dietary compounds is not fully known, there are strong indications that their 
chemopreventive capacities may be due to the modulation of activity or composition of phase 
II detoxification enzyme systems, such as GSTs and UGTs (34-36, 43-45). Changes in 
detoxification capacity may play a key role in the altered susceptibility to carcinogens we are 
exposed to daily, and thus may influence the risk for developing cancer. The biological 
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control of detoxification enzymes is complex, as they exhibit sex-, age-, tissue-, species-, and 
tumour-specific patterns of expression (27, 28). A diverse range of dietary components 
regulates detoxification enzyme systems. Many of the compounds that induce detoxification 
enzymes, themselves are substrates of these enzymes. This suggests that induction of 
detoxification enzymes represents part of an adaptive response mechanism to carcinogen-
induced cellular stress.  
 
Previous research at our institution demonstrated that several dietary naturally occurring or 
synthetic anticarcinogens increase rat hepatic and intestinal GST enzyme activity (46-48). In 
addition, a dose-dependent induction of rat hepatic and intestinal GST enzyme activity was 
observed after supplementation with the anticarcinogens α-angelicalactone or flavone in 
varying concentrations, either alone or in combination (49). High intake of fruits or 
vegetables in humans was associated with high gastrointestinal isoenzyme levels of the GST 
detoxification system (50, 51). Furthermore, an intervention study in 10 healthy controls 
revealed that daily consumption of 300 g Brussels sprouts for one week was able to increase 
rectal GSTA and GSTP1 levels (52). O'Dwyer et al. (53) found that a single dosage of 
oltipraz (125 or 250 mg/m2), a synthetic dithiolethione, resulted in an enhancement of 
glutathione S-transferase activity of ± 21% in the sigmoid of patients at increased risk for 
CRC. However, Clapper et al. (54) found no significant difference in GST-activity in the 
sigmoid of 29 patients at increased risk for CRC, who consumed 3g/day of broccoli 
components for 2 weeks. 
At present little information on the effects of dietary anticarcinogens on the UGT activity of 
the digestive tract is available. Recent data, mostly obtained from animal studies, have 
indicated that dietary agents may be able to elevate UGT activity (44, 55-58). 
 
The majority of malignant tumours in the digestive tract do develop in the colon, which has a 
detoxification capacity that is critically low, and this may contribute to the susceptibility of 
colon cancer in humans (19, 59-61). Enhancement of the activity of detoxification enzymes, 
such as GSTs and UGTs, potentially could increase the capacity to withstand the burden of 
toxic agents and (pre)carcinogens humans are exposed to daily (13, 14, 43, 45, 52), and 
knowledge of the exact protection mechanism(s) of the non-nutritive anticarcinogens may be 
of importance for the prevention of CRC.  
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Genetic polymorphisms 
 
Genetic polymorphisms are defined as commonly occurring variations in genes and are 
characterized by the presence of several distinct forms of a gene within a population. The 
genetic polymorphisms may be caused by single nucleotide substitutions, repetitive 
sequences, insertions or deletions of nucleotides. Polymorphisms in low-penetrance genes, 
such as those encoding for the detoxification enzymes, may account in part for the inter-
individual differences in the sensitivity to cancer-inducing or cancer-promoting compounds 
(22-24). Functional polymorphisms may result in enzymes with enhanced or reduced activity, 
or even in complete absence of enzyme activity. This might influence the conversion rates of 
toxic or carcinogenic compounds in the colon. Therefore, functional polymorphisms in 
detoxification enzymes could contribute to individual susceptibility to CRC and indeed some 
of these genetic polymorphisms have already been associated with altered CRC susceptibility 
(62-65). 
 
 
Reactive oxygen species and colorectal cancer 
 
It is suggested that reactive oxygen species (ROS) may also play a role in human cancer 
development (66-68). Sources of ROS may be both exogenous (drugs, ozone, radiation) and 
endogenous (NO, phagocytes, leakage from mitochondria; ref. 68). In a recent review, 
Klauning and Kamendulis (68) described the involvement of ROS in the various stages 
(initiation, promotion, progression) of the process of carcinogenesis. 
 
In healthy individuals, the generation of ROS appears to be counterbalanced by the 
antioxidant defence, which is recruited either from endogenous sources (glutathione, cysteine, 
uric acid, bilirubin, etc.) or from the diet (vitamins A, C and E; refs. 69, 70). An imbalance 
between ROS and antioxidant defences in favour of the former creates oxidative stress (70, 
71). This may occur when the antioxidant levels are low/depleted and when the formation of 
ROS is high. Severe oxidative stress affects a large variety of metabolic processes. For 
example, ROS can cause structural alterations in DNA and may affect cytoplasmic and 
nuclear signal transduction pathways (67). Furthermore, ROS can modulate the activity of 
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proteins that respond to stress, and which regulate genes that are involved in cell proliferation, 
differentiation and apoptosis (67).  
 
While it is clear that ROS may induce cellular changes, similar to those produced by known 
carcinogens (67), the precise mechanisms remain unclear. It is suggested that the 
overproduction of ROS, such as superoxide and hydrogen peroxide, by polymorphonuclear 
leukocytes (PNMs), might sometimes also play a role in initiation of carcinogenesis (72). 
Phagocytosis by PNMs results in the release of ROS, referred to as the respiratory burst, 
which plays an important role in host defence against certain micro-organisms. Excessive 
generation of ROS by these phagocytes may cause harm to surrounding tissue (72). When key 
genes or proteins responsible for intestinal cell homeostasis are targeted, dysplasia and 
subsequent development of adenoma or carcinoma may occur.  
Data on a role of ROS in the pathogenesis of CRC is accumulating. Recently, Schmielau and 
Finn (73) reported that patients with advanced cancer of the colon, pancreas or breast, showed 
signs of extensive granulocyte activation with release of ROS. In addition, Gackowski et al. 
(74) observed that the levels of 8-oxo-2’-deoxyguanosine, a typical product of ROS-induced 
DNA base modification, were significantly higher in lymphocytes of patients with CRC in 
comparison to those of control subjects. These data show that production of ROS may be 
higher in patients with CRC, but do not reveal whether this is a result of the disease itself. 
However, Keshavarzian et al. (75) found that normal-appearing rectal mucosa of patients with 
a history of CRC was able to produce significantly higher levels of luminol-enhanced 
chemiluminescence than corresponding mucosa of control subjects, which may indicate that 
overproduction of ROS could contribute to development of the disease.  
 
 
Aim of this thesis 
 
The main objectives of this thesis are to investigate: 1) the modulation of rat hepatic and 
intestinal UGTs by anticarcinogens, 2) whether genetic polymorphisms in detoxification 
enzymes may modulate the risk for CRC, and 3) whether neutrophil oxygen radical 
production may contribute to the aetiology of CRC.  
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Abstract 
 
Gastrointestinal tumours are among the most common malignancies in Western society, the 
majority of which are associated with dietary and lifestyle factors. Many dietary or lifestyle 
factors have been identified which may have toxic or carcinogenic properties. However, also 
several dietary compounds able to reduce gastrointestinal cancer rates both in humans and 
animals have been characterized. Though the exact mechanism leading to the anticarcinogenic 
action of these compounds is not fully known, it has been demonstrated that this 
chemopreventive capacity may be due to elevation of the glutathione S-transferase 
detoxification enzymes. Here we have investigated the effect of several anticarcinogens on 
the gastrointestinal UDP-glucuronosyltransferase (UGT) enzymes. Diets of male Wistar rats 
were supplemented with ellagic acid, ferulic acid, Brussels sprouts, quercetin,                       
α-angelicalactone, tannic acid, coumarin, fumaric acid, curcumin and flavone separately, and 
combinations of α-angelicalactone and flavone. Hepatic and intestinal (proximal, mid and 
distal small intestine and colon) UGT enzyme activities were quantified using 4-nitrophenol 
and 4-methylumbelliferone as substrates. All anticarcinogens tested increased UGT enzyme 
activity with both substrates, at one at least of the five different sites investigated.                 
α-Angelicalactone, coumarin and curcumin showed enhanced UGT enzyme activities at all 
five sites. Both small and large intestinal UGT enzyme activities were increased by quercetin, 
α-angelicalactone, coumarin, curcumin and flavone. Except for tannic acid, all agents induced 
hepatic UGT enzyme activity. Furthermore, dietary administration of α-angelicalactone and 
flavone, given individually or in combination, enhanced the UGT detoxification system in the 
liver and, to a lesser extent, in intestine. In conclusion, induction of gastrointestinal UGT 
enzyme activities after consumption of dietary anticarcinogens may contribute to a better 
detoxification of potentially carcinogenic compounds and subsequently to the prevention of 
gastrointestinal cancer. 
 
 
 
 
 
  22
Introduction 
 
Gastrointestinal tumours are among the most common malignancies in Western society. 
Epidemiological studies have shown the importance of dietary habits in the risk for 
gastrointestinal tumours in general and for colon cancer more particularly. Diets rich in 
vegetables and fruit are associated with a lower risk (1-3). In the face of these epidemiological 
associations many dietary non-nutritive constituents with anticarcinogenic properties have 
been identified (4-9). Though the exact mechanism(s) leading to the anticarcinogenic action 
of these compounds is not fully known, it has been suggested that their chemopreventive 
capacities may be due to elevation of detoxification enzymes (4, 6-8, 10, 11). Important 
detoxification or drug-metabolizing enzymes are UDP-glucuronosyltransferases (UGTs) and 
glutathione S-transferases (GSTs). UGTs catalyze the conjugation of exogenous and 
endogenous, mainly lipophilic compounds with glucuronic acid, while GSTs catalyze the 
reaction of glutathione with mainly exogenous electrophiles and endogenous products of 
oxidative stress. Some overlap in substrate specificity may occur between these detoxification 
enzymes. Glucuronidation or conjugation with glutathione in general results in less 
biologically active molecules and enhances the water solubility of the conjugated products, 
which facilitates excretion from the body via bile or urine (12). UGTs have been divided into 
two families, termed UGT1 and UGT2 (13). UGT1 enzymes mainly catalyze glucuronidation 
of exogenous agents (drugs, pesticides, benzo[a]pyrene, etc.) whilst UGT2 enzymes 
glucuronidate endogenous agents (steroid hormones and bile acids), however this 
classification is not that strict since, for instance, human UGT1A1 is the main enzyme 
catalyzing conjugation of the endogenous substrate bilirubin, whereas nonsteroidal anti-
inflammatory drugs are conjugated by rat UGT2B1 (14). 
 
In humans, glucuronidation capacity is prominently present in the liver, where most of the 
various UGT isoforms have been identified at relatively high levels. However, different 
isoenzymes of UGT1 have also been distinguished in extrahepatic tissues, including skin, 
kidney, oesophagus, stomach, small intestine, colon and many other organs (15, 16). Since the 
gastrointestinal tract is in direct contact with potentially toxic or (pre)carcinogenic agents, 
ingested by food, medication, drugs, etc. the intestinal mucosa acts as a first line barrier. A 
striking observation is the significantly lower glucuronidation rate in colon compared with 
those in liver and small intestine (15, 17, 18). Tissue-specific expression of the different UGT 
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genes encoding for the various isoenzymes in colon, liver and small intestine could partially 
contribute to the differences in UGT activity between these tissues (15, 18). However, 
because of the magnitude of the UGT enzyme activity differences between colon and liver or 
small intestine (15, 18), it cannot be ruled out that additional modifiers of UGT activity are 
responsible for the dramatic differences in functional UGT activities between these tissues.  
 
The majority of malignant tumours in the digestive tract develop in the colon, where UGT 
enzyme activity is low, and this may contribute to the susceptibility of colon cancer in 
humans (13, 15, 17). Enhancement of the activity of such enzymes could potentially increase 
the capacity to withstand the burden of toxic agents and (pre)carcinogens we are exposed to 
daily (7, 19 20). Knowledge of the exact protection mechanism(s) of anticarcinogenic 
compounds present in food may be of importance for the prevention of colon cancer. Previous 
research demonstrated that several dietary agents increase GST enzyme activity in liver and 
intestine of male Wistar rats (10). Therefore, we have now investigated the effects of several 
naturally occurring dietary anticarcinogens on rat hepatic and intestinal UGT enzyme activity. 
In an earlier study we showed a dose-dependent induction of rat hepatic and intestinal GST 
enzyme activity after supplementation with the anticarcinogens α-angelicalactone or flavone 
in varying concentrations, either alone or in combination (21). Now we have also investigated 
the effects of this dose-dependent and combination treatment on gastrointestinal UGT enzyme 
activities.  
 
 
Materials and methods 
 
Materials 
Ellagic acid, ferulic acid, quercetin, coumarin, curcumin, flavone, bovine serum albumin, 
dithiothreitol, 4-methylumbelliferone (4-MUB), UDP-glucuronic acid (UDPGA) and           
D-saccharic acid 1,4-lactone were purchased from Sigma Chemical Co. (St. Louis, MO). 
Ethanol and 4-nitrophenol (4-NP) were from Merck (Darmstadt, Germany).                        
α-Angelicalactone, tannic acid and fumaric acid were obtained from Aldrich Chemie 
(Zwijndrecht, The Netherlands). Brussels sprouts were collected from local shops.  
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Study design 
Hepatic and intestinal microsomes were prepared from Wistar rats, kept and treated as 
described in previous studies performed by Nijhoff et al. (10, 21). In short, male Wistar rats 
(Central Laboratory Animal Centre, University of Nijmegen, The Netherlands) were housed 
individually on wooden shavings in macrolon cages maintained at 20-25°C and 30-60% 
relative humidity. A ventilation rate of 7 air changes/h and a 12 h light/dark cycle were used. 
The rats were randomly assigned to one of the dietary treatment groups. All groups were fed 
powdered RMH-TM laboratory chow (Hope Farms, Woerden, The Netherlands). After 
acclimatization for 3 days, the animals were fed either the basal diet (control group) or one of 
the experimental diets.  
 
Diets 
Ellagic acid, ferulic acid, quercetin, tannic acid, fumaric acid and curcumin were incorporated 
at the level of 1% (w/w) in the basal diet. α-Angelicalactone and flavone were provided at the 
level of 0.5% (w/w) and coumarin at the level of 0.25% (w/w). Brussels sprouts were 
incorporated at the level of 20% (w/w) (10). α-Angelicalactone and flavone were 
incorporated into the diet, either separately or as a combination of both compounds, at 0.01, 
0.05, 0.1 and 0.5% (w/w), respectively (21). Food and water were available ad libitum. Food 
cups were replenished with freshly prepared diet every 2-3 days. Food consumption and gain 
in body weight was recorded daily. After 2 weeks the animals were killed by decapitation. 
 
Tissue preparation 
Tissue handling, isolation of liver and intestinal mucosa and preparation of microsomal pellet 
was performed as described previously (22). In short, liver tissue and intestinal mucosal 
scrapings were homogenized in buffer A (4 ml buffer A/g tissue or mucosal scraping; buffer 
A = 0.25 M saccharose, 20 mM Tris-HCl, 1 mM dithiothreitol, pH 7.4), followed by 
centrifugation at 9000 g (4°C) for 20 min. The resulting supernatant fraction was spun at    
150 000 g (4°C) for 50 min, resulting in the sedimentation of the microsomes. The 
microsomal pellet was resuspended in 5 vol of buffer A.  
 
Assays 
Protein concentration was assayed in duplicate by the method of Lowry et al. (23) using 
bovine serum albumin as the standard. 
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UGT activity with 4-NP and 4-MUB as substrates was measured in the microsomes as 
described previously (24, 25). Briefly, liver and intestinal microsomes were resuspended in 50 
mM Tris-HCl, pH 7.4, containing 0.25 M sucrose and 1 mM dithiothreitol. Treatment of 
microsomes with varying concentrations of Triton X-100 failed to activate microsomes and 
rather inhibited UGT enzyme activity at higher Triton concentrations. Therefore, we did not 
perform an activation step in the UGT enzyme activity assay. 
Conjugation of 4-NP was measured in a final volume of 0.1 ml Tris-HCl, pH 7.4, containing 
3.5 mM UDPGA, 10 mM MgCl2, 0.05-0.5 mg microsomal protein, 1mM saccharic acid     
1,4-lactone, and 1 mM 4-NP. 4-NP was dissolved in 0.01 M NaOH. After incubation for 1-20 
min at 37°C, the reaction was terminated by adding 2 ml of 0.3 M NaOH, followed by 
centrifugation for 10 min at 10 000 g. Absorbance was measured at 405 nm on a Perkin Elmer 
Lambda 12 spectrophotometer.  
Conjugation of 4-MUB was performed in the presence of 4 mM UDPGA, 10 mM MgCl2, 
0.025-0.25 mg microsomal protein, 1 mM saccharic acid 1,4-lactone and 0.1 mM 4-MUB in a 
final volume of 0.1 ml Tris-HCl, pH 7.4. 4-MUB was dissolved in ethanol (50 mM) and 
diluted with assay medium just before use. After incubation at 37°C for 0.5-20 min, 1 ml of 
0.5 M glycine/NaOH, pH 10.35, was added to the reaction mixture to terminate the reaction. 
Subsequently, samples were centrifuged for 10 min at 10 000 g. 4-MUB was determined 
fluorometrically with a Shimadzu RF-5000 spectrofluorophotometer (excitation 370 nm, 
emission 450 nm).  
All samples were measured in duplicate. In all assays a control sample without UDPGA was 
run simultaneously. The absorbance difference between the control sample and the sample 
incubated in the presence of UDPGA represents the amount of glucuronidated 4-NP or          
4-MUB. Effects of anticarcinogens on UGT enzyme activity are presented as ratios of treated 
to control. 
 
 
Statistical analysis  
Wilcoxon rank sum test was used to assess statistical significance of differences between 
control and treatment groups. Correlation analyses between enzyme activities were performed 
using Spearman rank correlation. P < 0.05 was considered to be significant. 
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Results 
 
The effects of the anticarcinogens on 4-NP UGT activity in the five different parts of the 
gastrointestinal tract investigated (proximal, mid and distal small intestine, large intestine and 
liver) are shown in Table I. All compounds tested, except fumaric acid, increased 4-NP UGT 
activity at one or more sites. The most striking statistically significant enhancement was seen 
in small intestine by curcumin (5.4×, 6.7× and 7.2× in the proximal-, mid- and distal part, 
respectively), in large intestine by curcumin (3.1×) and in liver by flavone (7.6×).                 
α-Angelicalactone and coumarin gave an enhancement in 4-NP UGT enzyme activity at all 
five sites investigated. 
 
Table I. Effects of naturally occurring anticarcinogens on intestinal and hepatic 4-NP UGT enzyme activity 
Treatment group n 4-NP UGT activity (ratio treated/control) 
  Small intestine Large intestine Liver 
  Proximal Mid Distal     
Ellagic acid 5 1.1 (0.5-11.0) 1.4 (0.6-7.0) 2.0 (1.5-9.0) 1.4 (0.6-3.7) 2.7 (1.2-3.4) a 
Ferulic acid 6 2.2 (0.4-10.3) 2.0 (0.7-4.1) 3.3 (0.7-4.2) 1.2 (0.5-1.8) 2.5 (1.8-2.8) b 
Brussels sprouts 3 0.4 (0.2-0.4) c 0.9 (0.8-1.1) 1.1 (0.5-1.5) 1.0 (0.7-1.4) 1.9 (1.4-2.6) c 
Quercetin 6 4.0 (0.4-13.3) 2.8 (0.9-6.6) 4.0 (1.4-8.3) c 3.8 (0.6-5.2) 1.5 (1.2-2.0) c 
α-Angelicalactone 6 2.8 (1.2-6.7) c 2.1 (1.5-3.0) c 3.9 (3.1-4.8) b 2.3 (1.7-3.0) b 3.4 (2.7-4.5) b 
Tannic acid 3 1.6 (0.7-4.9) 2.1 (1.2-3.1) 3.4 (1.6-3.6) c 1.4 (0.6-2.8) 1.2 (1.2-1.7) 
Coumarin 6 3.4 (1.8-6.2) c 3.0 (1.0-7.0) c 4.3 (2.2-5.5) a 3.0 (1.8-7.7) b 5.6 (3.7-6.3) b 
Fumaric acid 3 3.5 (0.6-4.7) 1.6 (1.4-2.5) 1.4 (0.8-1.9) 1.4 (1.4-1.5) 1.1 (1.1-1.6) 
Curcumin 6 5.4 (2.4-25.2) c 6.7 (2.0-8.9) a 7.2 (3.8-8.3) b 3.1 (1.3-6.1) b 1.5 (1.0-2.0) 
Flavone 6 1.2 (0.8-1.4) 1.5 (0.8-1.8) 1.5 (0.8-3.4) 1.9 (1.4-3.0) a 7.6 (6.4-10.3) b
4-NP UGT activity was measured in duplicate as described in Materials and methods.  
n, number of rats used in each group.  
Results are given as ratios of treated to control (median, range). In the control group (n = 9) 4-NP UGT  
activities (median, range) were 0.21 (0.06-1.18), 0.38 (0.12-1.59), 0.33 (0.14-0.90), 1.8 (0.51-4.4) and 30  
(16-55) nmol/min⋅mg protein for proximal, mid and distal small intestine, large intestine and liver,  
respectively.  
The Wilcoxon rank sum test was used for statistical evaluation; aP < 0.01, bP < 0.005, cP < 0.05. 
 
The effects of the anticarcinogens on 4-MUB UGT activity are more or less the same as 
observed for 4-NP UGT activity. However, quercetin was able to induce 4-MUB UGT 
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activity in the proximal small intestine (2.7×) and large intestine (2.2×), α-angelicalactone 
had no effect on mid small intestinal activity and tannic acid did not have any effect. On the 
other hand flavone induced distal small intestinal 4-MUB UGT activity (2.2×), whereas 
fumaric acid and curcumin increased hepatic activity (2.2× and 2.6×, respectively). 
  
The effects on 4-NP UGT activity in animals fed diets with α-angelicalactone, flavone or 
their combination are summarized in Table II. In general, 4-NP UGT activity was increased 
most in rats that were fed the highest dose of α-angelicalactone or flavone or the combination 
of both compounds. In large intestine and liver, treatment with the highest concentration of  
α-angelicalactone resulted in enhancement of 4-NP UGT activity.  
 
Table II. Effects of dietary α-angelicalactone and flavone, individually and in combination,  
on rat intestinal and hepatic 4-NP UGT enzyme activity 
Treatment group Per cent w/w 4-NP UGT activity (ratio treated/control) 
  Mid small intestine Large intestine Liver 
α-Angelicalactone 0.01 1.0 (0.6-1.1) 1.0 (0.7-1.2) 0.8 (0.6-0.9) 
 0.05 0.9 (0.7-1.4) 1.0 (0.9-1.3) 1.0 (0.7-1.8) 
 0.1 1.0 (0.9-1.4) 0.9 (0.7-1.2) 1.4 (1.3-1.8) a 
 0.5 1.0 (0.8-1.6) 1.1 (1.1-1.3) a 3.7 (3.2-5.0) b 
Flavone 0.01 0.8 (0.6-1.1) 1.1 (0.9-1.3) 1.6 (0.9-2.2) a 
 0.05 1.2 (0.8-1.4) 1.0 (0.7-1.3) 1.7 (1.3-2.7) b 
 0.1 1.2 (1.0-1.4) 1.2 (0.9-1.3) 3.3 (2.4-4.8) b 
 0.5 1.2 (1.1-1.3) a 1.4 (1.0-1.7) a 11.0 (6.4-14.2) b 
Combination 0.01/0.01 1.1 (0.9-1.3) 0.9 (0.7-1.3) 1.6  (1.4-2.1) b 
 0.05/0.05 1.2 (1.1-1.3) 0.9 (0.7-1.3) 3.1 (2.1-5.7) b 
 0.1/0.1 0.8 (0.7-1.4) 1.2 (0.9-1.7) 7.2 (5.8-8.8) b, c 
 0.5/0.5 1.7 (1.3-2.0) b 2.2 (1.5-3.0) a 10.7 (2.9-15.1) b 
4-NP UGT activity was measured in duplicate as described in Materials and methods.  
Number of animals: control group, n = 9; treatment groups, n = 6.  
Results are given as ratios of treated to control (median, range).  
The Wilcoxon rank sum test was used for statistical evaluation; aP < 0.05, bP < 0.005.  
c Synergistic induction of 4-NP UGT activity, P < 0.05.  
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Treatment with the highest dose of flavone or the combination of both agents increased 4-NP 
UGT activity at all sites investigated. Furthermore, treatment with flavone resulted in a larger 
increase in 4-NP UGT activity as compared with α-angelicalactone treatment. With 
increasing concentrations of α-angelicalactone, flavone or the combination of both agents, 
hepatic 4-NP UGT activity was gradually increased. Even the lowest concentration (0.01% 
w/w) of flavone and the combination treatment resulted in increased 4-NP UGT activity. 
Treatment with the mix of α-angelicalactone and flavone (0.1% w/w) resulted in a synergistic 
induction of 4-NP UGT enzyme activity. In contrast to effects on 4-NP UGT activity, 
enhancement of 4-MUB UGT activity occurred after treatment with 0.01 and 0.05% w/w     
α-angelicalactone and the 0.1% w/w combination treatment resulted in induction of the mid 
small and large intestinal enzyme activity. 
 
 
Discussion 
 
It is well known that environmental factors affect the development of human cancers. The 
human diet may contain a large number of (pre)carcinogens (19, 20). However, apart from 
carcinogens, our diet may also contain a wide variety of compounds which inhibit 
mutagenesis and/or carcinogenesis, as tested in laboratory models (19, 20, 26-28). These 
anticarcinogens are very diverse in chemical structure and their protective mechanisms are 
generally unclear. However, there are strong indications that anticarcinogens are effective by 
virtue of enhancing detoxification systems (4, 8, 10). In a recent study in humans by Hoensch 
et al. (11) high intake of fruits or vegetables was associated with high upper gastrointestinal 
levels of isoenzymes of the GST system. Detoxification systems such as UGTs and GSTs can 
minimize carcinogenicity by conjugation reactions, which add functional groups to the 
carcinogen, thereby lowering their biological activity and increasing their excretion. Although 
in a few studies induction of hepatic UGT enzyme activity has been suggested as a protective 
mechanism of some dietary anticarcinogens (29, 30), little is known about the effects of 
anticarcinogens on UGT enzyme activity in the small intestine or colon, the latter being the 
organ where most gastrointestinal tumours are formed.  
 
Flavone has been shown to induce hepatic 4-NP UGT activity (30, 31), which is in 
comparison with the results observed here. In our study, quercetin significantly increased 
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UGT enzyme activity in liver and proximal and distal small intestine. In contrast, Siess et al., 
Brouard et al. and Canivenc-Lavier et al. (30-32) found no effect on hepatic 4-NP UGT 
activity. This difference may be caused by variations in dietary treatment, since Siess et al. 
and Canivenc-Lavier et al. used a lower dose of quercetin (0.3 versus 1.0% w/w in our study). 
However, Brouard et al. also used a dose of 1% w/w quercetin for 2 weeks, suggesting that 
other factors influence the level of UGT activity. For example, starvation may affect UGT 
activity, since rats were fasted 18 h before collecting tissues in the study of Brouard et al. 
(31), whereas in our study animals had free access to food until decapitation. Since starvation 
is known to rapidly decrease phase II enzyme activity (33), an initial increase in UGT enzyme 
activity may have disappeared during this starvation period.  
 
After treatment with quercetin, increased UGT activity in proximal small intestine was only 
seen with 4-MUB as substrate. In distal small intestine this treatment induced both 4-NP and 
4-MUB UGT activity. In contrast, Brouard et al. (31) found no induction of intestinal 4-NP 
UGT activity after feeding quercetin to rats. This difference may be explained as follows: 
Brouard et al. studied the overall 4-NP UGT activity of the intestine, while we measured the 
UGT activity in three different parts of the intestine, revealing an increase in 4-NP UGT 
activity in the distal part of the intestine only. Furthermore, as mentioned above, due to a 
starvation period in the study of Brouard et al., eventual effects may have disappeared. Like 
Brouard et al. (31), we found no effect of flavone on intestinal 4-NP UGT activity, whereas 
dietary ellagic acid was shown by Ahn et al. (29) to increase hepatic 4-NP UGT activity, 
which was confirmed by us. However, we used a higher dose of ellagic acid, which resulted 
in a more elevated UGT activity. 
 
For all other compounds studied no effects on UGT enzyme activity have been reported 
before. All agents had an enhancing effect on UGT activity at one or more sites investigated, 
except for Brussels sprouts, which had an inhibitory effect on proximal small intestinal UGT 
activity. Nevertheless, Brussels sprouts were able to enhance hepatic UGT activity. This 
discrepancy might be explained by the fact that certain metabolites of glucosinolates present 
in Brussels sprouts may be responsible for induction of hepatic UGT activity, whereas these 
metabolites may not yet have been formed in the intestine. Colonic 4-NP UGT enzyme 
activity was significantly increased by α-angelicalactone, coumarin, curcumin and flavone, 
whereas the same agents as well as quercetin significantly induced colonic 4-MUB UGT 
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activity. In general, the same anticarcinogens enhanced both small intestinal as well as large 
intestinal UGT enzyme activities. 
  
A study on the dose-dependency effects of dietary flavone on hepatic 4-NP UGT activity was 
performed by Siess et al. (34). Increased 4-NP UGT activity was found after treatment with 
flavone at 0.002, 0.005, 0.02, 0.05 and 0.2% w/w. In accordance with these results, we found 
that both 4-NP and 4-MUB hepatic UGT activity was significantly induced by 0.01, 0.05, 0.1 
and 0.5% w/w flavone. In the intestinal tissues studied here, only the highest dose of dietary 
flavone resulted in enhancement of UGT activity. For α-angelicalactone, for which no data on 
dose-response effects have been reported before, a dose dependency for both 4-NP and         
4-MUB UGT activity was only seen in the liver. In conclusion, increasing concentrations of 
α-angelicalactone or flavone did show a gradual increase of hepatic UGT activities. 
 
Since humans may be exposed to mixtures of anticarcinogens in their diets, it may be 
worthwhile to study combinations of such compounds in laboratory animals in order to learn 
more on possible additional effects. In general, combination treatment with α-angelicalactone 
and flavone showed only additive effects. However, in small intestine the 4-MUB UGT 
activity was significantly enhanced in the 0.1 and 0.5% w/w combination groups (1.6- and 
1.8-fold, respectively), whereas in the corresponding flavone or α-angelicalactone groups no 
significant induction was noticed. In large intestine 4-MUB UGT activity was significantly 
induced in the 0.1% w/w combination group, whereas treatment with flavone or                    
α-angelicalactone alone did not result in a significant increase. In addition, a synergistic effect 
on hepatic UGT activity was seen after the 0.1% w/w combination treatment. Thus, exposure 
to mixtures of anticarcinogens can have additive or even synergistic effects on the activities of 
biotransformation enzymes. 
 
We observed higher UGT activities as measured with 4-NP, in rat large intestine as compared 
to small intestinal values. This is quite remarkable since in human studies phase II 
biotransformation enzymes were shown to be much more active in small intestine as 
compared with colon (17, 35). Contradictory data about rat large intestinal versus small 
intestinal UGT activities have been reported. Hänninen et al. (36), using mucosal scrapings, 
found that 4-NP UGT activity decreased along the small intestine, but except for the first part 
of the small intestine, large intestinal activity was found to be higher. However, Koster and 
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Noordhoek (37), measuring 1-naphthol or morphine glucuronidation capacity in intestinal 
cells isolated by vibration, measured much lower activities in cecum and colon as compared 
with the small intestine. 
 
It has often been reported that the specific activities of GSTs and UGTs in rats gradually 
decrease down the small intestine, when mucosal scrapings or isolated cells were analyzed 
(36-39). However, in studies with in situ perfused segments of the rat intestine no significant 
difference in the total glucuronidation capacity of proximal, intermediate and distal small 
intestine could be found (40, 41). In the study described here, the 4-NP or 4MUB UGT 
enzyme activity also remained constant in different parts of the rat small intestine. The 
apparent discrepancy in distribution of UGTs along rat small intestine may thus be explained 
by either the methods used for studying the intestinal tissue, as well as by the different UGT 
substrates used for measurement of enzyme activity. The latter is further supported by an 
earlier study by us (42), in which the distribution of UGT enzyme activities along the human 
small intestine showed various patterns, depending on the substrates used. The activity for 
bilirubin UGT declined, whereas the activity for 4-NP or 4-MUB UGT seemed to increase 
and remain constant, respectively. This may indicate that the different UGT isoenzymes may 
have different expression patterns along the small intestine.   
 
Finally, we examined the associations between 4-NP and 4-MUB UGT enzyme activities and 
GST activities, as measured in our earlier studies (10, 21). Like Bock et al. (43) a strong 
significant correlation was observed between 4-NP and 4-MUB UGT enzyme activity in all 
organs investigated. The correlation coefficient varied from 0.24 (P < 0.05) to 0.91               
(P < 0.0001) for mid small intestine and liver, respectively. This may be due to the fact that 
glucuronidation of both substrates may be mainly catalyzed by the same isoforms of UGT 
(12, 16). In rats, UGT1A1, 1A6 and 1A7 are highly expressed in liver and intestine (44) and 
therefore total UGT enzyme activity in these organs may be mainly covered by these UGT 
isoenyzmes. In liver there is also a strong association between GST and UGT enzyme 
activities (GST, 4-NP UGT, rs = 0.85, P < 0.0001; GST, 4-MUB UGT, rs = 0.84, P < 0.0001), 
which may be explained by the fact that both GST and UGT genes are regulated by the 
transcription factor Nrf2 (45). Surprisingly, no or only weak correlations were found between 
GST and UGT enzyme activities in the intestine. An explanation could be the different 
expression patterns of GST and UGT isoenzymes in rat intestine and liver, in combination 
with the different substrate specificities of the GST or UGT isoenzymes (35, 38). Since 
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expression of UGT or GST isoenzymes may differ considerably from one organ to another 
and since UGT or GST isoenzymes may have different substrate specificities, an association 
between UGT and GST enzyme activities as found in one organ (liver) does not necessarily 
mean that such an association also exists in another organ. 
 
In conclusion, most naturally occurring dietary anticarcinogens tested, and in particular        
α-angelicalactone, coumarin and curcumin, were able to increase UGT enzyme activity in 
liver and, to a lesser extent, in small and large intestine. Furthermore, dose-dependent effects 
of α-angelicalactone, flavone or a combination of both compounds on the UGT detoxification 
system of the liver, and to a lesser extent the intestine, was demonstrated. Such high 
detoxification capacity may account, at least in part, for the observed chemopreventive action 
of these compounds. However, one should realise that the dose of anticarcinogens applied 
here is unlikely to be reached in the human diet, but since the human diet may contain many 
of such compounds and since effects on UGTs may be additive or even synergistic, 
enhancement of UGT activity by these minor compounds could still play a significant role in 
the prevention of gastrointestinal tumours in humans.  
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Abstract 
 
Dietary compounds or nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce cancer 
rates. Elevation of phase II detoxification enzymes might be one of the mechanisms leading to 
cancer prevention. We investigated the effects of dietary anticarcinogens and NSAIDs on rat 
gastrointestinal UDP-glucuronosyltransferases (UGT). Diets of Wistar rats were 
supplemented with oltipraz, α-tocopherol, β-carotene, phenethylisothiocyanate (PEITC), 
sulforaphane analogue compound-30, indole-3-carbinol, D-limonene, relafen, indomethacin, 
ibuprofen, piroxicam, acetyl salicylic acid or sulindac. Hepatic and intestinal UGT enzyme 
activities were quantified using 4-nitrophenol and 4-methylumbelliferone as substrates. 
Compound-30, D-limonene, indomethacin, ibuprofen or sulindac enhanced proximal small 
intestinal UGT activities. Only compound-30 was able to induce mid and distal small 
intestinal UGT activities. Large intestinal UGT activities were increased by ibuprofen and 
sulindac, whereas oltipraz, PEITC and D-limonene gave enhanced hepatic UGT activities. In 
conclusion, mainly rat proximal small intestinal and hepatic UGT enzyme activities were 
induced by dietary anticarcinogens or NSAIDs. Enhanced UGT activities might lead to a 
more efficient detoxification of carcinogenic compounds and thus could contribute to 
prevention of gastrointestinal cancer.  
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Introduction 
 
There is considerable interest in identifying dietary or synthetic compounds with 
anticarcinogenic properties. From epidemiological studies there is growing evidence that diets 
containing abundant vegetables and fruit may reduce the risk of cancers, especially cancers of 
the gastrointestinal tract (1, 2). The human diet may contain a large number of both 
(pre)carcinogens as well as a variety of compounds with potential anticarcinogenic properties 
(3, 4).  
 
The carotenoids, α-tocopherol and β-carotene protected rodents against development of 
chemically-induced tumours in the gastrointestinal tract (5-7), whereas epidemiological data 
on their anticarcinogenic capacity are somewhat contradictory. A case-control study showed 
that α-tocopherol levels in blood were inversely correlated with cancer risk (8). Subsequently, 
β-carotene intake was also associated with a decreased risk for developing colorectal 
adenomas in a case-control study (9).  In addition, strong evidence was provided for a 
protective role of α-tocopherol or β-carotene against oesophageal, but not gastric cancer risk 
(10). However, in a prospective cohort study no significant association between dietary        
α-tocopherol or β-carotene and risk for colorectal cancer was found (11). 
Phenethylisothiocyanate (PEITC) and indole-3-carbinol, breakdown products of glucosinolate 
precursors present in cruciferous vegetables, posses anticarcinogenic properties. PEITC was 
shown to inhibit chemically-induced carcinogenesis in oesophagus and colon of rats (12, 13), 
while indole-3-carbinol was able to inhibit chemically-induced tumours in forestomach (14), 
colon (15, 16) and liver (17) in rodents. In contrast, indole-3-carbinol treatment for 25 weeks 
strongly induced glutathione S-transferase Pi (GST-Pi) foci in the liver of rats (16). The 
monoterpene D-limonene inhibited chemically-induced gastric (18), colonic (19) or hepatic 
cancer (20). Compound-30 is a structural analogue of sulforaphane (21) and a component of 
broccoli. Sulforaphane was demonstrated to have anticarcinogenic properties in colon of rats 
(13). Oltipraz is a substituted dithiolthione, which was used in humans as an antischistozomal 
drug. Dithiolthiones occur in cruciferous vegetables. Oltipraz was found to inhibit 
chemically-induced carcinogenesis in stomach (22), colon (23) and liver (24) of rats. The first 
clinical trial with oltipraz to investigate the effects on aflatoxin biomarkers was conducted in 
1995 in 234 residents of Qidong, who were at high risk for exposure to aflatoxin and 
development of hepatocellular carcinoma (25). Intermittent, high-dose oltipraz was shown to 
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inhibit phase I activation of aflatoxins, while sustained low-dose oltipraz increased phase II 
conjugation of aflatoxin (26). 
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most prescribed drugs 
worldwide and have anti-inflammatory, analgesic and antipyretic activities. In addition to 
their therapeutic use, there is strong evidence that NSAIDs may have anticarcinogenic effects 
in humans. Epidemiological, animal and clinical studies suggest that NSAIDs may reduce the 
risk for development of and mortality from gastrointestinal cancer (27).  
 
Relafen inhibited development of aberrant crypt foci (ACF) in azyxomethane-treated rats and 
suppressed development of intestinal tumours in adenomatosis polyposis coli (APC) Min 
mice (28). Indomethacin inhibited chemically-induced carcinogenesis in forestomach (29), 
colon (15) and liver (30). Ibuprofen also inhibited colon carcinogenesis (15, 27). Furthermore, 
ibuprofen reduced tumour multiplicity and incidence in the forestomach (31). Piroxicam 
inhibited carcinogen-induced ACF in colon of rats (27, 32). In APC Min mice piroxicam 
reduced tumour number and multiplicity (33). Chemically-induced carcinogenesis was 
inhibited by acetyl salicylic acid in colon (27, 32) and liver (34). Recently, a clinical trail with 
aspirin reported significant reduction in incidence of colorectal adenomas in patients with 
previous colorectal cancer (35). Sulindac suppressed the development of colonic 
preneoplastic lesions induced by azoxymethane (27, 36). In addition, sulindac reduced the 
relative risk of development of oesophageal cancer (37) and reduced tumour multiplicity and 
incidence in the forestomach (31). In patients treated with sulindac a reduced polyp number in 
the rectal segment was observed (38). However, this was not confirmed by Giardiello et al. 
(39). 
 
The exact mechanisms of action of above-mentioned inhibitors of carcinogenesis have not 
been clearly defined yet. Although the chemopreventive potential of these dietary and 
synthetic compounds may be due to multiple mechanisms, one mode of action may be 
enhancement of phase II detoxification enzymes, such as UDP-glucuronosyltransferases 
(UGTs; ref. 40) and glutathione S-transferases (GSTs; ref. 41). UGTs conjugate a wide 
variety of compounds to UDP-glucuronic acid (UDPGA), while GSTs catalyze the 
conjugation with glutathione. Conjugation with glucuronic acid or glutathione in general 
results in less biologically active molecules and enhances the water solubility of the 
conjugated products, which facilitates excretion from the body via bile or urine (42). In the 
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digestive tract, the colon is the site where the majority of malignant tumours do develop, 
whereas the detoxification capacity in the colon may be critically low (43). Therefore, 
enhancement of the activity of such enzymes could potentially increase the capacity to 
withstand the burden of toxic agents and (pre)carcinogens we are exposed to daily (3, 4). 
Knowledge of the exact protection mechanism(s) of dietary anticarcinogens and NSAIDs may 
be of importance for the prevention of gastrointestinal cancer. Previous research demonstrated 
that several dietary agents and NSAIDs increased GST enzyme activities in liver and intestine 
of male Wistar rats (44-46). Therefore, we here investigated the effects of naturally occurring 
or synthetic anticarcinogens and NSAIDs on rat hepatic and intestinal UGT enzyme activities. 
 
 
Materials and methods 
 
Materials 
Oltipraz was from Rhone Poulenc Rorer (France). Bovine serum albumin, dithiothreitol,       
4-methylumbelliferone (4-MUB), UDPGA and D-saccharic acid 1,4-lactone, α-tocopherol,  
β-carotene, phenethylisothiocyanate (PEITC), indole-3-carbinol, relafen, indomethacin, 
ibuprofen, piroxicam, acetyl salicylic acid and sulindac were purchased from the Sigma 
Chemical Company (USA). D-limonene was obtained from Aldrich Chemie (Germany).       
4-Nitrophenol (4-NP) was from Merck (Germany). Sulforaphane analogue compound-30 was 
synthesized as described before (21). All dietary anticarcinogens and NSAIDs used were of 
the highest grade purity commercially available. 
 
Study design 
Hepatic and intestinal microsomes were prepared from Wistar rats, kept and treated as 
described in previous studies performed by Van Lieshout et al. (44-46). In short, male Wistar 
rats (Central Laboratory Animal Centre, University of Nijmegen, The Netherlands) were 
housed in pairs on wooden shavings in macrolon cages maintained at 20-25°C and 30-60% 
relative humidity. A ventilation rate of 7 air cycles/h and a 12 h light/dark cycle were used. 
The rats were randomly assigned to one of the dietary treatment groups. All groups were fed 
powdered RMH-TM laboratory chow (Hope Farms, Woerden, The Netherlands). After 
acclimatization for seven days, the animals were fed either the basal diet (control group) or 
one of the experimental diets.  
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Diets 
The diets were prepared by supplementation with either one of the dietary compounds: 0.03% 
(w/w) oltipraz, 0.02% (w/w) α-tocopherol, 0.02% (w/w) β-carotene, 0.045% (w/w) PEITC, 
0.145% (w/w) sulforaphane analogue compound-30, 0.025% (w/w) indole-3-carbinol and 
1.0% (w/w) D-limonene, or with one of the following NSAIDs: 0.02% (w/w) relafen, 
0.0025% (w/w) indomethacin, 0.04% (w/w) ibuprofen, 0.04% (w/w) piroxicam, 0.04% (w/w) 
acetyl salicylic acid and 0.032% (w/w) sulindac. Food and water were available ad libitum. 
Food cups were replenished every 2-3 days. Food consumption and gain in body weight was 
recorded daily. After 2 weeks the animals were killed by decapitation. 
 
Tissue preparation 
Tissue handling, isolation of liver and intestinal mucosa and preparation of microsomal pellet 
was performed as described previously (44). In short, liver tissue and intestinal mucosa were 
homogenised in buffer A (4 ml buffer A/g tissue (liver) or mucosal scraping (intestine); buffer 
A = 0.25 M saccharose, 20 mM Tris-HCl, 1 mM dithiothreitol, pH 7.4), followed by 
centrifugation at 9000 g (4°C) for 30 min. The resulting supernatant fraction was spun at    
150 000 g (4°C) for 60 min, resulting in the sedimentation of the microsomes. The 
microsomal pellet was resuspended in 5 vol. of buffer A.  
 
Assays 
Protein concentration was assayed in duplicate by the method of Lowry et al. (47) using 
bovine serum albumin as the standard. 
UGT activity with 4-MUB or 4-NP as substrates was measured in the microsomes as 
described previously (48). Briefly, liver and intestinal microsomes were resuspended in 50 
mM Tris-HCl, pH 7.4, containing 0.25 M sucrose and 1 mM dithiothreitol.  
Conjugation of 4-MUB was performed in the presence of 4 mM UDPGA, 10 mM MgCl2, 
0.025-0.25 mg microsomal protein, 1 mM saccharic acid 1,4-lactone and 0.1 mM 4-MUB in a 
final volume of 0.1 ml Tris-HCl, pH 7.4. 4-MUB was dissolved in ethanol (50 mM) and 
diluted with assay medium just before use. After incubation at 37°C for 0.5-20 min, 1 ml 0.5 
M glycine/NaOH, pH 10.35, was added to the reaction mixture to terminate the reaction. 
Subsequently, samples were centrifuged for 10 min at 10 000 g. 4-MUB was determined 
fluorometrically with a Shimadzu RF-5000 spectrofluorophotometer (excitation 370 nm, 
emission 450 nm).  
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Conjugation of 4-NP was measured in a final volume of 0.1 ml Tris-HCl, pH 7.4, containing 
3.5 mM UDPGA, 10 mM MgCl2, 0.05-0.5 mg microsomal protein, 1mM saccharic acid     
1,4-lactone, and 1 mM 4-NP. 4-NP was dissolved in 0.01 M NaOH. After incubation for 1-20 
min at 37°C, the reaction was terminated by adding 2 ml of 0.3 M NaOH, followed by 
centrifugation for 10 min at 10 000 g. Absorbance was measured at 405 nm on a Perkin Elmer 
Lambda 12 spectrophotometer. All samples were measured in duplicate. In all assays a 
control sample without UDPGA was run simultaneously. The absorbance difference between 
the control sample and the sample incubated in the presence of UDPGA represents the 
amount of 4-MUB or 4-NP that was conjugated. Effects of anticarcinogens on UGT enzyme 
activity are presented as ratios of treated to control. 
 
Statistical analysis  
Wilcoxon rank sum test was used to assess statistical significance of differences between 
control and treatment groups. Correlation analyses between enzyme activities were performed 
using Spearman rank correlation. P < 0.05 was considered to be significant. 
 
 
Results 
 
The effects of feeding the dietary agents and NSAIDs on intestinal and hepatic 4-MUB UGT 
enzyme activities are summarized in Table I. Compound-30 was able to induce 4-MUB UGT 
activity in all studied parts of the small intestine (1.4×, 1.5× and 1.4×, respectively). Proximal 
small intestinal 4-MUB UGT activity was also enhanced by D-limonene (1.2×), 
indomethacin, ibuprofen and sulindac (1.1×, 1.2×, and 1.2×, respectively). Large intestinal    
4-MUB UGT activity was only increased by ibuprofen (1.4×). Furthermore, hepatic 4-MUB 
UGT activity was enhanced after treatment with oltipraz (2.4×), PEITC (2.1×) and                
D-limonene (3.2×). No statistically significant changes in 4-MUB UGT activity were found 
with α-tocopherol, β-carotene, indole-3-carbinol, relafen and acetyl salicylic acid in all organs 
investigated. The effects of the different anticarcinogens on intestinal and hepatic 4-NP UGT 
enzyme activities are the same as observed for 4-MUB UGT activity, except for acetyl 
salicylic acid which also induced 4-NP UGT activity in the proximal small intestine (1.3×). 
However, sulindac was not able to enhance 4-NP UGT activity in the proximal small 
intestine, though it increased large intestinal 4-NP UGT enzyme activity (1.7×).  
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Table I. Effects of dietary anticarcinogens or NSAIDs on rat intestinal- and hepatic 4-MUB UGT  
enzyme activities 
Treatment group n 4-MUB UGT activity (ratio treated/control) 
  Small intestine Large intestine Liver 
  Proximal Mid Distal     
Oltipraz 8 1.3 (0.8-1.8) 0.69 (0.6-2.9) 0.90 (0.6-2.8) 1.1 (0.6-1.8) 2.4 (1.0-4.9) a 
α-Tocopherol 8 1.1 (0.8-2.0) 0.88 (0.4-1.8) 1.4 (0.6-2.7) 0.81 (0.5-2.7) 1.1 (0.4-1.9) 
β-Carotene 8 0.89 (0.8-1.0) 0.66 (0.5-0.9) 1.4 (0.7-3.3) 0.73 (0.4-1.8) 1.4 (0.6-2.4) 
PEITC 8 0.86 (0.8-1.1) 0.69 (0.5-1.3) 1.3 (1.0-3.1) 0.87 (0.4-1.6) 2.1 (0.8-3.4) a 
Compound-30 8 1.4 (1.0-2.1) b 1.5 (1.3-2.0) a 1.4 (1.2-1.8) a 1.0 (0.9-1.5) 1.0 (0.6-3.1) 
Indole-3-carbinol 8 1.1 (0.7-1.8) 1.1 (0.8-2.6) 0.87 (0.5-1.5) 1.1 (0.6-1.5) 1.1 (0.7-4.7) 
D-Limonene 8 1.2 (1.0-2.0) a 1.0 (0.8-1.4) 1.3 (0.7-2.1) 0.84 (0.4-1.0) 3.2 (2.2-4.9) b 
Relafen 8 1.0 (0.5-1.3) 1.1 (0.9-1.5) 0.86 (0.71-1.4) 0.86 (0.7-1.0) 1.5 (0.5-2.3) 
Indomethacin 8 1.1 (1.0-1.6) a 1.1 (0.8-1.6) 1.2 (1.0-1.4) 1.1 (0.4-1.6) 1.0 (0.6-1.9) 
Ibuprofen 8 1.2 (1.0-1.7) a 1.0 (0.7-1.4) 1.1 (0.7-1.2) 1.4 (1.0-2.2) a 1.0 (0.5-2.1) 
Piroxicam 8 1.0 (0.8-1.4) 0.95 (0.8-1.4) 0.98 (0.7-1.3) 0.83 (0.6-1.2) 0.85 (0.6-2.9) 
Acetyl salicylic acid 8 1.1 (0.7-1.6) 1.1 (1.0-1.3) 0.95 (0.8-1.3) 1.0 (0.6-1.3) 1.0 (0.8-1.8) 
Sulindac 8 1.2 (1.0-1.4) a 1.0 (0.8-1.2)  0.90 (0.6-1.1) 1.1 (0.4-1.9) 0.91 (0.7-2.0) 
4-MUB UGT activity was measured in duplicate as described in Materials and methods.  
n, number of rats used in each group.  
Results are given as median ratios of treated to control (range). In the control group (n = 8) median 4-MUB 
UGT activities (range) were 0.25 (0.17-0.29), 0.29 (0.21-0.41), 0.31 (0.20-0.49), 0.24 (0.10-0.33) and 10 (6-15) 
nmol/min⋅mg protein for proximal-, mid- and distal  
small intestine, large intestine and liver, respectively.  
The Wilcoxon rank sum test was used for statistical evaluation; aP < 0.05, bP < 0.01. 
 
 
Discussion 
 
It is well known that environmental factors affect the development of human cancers. The 
human diet contains a large number of both (pre)carcinogens as well as a variety of 
compounds that may inhibit mutagenesis and/or carcinogenesis as tested in laboratory models 
(3, 4). Anticarcinogens are very diverse in chemical structure and their protective mechanisms 
are generally unclear. Although prevention of cancer may be due to multiple mechanisms, one 
mode of action of anticarcinogens may be enhancement of the carcinogen detoxification 
systems, such as UGTs and GSTs (40, 41). These detoxification systems can minimize 
  44
carcinogenicity by conjugation reactions, which add functional groups to the carcinogen, 
thereby lowering their biological activity and increasing their excretion.  
 
In human organs at high risk for cancer development, low UGT levels were measured (43). At 
present little information on the effects of dietary and synthetic anticarcinogens on the UGT 
activity of the digestive tract is available. Recent data, mostly obtained from animal studies, 
have indicated that naturally occurring dietary anticarcinogens may be able to elevate UGT 
activity (49, 50).  
 
Oltipraz has been shown to elevate hepatic 4-NP UGT enzyme activity (23, 49, 51), which is 
similar to the results observed here. Rao et al. (23) also described a significant induction of 
colonic 4-NP UGT activity after oltipraz treatment in F344 rats, whereas we found no effect 
on colonic UGT activities in Wistar rats. Furthermore, oltipraz treatment did not significantly 
change UGT activities in rat proximal small intestine (51) and in other parts of the small 
intestine investigated here.  
In agreement with the results reported by Astorg et al. (52), we found no effect of β-carotene 
on hepatic 4-NP UGT enzyme activity.  
For PEITC, we found hepatic 4-NP UGT enzyme activity to be significantly increased, 
whereas a somewhat lower enhancement was also observed by Guo et al. (50), which may be 
explained by monitoring 48 h after treatment.  
Except for one recent report on changes in UGT1A1 mRNA and protein levels in HepG2 and 
HT29 cells (53), induction of UGT enzyme activity by sulforaphane or one of its analogues 
has not been reported before. Here we now demonstrate that the sulforaphane analogue 
compound-30 significantly enhances UGT enzyme activities in small intestine, but not in 
large intestine and liver.  
In the past, effect of indole-3-carbinol on hepatic UGT enzyme activity was only examined 
using 1-naphthol as substrate, and no effect could be observed [54]. This is in accordance 
with our results since we found no effect of indole-3-carbinol on either hepatic or intestinal 
UGT enzyme activity with both 4-NP and 4-MUB as substrates.  
Like Elegbede et al. (55), we investigated the effects of D-limonene treatment on hepatic 
UGT enzyme activity. We found that 1% D-limonene significantly elevated 4-NP and 4-MUB 
UGT activities, whereas Elegbede et al. only observed an inducing effect with 5% and not 1% 
D-limonene on α-naphthol UGT activity. Such variations in results may be either caused by 
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the use of different substrates (4-NP versus α-naphthol) or by the different strains of rats. 
With regard to the effects of NSAIDs, Falzon et al. (56) described that 8.5 mg/kg 
indomethacin given intraperitoneally for 3 days, significantly decreased hepatic 4-NP UGT 
activity by 22%. Furthermore, pallor of the liver and severe intestinal lesions were observed. 
We found no macroscopic signs of toxicity of indomethacin in all organs studied. In addition, 
we observed no inhibitory effects of indomethacin on 4-NP or 4-MUB UGT enzyme 
activities.  
No earlier reports on the effects of α-tocopherol, relafen, ibuprofen, piroxicam, acetyl 
salicylic acid and sulindac on hepatic or intestinal UGT enzyme activity were found.  
 
Until recently, the tissue distribution of only the UGT1A family had been examined in liver 
and gastrointestinal tract of rats (57). Now, Shelby et al. (58) reported on the mRNA 
expression of the different members of the UGT1 and UGT2 family in the rat gastrointestinal 
tract. In the intestine many UGT1 and only few UGT2B mRNAs were expressed, in contrast 
with the liver where many UGT2B mRNAs were predominantly expressed. The 
glucuronidation of NSAIDs may be mainly catalyzed by the isoenzymes UGT1A6 (intestine) 
and UGT2B (liver; ref. 59). In this study we measured UGT enzyme activity with 4-NP and 
4-MUB as substrates: both substrates mainly react with the isoenzymes of UGT1 family (40, 
42). This might explain why we did not find any effect of NSAIDs on the UGT enzyme 
activity in the liver. 
 
Finally, we examined the associations between 4-MUB and 4-NP UGT, and GST enzyme 
activities, as measured in our earlier studies (44-46), and the data are presented in Table II. In 
general, strong correlations were observed between 4-MUB and 4-NP UGT enzyme activities 
in liver and, to a much lesser extent in small and large intestine. Bock et al. (60) also found a 
strong association between 4-MUB and 4-NP UGT activities in the liver. This may be due to 
the fact that glucuronidation of both substrates may be mainly catalyzed by the same UGT 
isoforms, and that by far the highest activities are present in liver (40, 42). In rats UGT1A1, 
1A6 and 1A7 are highly expressed in liver and intestine (57), and therefore total UGT enzyme 
activity in these organs may be mainly covered by these UGT isoforms. Furthermore, 
significant associations between GST and UGT enzyme activities are also observed, however, 
the correlation coefficients are low. The associations found may be explained by the fact that 
both GST and UGT genes are regulated by the same transcription factor Nrf2 (61).  
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Table II. Correlations between UGT and GST enzyme activities 
Study (ref.) Associations studied Correlation coefficients (rs) 
  Small intestine Large intestine Liver 
  Proximal Mid Distal   
Van Lieshout 1996 (44) GST, 4-NP UGT ND ND ND 0.35 a 0.35 a 
 GST, 4-MUB UGT ND ND ND 0.28  0.31 a 
 4-NP UGT, 4-MUB UGT ND ND ND 0.43 a 0.94 b 
Van Lieshout 1998 (46) GST, 4-NP UGT 0.49 c 0.22 0.29  0.072 0.067 
 GST, 4-MUB UGT 0.41 a 0.23 0.28  0.20 0.066 
 4-NP UGT, 4-MUB UGT 0.66 b 0.54 c 0.63 b 0.084 0.70 b 
Van Lieshout 1997 (45) GST, 4-NP UGT 0.35 a 0.58 b 0.29  0.075 0.26  
 GST, 4-MUB UGT 0.40 a 0.53 c 0.17 0.23 0.23  
 4-NP UGT, 4-MUB UGT 0.31 a 0.071 0.31 a 0.48 c 0.69 b 
Correlation analyses between GST and 4-NP UGT, GST and 4-MUB UGT, 4-NP and 4-MUB UGT  
enzyme activities were performed using values from individual animals.  
GST data are from earlier studies by us (44-46).  
ND: no GST and 4-NP UGT data available. 
Spearman rank correlation was used for statistical evaluation; aP < 0.05, bP < 0.0001, cP < 0.005.  
 
 
In the present study we demonstrated that dietary anticarcinogens or NSAIDs are capable of 
inducing UGT enzyme activities in the rat gastrointestinal tract, particularly in the proximal 
small intestine or liver. This may be of direct significance in the protection against cancer in 
the particular organ. However, organs such as the colon could also benefit from a more 
efficient detoxification in the proximal part of the digestive tract, since lower levels of 
carcinogens may reach the colon.  
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Abstract 
 
Colorectal cancer (CRC) is one of the most common malignancies in the Western world 
showing an increasing incidence, and has been associated with genetic and lifestyle factors. 
Individual susceptibility to CRC may be due partly to variations in detoxification capacity in 
the gastrointestinal tract. Genetic polymorphisms in detoxification enzymes may result in 
variations in detoxification activities, which subsequently might influence the levels of 
toxic/carcinogenic compounds, and this may influence the risk for CRC. To determine 
whether genetic polymorphisms in detoxification enzymes predispose to the development of 
CRC, 371 patients with sporadic CRC and 415 healthy controls were genotyped for 
polymorphisms in the important detoxification enzymes UDP-glucuronosyltransferase 
UGT1A1, UGT1A6, UGT1A7 and UGT1A8, and glutathione S-transferase GSTA1, GSTM1, 
GSTP1 and GSTT1. Patients and controls were all of Caucasian origin. DNA was isolated 
from either blood or tissue and tested by polymerase chain reaction followed by restriction 
fragment length polymorphism analyses. Logistic regression analyses showed significant age- 
and gender-adjusted risks for CRC associated with variant genotypes of UGT1A6 [OR 1.5, 
95% confidence interval (CI) 1.03-2.3] and UGT1A7 (OR 2.4, 95% CI 1.3-4.6), whereas no 
associations were found between CRC and the other polymorphic genes as mentioned above. 
In conclusion, these data suggest that the presence of variant UGT1A6 and UGT1A7 
genotypes with expected reduced enzyme activities, might enhance susceptibility to CRC. 
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Introduction 
 
Colorectal cancer (CRC) is an important cause of death in Western countries. In The 
Netherlands, it is the second cause of death from malignant disease in women, and the third 
cause of death in men (1). It is estimated that up to 10% of CRC cases can be attributed to 
hereditary factors of high penetrance (2) leaving ∼90%, so called sporadic CRC cases, which 
may be attributed to diet, lifestyle factors and genetic factors of low penetrance. 
Epidemiological studies have shown that diets low in fruit and vegetables, and high in red 
meat and fat are associated with an increased risk of CRC (3, 4). Humans may be exposed 
daily to a large variety of toxic or even carcinogenic compounds, present in food (5) or as a 
result of lifestyle habits such as smoking of cigarettes (6, 7). However, humans also possess a 
highly efficient system of defence against such harmful compounds, and the detoxification 
enzymes are a main part of this.  
 
Detoxification enzymes such as UDP-glucuronosyltransferases (UGTs; ref. 8) and glutathione 
S-transferases (GSTs; 9) are responsible for the efficient modification of harmful molecules, 
making them less biologically active and facilitating their excretion. These enzymes are 
present predominantly in the gastrointestinal tract, especially in the liver, where detoxification 
enzymes have been identified at very high levels. However, these enzymes have also been 
distinguished in extra-hepatic tissues, including skin, kidney, intestine and many other organs 
(8-11). Since the gastrointestinal tract is in direct contact with potentially carcinogenic agents, 
ingested by food, medication, drugs, etc. the intestinal mucosa acts as a first line barrier. 
Tissue-specific expression of the various isoforms of detoxification enzymes in colon and 
liver was shown to contribute to the differences in enzyme activities observed in these tissues 
(10-13). In addition, variations due to the presence of genetic polymorphisms may contribute 
to the inter-individual differences in expression levels and enzyme activities of these enzymes 
(9, 14). These genetic polymorphisms may result in variations in detoxification activities, 
which also might influence the levels of toxic/carcinogenic compounds in the colon. 
Therefore, polymorphisms in the detoxification enzymes could contribute to individual 
susceptibility to CRC.   
 
UGTs and GSTs are important families of detoxification enzymes. UGTs catalyze the 
conjugation of a wide variety of exogenous (e.g. drugs, pesticides, components of tobacco 
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smoke) and endogenous (e.g. bilirubin, bile acids, steroid hormones) compounds to 
glucuronic acid (8), while GSTs catalyze the reaction of glutathione with exogenous 
electrophiles (e.g. polycyclic aromatic hydrocarbons, heterocyclic amines) and endogenous 
products of oxidative stress (9, 10). The metabolites formed by these reactions are generally 
less toxic and more water soluble, which facilitates their biliary and renal excretion. 
Polymorphic variations in these detoxification enzymes may influence the rates of conversion 
of toxic or carcinogenic compounds. Many genetic polymorphisms in UGTs or GSTs have 
been described and some have been associated with increased CRC susceptibility (15-18). 
 
In humans, two UGT families have been classified: UGT1A and UGT2 (19). So far, nine 
functional UGT1A isoenzymes (UGT1A1, UGT1A3-UGT1A10) have been characterized, all 
derived from a single gene locus on chromosome 2 (8, 20). UGT1A enzymes are mainly 
involved in the metabolism of exogenous compounds, this is not strictly the case however as 
bilirubin and steroid hormones are important endogenous substrates. UGT2 isoenzymes 2A1, 
2B4, 2B7, 2B10, 2B11, 2B15 and 2B17 are involved mainly in the glucuronidation of 
endogenous compounds and therefore were not studied further here. Most UGT1A family 
members are expressed at low levels in the colon. UGT1A7, UGT1A8 and UGT1A10 are 
expressed only extra-hepatically and may be highly relevant for colonic detoxification (21). 
Several functional polymorphisms in UGT1A family isoenzymes have been identified (8, 14, 
22, 23). In Caucasians homozygosity for the UGT1A1*28 polymorphism in the UGT1A1 
promoter results in significantly reduced hepatic bilirubin UGT enzyme activity (24, 25), 
leading to a mild form of hyperbilirubinemia, known as Gilbert’s syndrome (26, 27). Two 
missense mutations in exon 1 of UGT1A6 have been described, which results in T181A and 
R184S amino acid changes (28). These polymorphisms are usually linked on one allele 
(UGT1A6*2), although alleles carrying only the R184S polymorphism (UGT1A6*3) are 
found occasionally. Metabolism rates of phenols by recombinant UGT1A6*2 were lower than 
those of the most common enzyme. For UGT1A7, eight allelic variants of the most common 
UGT1A7*1 allele have been described (29, 30); however, only UGT1A7*1 to *4 have been 
identified in Caucasians. Complete loss, or a very strong reduction, of activity was reported 
for UGT1A7*3 (29), whereas substantial reduction of activity was demonstrated for 
UGT1A7*2 and UGT1A7*4. In UGT1A8, two missense mutations in exon 1 were identified, 
resulting in an A173G substitution with little impact on catalytic activity, in contrast to the 
substitution of C277Y yielding an inactive enzyme (22).   
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In humans, the GST family comprises four main classes (alpha, mu, pi, theta) which genes are 
mapped on different chromosomes (9). Coles et al. described a polymorphism at nucleotide 
69 in 5’-regulatory region of the GSTA1 gene (31). Homozygotes for this polymorphism 
(GSTA1*B) have reduced enzyme activity compared with GSTA1*A homozygotes. Five 
GST Mu class genes (M1 to M5) have been identified clustered on chromosome 1 (32). For 
intestine GSTM1 seems most important, however 40 to 60% of the Caucasians do not express 
GSTM1 due to the GSTM1 null genotype (16, 33). GSTP1, the only member of the GST Pi 
class, appears to be the most widely distributed GST isoenzyme (10). A functional 
polymorphism has been described for GSTP1 resulting in an I105V substitution (34) and 
leading to a lower enzyme activity (35, 36). Two GST Theta class genes, GSTT1 and GSTT2, 
have been characterized and in humans a GSTT1 null genotype may be present at a frequency 
of ∼10-20% in Caucasians (16, 37).  
 
Aim 
To determine whether genetic polymorphisms in several important isoenzymes of the UGT 
and GST family predispose to the development of CRC, 371 Caucasian patients with sporadic 
CRC and 415 Caucasian healthy controls were genotyped for polymorphisms in UGT1A1, 
UGT1A6, UGT1A7, UGT1A8, GSTA1, GSTM1, GSTP1 and GSTT1.  
 
 
Materials and Methods 
 
Patients and control subjects 
A total of 371 patients (212 males, 159 females; mean age 64 ± 11 yrs) with sporadic CRC 
were recruited at the Departments of Gastroenterology and General Surgery, University 
Medical Centre St Radboud, Nijmegen, The Netherlands. 415 healthy subjects (168 males, 
247 females; mean age 42 ± 12 yrs) served as controls and were recruited by advertisement in 
a local paper. All subjects were of Caucasian origin.  
 
DNA isolation 
Whole blood from 280 CRC patients and 415 healthy controls was obtained by venapuncture 
in sterile vacutainer tubes anti-coagulated with EDTA and stored at –20ºC until use. Most 
blood samples from CRC patients were collected at the Department of Clinical Chemistry. 
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DNA was isolated from whole blood using the Pure Gene DNA isolation kit (Gentra Systems, 
Minneapolis, MN) according to the instructions of the manufacturer and stored at 4ºC. For 91 
patients with CRC no blood samples were available and here DNA was isolated from resected 
normal colorectal tissue obtained at the Department of Surgery. After surgical resection, 
tissue specimens were immediately frozen in liquid nitrogen and stored at –80ºC until use. 
DNA was extracted from normal colorectal mucosa using phenol-chloroform-isoamylalcohol 
extraction according to Maniatis et al. (38). Cancer diagnosis was confirmed by 
histopathological investigation of tissue specimens by a pathologist. Cases were classified 
according to Dukes’ stages (A, B, C, D) and according to location of the tumour in the large 
intestine as either proximal (cecum, ascending or transverse) or distal (descending, sigmoid, 
rectosigmoid junction or rectum).  
 
Genotyping 
UGT1A1. The number of TA repeats in the promoter region of the UGT1A1 gene was 
analyzed using the polymerase chain reaction (PCR) conditions and primers (Table I) as 
described by Monaghan et al. (24). Amplification was confirmed by agarose electrophoresis 
before fragments were resolved on 12% polyacrylamide gels (19:1 acrylamide/bisacrylamide; 
Biorad) in Tris-borate-EDTA buffer. Gels (20 × 20 × 0.075 cm) were run at 400 V for 3 h and 
stained with ethidium bromide for 30 min (25). Fragments of 98 bp indicate the UGT1A1*1 
allele, containing six TA repeats, and fragments of 100 bp indicate the UGT1A1*28 allele, 
containing seven TA repeats.  
 
GSTM1 and GSTT1. The GSTM1 genetic polymorphism was determined by PCR according to 
the method of Brockmöller et al. (33). As an internal positive control, the β-globin gene was 
co-amplified, whereas sterile H2O was substituted for genomic DNA and served as a negative 
control. PCR primers are given in Table I. PCR products were subjected to electrophoresis on 
1% agarose gels and analyzed for the presence of a 650-bp product, which is indicative of at 
least one functional GSTM1 allele. The lack of an amplification product is consistent with the 
null genotype. The procedure followed to detect the GSTT1 null polymorphism is similar to 
that of GSTM1 and it is based on the method of Pemble et al. (37). PCR reactions and 
electrophoretic analyses were performed under the same conditions as described for GSTM1. 
Amplifications were performed in duplicate. The visualization of a 480-bp product indicates 
the presence of a least one functional GSTT1 allele. 
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Other investigated genes. The polymorphisms in all other investigated genes were studied 
using PCRs followed by restriction fragment length polymorphism (RFLP) analyses. The 
primers and restriction enzymes used for PCR-RFLP are shown in Table I.  
 
Table I. Primers and restriction enzymes used for genotyping analyses  
Gene Primers (5’-3’; F = forward, R = reverse) Restriction enzyme
UGT1A1 F: GTC ACG TGA CAC AGT CAA AC 
R: TTT GCT CCT GCC AGA GGT T 
- 
UGT1A6 codon 181 and 184 F: GGA AAA TAC CTA GGA GCC CTG TGA 
R: AGG AGC CAA ATG AGT GAG GGA G 
T181A: NsiI  
R184S: Fnu4HI 
UGT1A7 codon 129 and 131 F1: AAT TGC AGG AGT TTG aTT AA a 
F2: AAT TGC AGG AGT TTG aTT A a 
R1: TTC AGA GGC TAT TTC TAA GA 
VspI 
VspI 
UGT1A7 codon 208 F3: ATG CTC GCT GGA CGG CAC CAT TG 
R2: TGC CGT GAC AGG GGT TTG GAG A 
RsaI 
UGT1A7 allele specific F4: ATT GCA GGA GTT TGT TTA AGG ACA 
R1: TTC AGA GGC TAT TTC TAA GA 
RsaI 
UGT1A8 codon 173 F: CAG TTC TCT CAT GGC TCG CA 
R: GTG TGG CTG TAG AGA TCA TAT GCT 
AluI 
UGT1A8 codon 277 F: TCT TCA TTG GTG GTA TCA GCT a 
R: AAA ATT TGA TAA CTG ATG AGT ACA TA 
PvuII 
GSTA1 F: TGT TGA TTG TTT GCC TGA AAT T 
R: GTT AAA CGC TGT CAC CGT CC 
EarI 
GSTM1 F: CTC CTG ATT ATG ACA GAA GCC 
R: CTG GAT TGT AGC AGA TCA TGC 
- 
β-Globin F: CAA CTT CAT CCA CGT TCA CC 
R: GAA GAG CCA AGG ACA GGT AC 
- 
GSTP1 codon 105 F: GTA GTT TGC CCA AGG TCA AG 
R: AGC CAC CTG AGG GGT AAG 
Alw26I 
GSTT1 F: TTC CTT ACT GGT CCT CAC ATC TC 
R: TCA CCG GAT CAT GGC CAG CA 
- 
a Bold ‘a’ in the primer sequence denotes site-directed mutagenesis for introduction of a VspI restriction  
site in the wild-type allele; bold ‘G’ in the primer sequence creates a restriction site for PvuII in the  
wild-type allele. 
 
PCR-RFLP assays were adapted from methods described earlier and were used to identify the 
polymorphic variants of the following genes: UGT1A6 (28, 39), GSTA1 (31) and GSTP1 (35). 
Polymorphic variants in the UGT1A7 and UGT1A8 genes were identified by PCR-RFLP 
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methods developed in our laboratory. In short, to detect the variations at UGT1A7 codons 
129/131, we used the forward primers F1 and F2 (the ‘a’ in the primer sequence denotes site-
directed mutagenesis for introduction of a VspI restriction site in the wild-type allele) and the 
reverse primer R1 (Table I). F1 only detects the N129K/R131K polymorphism; F2 detects 
both the N129K/R131K and N129R/R131K polymorphisms (see Figures 1A and 1B).  
 M      1       2       3       4       5       6     7 M      1       2       3       4       5       6     7 
 
 
 
 
 
 
 
 
333 bp 
315 bp 
333 bp 
315 bp 
103 bp 
440 bp 
337 bp 
332 bp 
253 bp 
CA 
DB  
Fig. 1. Genotyping of UGT1A7 129/131 and 208 polymorphisms with PCR-RFLP. (A) N129K/R131K PCR 
fragment digested with VspI: most common: 315 + 18 bp; heterozygous: 333 + 315 + 18 bp; homozygous 333 
bp. (B) N129K/R131K or N129R/R131K PCR fragment digested with VspI: most common: 315 + 18 bp; 
heterozygous: 333 + 315 + 18 bp; homozygous 333 bp. (C) W208R PCR fragment digested with RsaI: most 
common: 440 bp; heterozygous: 440 + 337 + 103 bp; homozygous: 337 + 103 bp. (D) Allele specific PCR for 
the detection of N129K/R131K or N129R/R131K variations, digested with RsaI: no product: the 129/131 
mutations are not present; 332 bp product: only the 129/131 mutations are present or the 129/131 mutations are 
not in the same allele as the 208 mutation; 253 + 79 bp products: the 129/131 mutations are in the same allele as 
the 208 mutation; 332 + 253 + 79 bp products: the 129/131 mutations are present in one allele and in the other 
allele the 129/131 mutations and the 208 mutation are present. Lane M, 100 bp marker; lane 1, UGT1A7*1*1; 
lane 2, UGT1A7*1*2; lane 3, UGT1A7*1*3; lane 4, UGT1A7*2*2; lane 5, UGT1A7*2*3; lane 6, UGT1A7*3*3; 
lane 7, UGT1A7*1*10 (genotype UGT1A7*2*4 was not identified; alleles carrying only the W208R 
polymorphism were not found). The sizes of the PCR fragments are indicated. 
 
To detect the W208R alteration, we used the forward primer F3 and the reverse primer R2 
(Table I and Figure 1C). To determine whether the N129K/R131K or N129R/R131K and 
W208R occur cis or trans, we use the primers F4 and R1 (Table I and Figure 1D). PCR 
conditions were 5 min at 95ºC, then 37 cycles of 30 s at 95ºC, 30 s at 55ºC (codons 129/131) / 
65ºC (codon 208) / 56ºC (allele specific), and 30 s at 72ºC, and finally an elongation step at 
72ºC for 5 min. Aliquots of 10 µl of the PCR product were digested with the restriction 
  60
enzyme VspI (codons 129/131) or RsaI (codon 208 / allele specific) for at least 1 h at 37ºC 
(see Figure 1).  
 
The polymorphisms in the UGT1A8 gene corresponding with amino acid substitutions at 
position 173 and 277 were analyzed with two separate PCRs followed by RFLP analyses. The 
primers used for the PCR to detect the A173G substitution are shown in Table I. The PCR 
conditions were 4 min at 95ºC, then 35 cycles of 30 s at 95ºC, 1 min at 58ºC, and 1 min at 
72ºC, and finally an elongation step at 72ºC for 7 min. A 750-bp product was amplified and 
aliquots of 5 µl of the PCR mixture were digested for 1 h at 37°C with the restriction enzyme 
AluI, followed by electrophoresis on 3% agarose gel, containing ethidium bromide. The 
UGT1A8*2 allele (A173G) contains only one restriction site for AluI, instead of two 
restriction sites for the UGT1A8*1 and UGT1A8*3 alleles (see Figure 2A).  
 
M           1            2            3           M            1            2 
 
440 bp 
90 bp 
220 bp 
660 bp  
 
195 bp 
215 bp 
 
 
 A B 
 
Fig. 2. Genotyping of UGT1A8 173 and 277 polymorphisms with PCR-RFLP. (A) Electrophoresis patterns of 
PCR fragments after digestion with AluI for detection of the A173G polymorphism and (B) after digestion with 
PvuII for the C277Y polymorphism. Lane M, 100 bp marker; lane 1, homozygosity for the common allele; lane 
2, heterozygosity; lane 3, homozygosity for the variant allele (homozygosity for the C277Y polymorphism was 
not found). The sizes of the PCR fragments are indicated. 
 
The primers used to detect the C277Y substitution by PCR are shown in Table I (the last G of 
the forward primer creates a restriction site for PvuII in the wild-type allele). Except for the 
annealing temperature, which was 1 min at 49ºC, similar PCR conditions were used as 
described above for detection of the A173G substitution. The digestion of the 215-bp PCR 
product with PvuII was carried out under similar conditions as described above. The 
UGT1A8*3 allele (C277Y) contains no restriction site for PvuII, distinct from the UGT1A8*1 
and UGT1A8*2 alleles, which have one PvuII restriction site (Figure 2B). During each PCR 
analysis, sterile H2O was added instead of genomic DNA in several wells of the 96-wells PCR 
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plate, which served as negative control for amplification. All genotypes analyzed are 
summarized in Table II. 
 
Table II. Polymorphic variants of the detoxification enzymes investigated 
Polymorphic variant Allelic variation a 
UGT1A1*1 (TA)6TAA 
UGT1A1*28 (TA)7TAA 
UGT1A6*1 T181R184 
UGT1A6*2 A181S184 
UGT1A6*3 T181S184 
UGT1A7*1 N129R131W208 
UGT1A7*2 K129K131W208 
UGT1A7*3 K129K131R208 
UGT1A7*10 R129K131R208 
UGT1A8*1 A173C277 
UGT1A8*2 G173C277 
UGT1A8*3 A173Y277 
GSTA1*A -69C 
GSTA1*B -69T 
GSTM1 + At least one functioning allele  
GSTM1 null  Deletion in both alleles 
GSTP1 Ile 105 I105 
GSTP1 Val 105 V105 
GSTT1 + At least one functioning allele  
GSTT1 null Deletion in both alleles 
a Bold characters indicate nucleotide or amino acid changes as compared  
to the most common allele. 
 
Statistical analyses 
Differences between characteristics of patients and controls were analyzed with χ2 test and    
t-test. All genotypes investigated among controls and patients were tested whether they were 
distributed according to the Hardy-Weinberg equilibrium. Furthermore, χ2 statistic was used 
to test for differences in the distribution of the genotypes between the two study groups, or to 
estimate differences in allele frequencies. In total, four genetic polymorphisms of the UGT1A 
family were analyzed. Because the different UGT1A isoforms are derived from one single 
gene locus, we corrected for multiple testing with Bonferroni, meaning that a P-value of        
< 0.013 instead of 0.05 was considered to represent statistical significance. Odds ratios (OR) 
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with 95% confidence interval (95% CI) were calculated by logistic regression analyses for 
genotypes associated with normal enzyme activity versus genotypes associated with expected 
reduced enzyme activity (variant genotypes). All statistical analyses were performed with 
SAS (version 8.0; SAS Institute, Cary, NC).  
 
 
Results 
 
Characteristics of patients and controls 
Descriptive statistics of CRC patients and controls are given in Table III. The mean age of 
CRC patients (64 ± 11 years) is significantly higher compared with that of the control group 
(42 ± 12 years; P < 0.0001). 
 
Table III. Clinical characteristics of patients with sporadic CRC and controls 
Characteristics Group Controls (%) CRC patients (%) 
Number of subjects  415 371 
Age (years; mean ± SD)  42 ± 12 64 ± 11 a 
Gender Male 168 (40.5) 212 (57.1) a 
 Female 247 (59.5) 159 (42.9) 
Location tumour b Cecum  40/310 (12.9) 
 Ascending colon  22/310 (7.1) 
 Transverse colon  17/310 (5.5) 
    Proximal     89/324 (27.5) c 
 Descending colon  8/310 (2.6) 
 Sigmoid colon  85/310 (27.4) 
 Rectosigmoid junction  40/310 (12.9) 
 Rectum  98/310 (31.6) 
    Distal     235/324 (72.5) c 
Stage tumour d Dukes A  7/293 (2.4) 
 Dukes B  103/293 (35.2) 
    Dukes A/B     112/299 (37.5) e 
 Dukes C  81/293 (27.6) 
 Dukes D  102/293 (34.8) 
    Dukes C/D      187/299 (62.5) e 
a Controls versus CRC patients, P < 0.0001. 
b For 61 CRC cases, no information on the exact location of the tumour is available. 
c For some patients only proximal or distal location was reported in the medical files. 
d For 78 cases, no information on the exact stage of the tumour is available. 
e For some patients only stage Dukes A/B or C/D was reported in the medical files. 
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There is also a statistically significant difference in gender between CRC patients and healthy 
controls, with more female subjects in the control group (P < 0.0001). 
 
 
Polymorphisms in genes of biotransformation enzymes 
Genotype distributions of the UGT and GST biotransformation enzymes investigated are 
summarized in Table IV, and corresponding allele frequencies are shown in Table V. The 
genotype distributions and allele frequencies in patients are based on PCR-RFLP, using DNA 
extracted from either whole blood or normal colorectal mucosa. All genotype distributions 
tested here fulfilled the Hardy-Weinberg criteria. χ2 analyses revealed no significant 
differences for the investigated polymorphisms between CRC patients and controls.  
 
 
Calculation of odds ratios of genotypes associated with normal enzyme activity versus 
genotypes associated with expected reduced enzyme activity (variant genotypes) with logistic 
regression analyses showed significant age- and gender-adjusted risks for CRC associated 
with variant genotypes of UGT1A6 (OR 1.5, 95% CI 1.03-2.3) and UGT1A7 (OR 2.4, 95% CI 
1.3-4.6). There were no statistically significant differences between cases and controls for the 
other genotype distributions investigated in this study (Table IV).  
 
 
χ2 analyses revealed no significant differences in the presence of variant alleles between CRC 
patients and controls, for all enzymes investigated. When combining alleles that provide 
normal catalytic properties and alleles that may yield lower enzyme activity we calculated the 
odds ratios for CRC risk (Table V). Logistic regression analyses showed significant age- and 
gender-adjusted risks for CRC associated with variant UGT1A7 alleles (OR 1.5, 95% CI 1.1-
2.0).  
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Table IV. Distribution of genotypes of UGT and GST detoxification enzymes in patients with CRC and controls 
Gene Genotype Controls  
(%) a 
CRC patients  
(%) a 
Crude OR  
(95%CI) b  
Adjusted OR  
(95%CI) c 
UGT1A1 *1*1 183/399 (45.9) 175/371 (47.2)   
 *1*28 169 (42.4) 159 (42.9)   
 *28*28 47 (11.8) 37 (10.0) 0.95 (0.71-1.3) 1.2 (0.83-1.8) 
UGT1A6 *1*1 171/413 (41.4) 142/363 (39.1)   
 *1*2 175 (42.4) 160 (44.1)   
 *2*2 54 (13.1) 38 (10.5)   
 *1*3 9 (2.2) 15 (4.1)   
 *2*3 4 (1.0) 8 (2.2) 1.1 (0.82-1.5) 1.5 (1.03-2.3) d 
UGT1A7 *1*1 51/405 (12.6) 35/367 (9.5)   
 *1*2 71 (17.5) 63 (17.2)   
 *2*2 27 (6.7) 28 (7.6)   
 *1*3 102 (25.2) 105 (28.6)   
 *2*3 79 (19.5) 75 (20.4)   
 *3*3 70 (17.3) 60 (16.3)   
 *1*10 5 (1.2) 1 (0.3) 1.4 (0.87-2.2) 2.4 (1.3-4.6) d 
UGT1A8 *1*1 216/404 (53.5) 186/370 (50.3)   
 *1*2 143 (35.4) 138 (37.3)   
 *2*2 25 (6.2) 29 (7.8)   
 *1*3 14 (3.5) 15 (4.1)   
 *2*3 6 (1.5) 2 (0.5) 0.92 (0.48-1.8) 0.69 (0.30-1.6) 
GSTA1 *A*A 168/411 (40.9) 158/371 (42.6)   
 *A*B 184 (44.8) 160 (43.1)   
 *B*B 59 (14.4) 53 (14.3) 0.93 (0.70-1.2) 0.80 (0.54-1.2) 
GSTM1 + 212/415 (51.1) 186/370 (50.3)   
 null 203 (48.9) 184 (49.7) 1.0 (0.78-1.4) 0.81 (0.54-1.2) 
GSTP1 Ile/Ile 174/414 (42.0) 155/369 (42.0)   
 Ile/Val 185 (44.7) 175 (47.4)   
 Val/Val  55 (13.3) 39 (10.6) 1.0 (0.75-1.3) 0.93 (0.62-1.4) 
GSTT1 + 346/415 (83.4) 299/371 (80.6)   
 null 69 (16.6) 72 (19.4) 1.2 (0.84-1.7)  1.0 (0.64-1.7) 
a In both the CRC and control group there are some missing data because of insufficient amount of DNA or  
unsuccessful PCR. 
b Genotypes were combined on the basis of an expected phenotype-genotype relationship (variant genotypes with  
reduced enzyme activity versus genotypes with normal enzyme activity) and crude OR were calculated. 
c OR adjusted by age and gender were calculated. 
d Statistically significant. 
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Table V. Allele frequencies of UGT and GST genes investigated in patients with CRC and controls 
Alleles Controls  
(number/total) a 
CRC patients 
(number/total) a 
Crude OR (95% CI) b  Adjusted OR (95% CI) c 
UGT1A1*1 0.67 (535/798) 0.69 (509/742)   
UGT1A1*28 0.33  0.31  0.93 (0.75-1.2) 1.1 (0.84-1.5) 
UGT1A6*1 0.64 (526/826) 0.63 (459/726)   
UGT1A6*2 0.35  0.34    
UGT1A6*3 0.016  0.032  1.0 (0.83-1.3) 1.2 (0.94-1.7) 
UGT1A7*1 0.35 (280/810) 0.33 (239/734)   
UGT1A7*2 0.25  0.26    
UGT1A7*3 0.40  0.41    
UGT1A7*10 0.0062  0.0014  1.1 (0.89-1.4) 1.5 (1.1-2.0) d 
UGT1A8*1 0.73 (589/808) 0.71 (525/740)   
UGT1A8*2 0.25  0.27    
UGT1A8*3 0.025  0.023  0.95 (0.49-1.8) 0.98 (0.72-1.3) 
GSTA1*A 0.63 (520/822) 0.64 (476/742)   
GSTA1*B 0.37  0.36 0.96 (0.78-1.2) 0.87 (0.66-1.2) 
GSTM1 + 0.51 (424/830) 0.50 (372/740)   
GSTM1 null 0.49  0.50 1.0 (0.85-1.3) 0.81 (0.61-1.1) 
GSTP1 Ile 0.64 (533/828) 0.66 (485/738)   
GSTP1 Val  0.36  0.34 0.94 (0.77-1.2) 0.87 (0.65-1.2) 
GSTT1 + 0.83 (692/830) 0.81 (598/742)   
GSTT1 null 0.17  0.19 1.2 (0.93-1.6) 1.0 (0.74-1.5) 
a In both controls and cases there are missing data because of insufficient amount of DNA or unsuccessful  
PCR. 
b Alleles were combined on the basis of an expected phenotype-genotype relationship (variant alleles with  
reduced enzyme activity versus alleles with normal enzyme activity) and crude OR were calculated. 
c OR adjusted by age and gender were calculated. 
d Statistically significant. 
 
 
Possible associations of genotype distributions of the UGT and GST biotransformation 
enzymes and clinical characteristics, such as tumour location and tumour stage were also 
investigated and the results are summarized in Table VI. These analyses revealed an 
association of UGT1A6 variant genotypes with proximal CRC (adjusted OR 2.1 95% CI 1.1-
4.1), whereas UGT1A7 variant genotypes were associated with distal CRC (adjusted OR 3.0, 
95% CI 1.5-6.2).  
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Table VI. Distribution of genotypes of UGT and GST detoxification enzymes with respect to tumour location and tumour 
stage in patients with CRC  
Gene Genotype Proximal CRC (%) a Distal CRC (%) a CRC Dukes A/B (%) a CRC Dukes C/D (%) a 
UGT1A1 *1*1 39/89 (42.8) 112/235 (45.9) 52/112 (46.4) 84/187 (44.9) 
 *1*28 41 (46.1) 98 (42.3) 51 (45.5) 83 (44.3) 
 *28*28 9 (10.1) 25 (11.8) 9 (8.0) 20 (10.7) 
UGT1A6 *1*1 31/88 (35.2) b, c 92/230 (40.0) 51/112 (45.5)  62/183 (33.9) b, c  
 *1*2 40 (45.4) 99 (43.0) 42 (37.5) 92 (50.3) 
 *2*2 10 (11.4) 25 (10.9) 10 (8.9) 21 (11.5) 
 *1*3 5 (5.7) 9 (3.9) 3 (2.7) 7 (3.8) 
 *2*3 2 (2.3) 5 (2.2) 6 (5.4) 1 (0.55) 
UGT1A7 *1*1 8/88 (9.1) 23/232 (9.9) b, c 13/111 (11.7) b, c 15/184 (8.2) b, c 
 *1*2 13 (14.8) 43 (18.5) 28 (25.2) 22 (12.0) 
 *2*2 7 (8.0) 17 (6.9) 9 (8.1) 14 (7.6) 
 *1*3 23 (26.1) 64 (26.1) 27 (24.3) 58 (31.5) 
 *2*3 19 (21.6) 47 (19.8) 17 (15.3) 45 (24.5) 
 *3*3 18 (20.4) 37 (16.8) 17 (15.3) 30 (16.3) 
 *1*10 0 (0) 1 (0.94) 0 (0) 0 (0) 
UGT1A8 *1*1 46/89 (51.7) 118/234 (50.4) 51/112 (45.5) 97/186 (52.2) 
 *1*2 34 (38.2) 84 (35.9) 46 (41.0) 67 (36.0) 
 *2*2 7 (7.9) 19 (8.1) 10 (8.9) 16 (8.6) 
 *1*3 2 (2.3) 11 (4.7) 4 (3.6) 5 (2.7) 
 *2*3 0 (0) 2 (0.85) 1 (0.89) 1 (0.54) 
GSTA1 *A*A 41/89 (46.1) 95/235 (40.4) 48/112 (42.9) 80/187 (42.8) 
 *A*B 36 (40.4) 106 (45.1) 52 (46.4) 74 (39.6) 
 *B*B 12 (13.5) 34 (14.5) 12 (10.7) 33 (17.7) 
GSTM1 + 47/89 (52.8) 118/234 (50.4) 63/112 (56.3) b, c 90/186 (48.4) 
 null 42 (47.2) 116 (49.6) 49 (43.8) 96 (51.6) 
GSTP1 Ile/Ile  35/87 (40.2) 99/235 (42.1) 52/112 (46.4) 78/185 (42.2) 
 Ile/Val 44 (50.6) 110 (46.8) 59 (43.8) 85 (46.0) 
 Val/Val 8 (9.2) 26 (11.1) 11 (9.8) 22 (11.9) 
GSTT1 + 76/89 (85.4) 187/235 (79.6) 93/112 (83.0) 149/187 (79.7) 
 null 13 (14.6) 48 (20.4) 19 (17.0) 38 (20.3) 
a (%: number/total); Among cases there are some missing data because of insufficient amount of DNA or unsuccessful  
PCR. 
b Genotypes were combined on the basis of an expected phenotype-genotype relationship (variant genotypes with reduced 
enzyme activity versus genotypes with normal enzyme activity) and statistically significant OR adjusted by age and gender 
were calculated.  
UGT1A6: proximal CRC 2.1 (1.1-4.1); CRC Dukes C/D 2.0 (1.2-3.2);  
UGT1A7: distal CRC 3.0 (1.5-6.2); CRC Dukes A/B 2.5 (1.1-6.3); CRC Dukes C/D 2.8 (1.4-6.0); 
GSTM1: CRC Dukes A/B 0.47 (0.25-0.83). 
c Statistically significant. 
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In addition, logistic regression analyses showed significant age- and gender-adjusted risks for 
Dukes C/D CRC associated with variant genotypes of UGT1A6 (OR 2.0, 95% CI 1.2-3.2), 
whereas presence of GSTM1 was associated with a reduced risk for Dukes A/B CRC (OR 
0.47, 95% CI 0.25-0.83). Risk for CRC associated with variant UGT1A7 genotypes was 
independent of tumour stage (Dukes A/B: OR 2.5 (1.1-6.3); Dukes C/D: OR 2.8 (1.4-6.0)). 
 
 
Discussion 
 
The risk of sporadic CRC is associated mainly with lifestyle factors and may be further 
modulated by several genetic factors of low penetrance (1-6). Since the gastrointestinal tract 
is in direct contact with potentially toxic or (pre)carcinogenic agents, the intestinal mucosa 
acts as a first-line barrier. In humans, detoxification enzymes are present predominantly in the 
liver. However, these enzymes have also been distinguished in extra-hepatic tissues of the 
gastrointestinal tract (8-11). Polymorphic variations in the detoxification enzymes may 
modulate the rate of conversion of toxic or carcinogenic compounds in the epithelium lining 
the lumen of the gastrointestinal tract. Several polymorphisms of genes encoding for the 
detoxification enzymes have been described and have sometimes been associated with 
increased CRC susceptibility (15-17). In the present study we investigated the relationship 
between sporadic CRC and polymorphisms in UGT and GST genes, which are associated with 
functional changes in enzyme activity.  
 
In this study, a significant age- and gender-adjusted risk for CRC associated with variant 
genotypes of UGT1A6 was revealed. In particular, variant genotypes of UGT1A6, with an 
expected reduction of the corresponding enzyme activities, were associated with tumours of 
the proximal colon and with Dukes C/D tumour stages. The frequency of the UGT1A6*2 
allele in healthy subjects was estimated at 35%, which is higher than the 16.8% reported by 
Ciotti et al. (28), but comparable to 30.7% and 32.5% found by Lampe et al. (40) and Köhle 
et al. (41), respectively. Earlier, Bigler et al. (42) described an inverse association with intake 
of aspirin and colon adenoma risk, for individuals who carried the variant UGT1A6 alleles. 
The low activity alleles were protected against adenomas by aspirin intake whereas the 
individuals bearing only high activity alleles were not. UGT1A6 primarily metabolizes simple 
phenols (43) and planar heterocyclic amines (HCAs; ref. 44). HCAs are formed in protein-
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rich foods, such as meat, as a result of pyrolysis during cooking. Meat intake, specifically red 
meat, has been associated with higher CRC risk (45). Recently, Butler et al. (46) examined 
the association between CRC and meat intake categorized by the stage of the cooking process, 
cooking method, and estimated levels of HCAs. They reported moderate, dose-dependent 
associations between CRC and red meat intake, in particular for pan-fried and well-done red 
meat, which showed the strongest correlations with the investigated HCAs. Individuals 
bearing variant UGT1A6 genotypes, associated with reduced enzyme activity to detoxify these 
meat-derived HCAs sufficiently, may therefore be at an increased risk for CRC.  
 
Strassburg et al. (18) showed a significant association of CRC and the presence of the variant 
UGT1A7*3 allele (OR 2.8, 95% CI 1.6-4.7). We found only a weak association; presence of 
the UGT1A7*3 allele yielded an OR of 1.2 (95% CI 0.91-1.6), which was not statistically 
significant. However, the combination of all variant alleles revealed a significant association 
with CRC (OR 1.5, 95% CI 1.1-2.0). Furthermore, an increased risk for CRC was specifically 
observed among patients with distal CRC who had the variant UGT1A7 genotypes compared 
with subjects who had the most common genotype (OR 3.0). The differences between our 
results and those published by Strassburg et al. could be explained by the relatively low 
frequency of the UGT1A7*3 allele in their control subjects (18). In our study, the frequency 
of the UGT1A7*3 allele averaged 40% in healthy controls. This is comparable with 
frequencies of 32, 36 or 37% in Caucasian control subjects reported by Villeneuve et al., 
Guillemette et al. and Köhle et al., respectively (29, 30, 41), but is much higher than values of 
16-21%, as reported by Strassburg et al. (18, 47-49). UGT1A7 has been demonstrated to 
catalyze the glucuronidation of tobacco smoke-derived polycyclic aromatic hydrocarbons, 
such as benzo[a]pyrene, as well as dietary-derived heterocyclic amines (21, 50), all of which 
are known carcinogens. The risk factors for CRC identified here, the polymorphisms 
UGT1A7*2 and UGT1A7*3, have been shown to result in significant reduction of enzyme 
activity towards carcinogenic metabolites of benzo[a]pyrene in catalytic studies (18). Because 
these polymorphisms can result in reduced detoxification activities, accumulation of 
carcinogenic compounds, such as benzo[a]pyrene, may occur in individuals bearing variant 
UGT1A7 genotypes, which eventually may result in an increased risk for developing CRC. In 
addition, epidemiological studies showed that smoking of cigarettes is a risk factor for CRC 
with a long lag time of up to 35-40 years (51). This association between smoking and CRC 
risk may be due partly to insufficient detoxification of carcinogenic components of cigarette 
smoke by genetic polymorphisms in UGT1A7. 
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For UGT1A1 and UGT1A8 we found no difference in the distributions of the polymorphic 
variants in healthy controls compared to CRC patients. This suggests that individuals carrying 
the UGT alleles, encoding for less active enzymes do not have a higher risk for developing 
CRC. The frequency of the UGT1A1*28 allele was 33% in healthy controls. This is 
comparable with the frequencies (29-39%) reported in Caucasian control subjects by several 
other groups (40, 41, 52-54). The detected frequency of 2.5% for the UGT1A8*3 allele in 
healthy controls was similar to 2.2% as reported by Huang et al. (22).  
 
The different UGT1A isoforms investigated here are derived from one single gene locus and 
recently, frequent co-occurrence of variant alleles of UGT1A1, UGT1A6 or UGT1A7 has been 
reported (39, 41). Both UGT1A6 and UGT1A7 variant genotypes were associated with an 
increased CRC risk after adjustment for age and gender, as described above. Therefore, we 
also performed logistic regression analyses with both UGT1A6 and UGT1A7 in the 
regression model. This revealed an age- and gender adjusted OR of 1.3 (95% CI 0.85-2.1) for 
UGT1A6 and an OR of 2.0 (95% CI 0.98-3.9) for UGT1A7. This means that the UGT1A7 
polymorphism is the most important risk factor for development of CRC in comparison with 
the other UGT1A polymorphisms investigated here. 
 
In this study, similar frequencies for the homozygous GSTA1*B genotype were observed in 
controls (14%) and cases (14%), which is not consistent with the data of Coles et al. (55) that 
14% of the control subjects and 24% of the CRC patients bore this genotype. This 
discrepancy could possibly be explained by the much larger population of controls (415) and 
CRC patients (371) we examined, as compared to the 226 control and 100 case subjects 
investigated by Coles et al.. 
 
The relationship between CRC risk and GSTM1 polymorphism has been most extensively 
studied and recently, two meta-analyses have been published by de Jong et al. (16) and 
Houlston and Tomlinson (17). Both pooled analyses revealed no association of the GSTM1 
polymorphism with CRC. Our results are in accordance with these observations. In contrast, a 
significant association for GSTM1 null genotype carriers and an increased CRC risk was 
described in a recent study by Sachse et al. (15). Earlier, Zhong et al. (56) reported that the 
risk of CRC associated with GSTM1-deletion was restricted to proximal disease, but this 
association was not seen either in our study or in the meta-analyses, mentioned above (16, 
17). A striking observation was the association between GSTM1 null genotype carriers and a 
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reduced risk of Dukes A/B CRC. The primary hypothesis is that individuals with the GSTM1 
null genotypes eventually are at higher cancer risk because of reduced capacity to dispose of 
carcinogens. However, GSTM1 also plays an important role in the disposition of 
isothiocyanates (ITC), breakdown products of glucosinolates, which are abundant in 
cruciferous vegetables, and which are strong inducers of the GSTs and other detoxification 
enzymes. The GSTM1 null polymorphism, associated with reduced enzyme activity, may 
result in longer circulating half-lives of ITC and potentially greater chemopreventive effects 
of cruciferous vegetables (57). Some case-control studies provide evidence that presence of 
GSTM1 in conjunction with low intake of cruciferous vegetable is an important risk factor for 
CRC or pre-cancerous lesions (58, 59). Using ITC as biomarker of cruciferous vegetable 
exposure, Seow et al. and London et al. (60, 61) further strengthened the understanding of 
this gene-diet interaction. Seow et al. reported that high dietary ITC is associated with a 
significantly lower risk of CRC among individuals who are both GSTM1 null and GSTT1 null 
and London et al. observed that men with null genotypes of GSTM1 or GSTT1, who had 
consumed cruciferous vegetables were at lower risk for lung cancer. A similar explanation as 
given above may be valid here, and it may be hypothesized that: in early stages of CRC, ITC 
may be involved in prevention of the development of CRC in GSTM1 null or GSTT1 null 
genotype carriers. However we do not have any data on consumption of cruciferous 
vegetables by the CRC patients or controls investigated here to test this hypothesis. 
 
Several studies reported on the genetic polymorphism in codon 105 of the GSTP1 gene as a 
possible risk factor for CRC (15, 62-64). However, pooled analyses by de Jong et al. (16) and 
Houlston and Tomlinson (17) did not show an increased risk of this polymorphism for CRC, 
which is in accordance with our results. 
 
Conflicting findings have also been reported on the relationship between GSTT1 status and 
CRC (15-17). We found no association between the GSTT1 null genotype and CRC risk, in 
agreement with the results found in the meta-analysis by Houlston and Tomlinson (17). 
However, the meta-analysis by de Jong et al. (16) reported the opposite. The overall odds 
ratio for GSTT1 calculated by de Jong et al. was based on the crude data of the different 
studies, without corrections for age and gender. This may be crucial, as outlined recently by 
Butler et al. (65); crude data revealed a statistically significant association between GSTT1 
null genotype and CRC risk, whereas after adjustment for age the increased risk was not 
observed anymore. Subgroup analysis for tumour location revealed no association between 
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GSTT1 null and CRC in our study, which is in accordance with the results of the meta-
analysis by de Jong et al. (16). 
 
Our findings have to be viewed in the perspective of potential limitations. Odds ratios can 
only be calculated correctly when confounding factors, such as age, gender, diet and lifestyle 
factors, are taken into consideration. In this study we observed a statistically significant 
difference in age and gender between CRC patients and controls. By including both age and 
gender in the logistic regression analyses we corrected the calculated odds ratios for 
differences in these factors. This is necessary because younger control subjects in comparison 
to CRC patients, have a shorter time of exposure to carcinogens and thus at the moment they 
reach the age of the CRC patients, some of them may also have developed CRC. It would be 
preferable to better match control and patient populations implicating that no afterwards 
corrections is needed, but in practice it appeared very difficult to realize. In this study no 
information was available on the dietary habits, alcohol use and smoking patterns of both 
patients and controls, which may also be confounding factors. Possibly some of the low-
penetrance genes investigated here only contribute to CRC in combination with (some of) 
these dietary or lifestyle factors. 
 
Polymorphic variations in detoxification enzymes may determine in part the rates of 
conversion of toxic or carcinogenic compounds, and thus may influence their levels in the 
gastrointestinal tract. We conclude that individuals carrying the low enzyme activity 
associated genotypes of UGT1A6 and UGT1A7 might be more prone to develop CRC. It is 
hard to estimate the actual impact of a respective 1.5- and 2.4-fold increased risk, however 
these findings may guide the research to the search of relevant substrates of these enzymes, as 
important risk factors for CRC. Such factors may be components of cigarette smoke and 
heterocyclic amines, present in protein rich food such as meat. However, other UGT family 
members may compensate reduced conversion rates because detoxification enzymes possess 
overlapping substrate-specificity. Furthermore, dietary anticarcinogens are able to enhance the 
activity of detoxification enzymes. Therefore, it is also a challenge to investigate whether 
such anticarcinogens can compensate for the reduced enzyme activities caused by the genetic 
polymorphisms studied here. 
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Abstract 
 
Colorectal cancer (CRC) is one of the most common forms of cancer in Western countries. 
CRC has been associated with genetic and lifestyle factors. Individual susceptibility to CRC 
may be due partly to variations in detoxification capacity in the gastrointestinal tract. Genetic 
polymorphisms in detoxification enzymes may result in variations in detoxification activities, 
which subsequently might influence the levels of toxic/carcinogenic compounds, and this may 
influence the risk for CRC. Therefore, we determined whether polymorphisms in the genes 
coding for microsomal epoxide hydrolase (EPHX1), NAD(P)H:quinone oxidoreductase 
(NQO1), cytochrome P450 2E1 (CYP2E1) and alcohol dehydrogenase (ADH3) predispose to 
the development of CRC. DNA samples were obtained from 371 patients with sporadic CRC 
and 415 healthy controls. Patients and controls were all of Caucasian origin. All genetic 
polymorphisms were determined by polymerase chain reaction, eventually followed by 
restriction-fragment-length-polymorphism analyses, except for the EPHX1 codon 113 
polymorphism, which was genotyped by an allele-specific discrimination assay. Calculation 
of crude Odds Ratios (ORs) revealed an increased risk for CRC associated with variant NQO1 
(OR 1.5, 95% CI 1.1-2.0) and CYP2E1 intron 6 genotypes (OR 2.2, 95% CI 1.3-3.8). 
However, after adjustment for age and gender, logistic regression analyses only showed a 
statistically significant risk for CRC associated with variant NQO1 genotypes (OR 1.6,     
95% CI 1.03-2.4). No associations were found between CRC and the other polymorphic genes 
as mentioned above. In conclusion, these data suggest that the presence of variant NQO1 
genotypes, with expected reduced enzyme activities might enhance susceptibility to CRC. 
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Introduction 
 
Colorectal cancer (CRC) is one of the most common malignancies in the Western world 
showing an increasing incidence. In the Netherlands, cancer incidence rates in women are 
highest for breast cancer followed by CRC, whereas in men CRC cancer incidence rates are 
third highest after lung and prostate cancer (1). The risk of sporadic CRC is mainly associated 
with lifestyle factors and may be modulated by several genetic factors of low penetrance     
(1-6). Epidemiological studies have shown the importance of dietary habits in the risk for 
CRC. Diets low in fruit and vegetables, and high in red meat and fat are associated with an 
increased risk of CRC (3, 4). Humans may be daily exposed to a large variety of toxic or even 
carcinogenic compounds, present in food (7) or as a result of lifestyle habits such as smoking 
of cigarettes and drinking alcohol (5, 6, 8). Tumour formation may result from interaction 
between external (environmental carcinogen exposure) and internal (genetic) factors. Phase I 
and II detoxification enzymes play an important role in this process.  
 
In humans, detoxification enzymes are present at high levels in the liver. However, these 
enzymes have also been distinguished in large amounts in extra-hepatic tissues of the 
gastrointestinal tract (9-15). Variations due to genetic polymorphisms may play an important 
role in the inter-individual differences in expression levels and enzyme activities of separate 
members of these detoxification enzymes (16-18). Furthermore, genetic polymorphisms may 
result in an imbalance between Phase I and II reactions, which may lead to accumulation of 
toxic/carcinogenic compounds in the colonic lumen or mucosa. Therefore, individual 
susceptibility to CRC could be due partly to polymorphic variations in detoxification 
enzymes.  
 
The phase I enzymes, epoxide hydrolase, NAD(P)H:quinone oxidoreductase 1 (NQO1), 
cytochrome P450 (CYP) and alcohol dehydrogenase (ADH) play an important role in the 
metabolism of toxic or potentially carcinogenic compounds. In general, the metabolic 
pathways ultimately leading to detoxification consist of a number of successive reactions, 
catalyzed by phase I and phase II enzymes, respectively. Phase I enzymes hydrolyze, reduce 
or oxidize ingested chemical compounds, often leading to bioactivation into ultimate toxins or 
carcinogens. The products of phase I reactions in general however are rapidly conjugated 
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(phase II), leading to more water-soluble and biologically less active molecules that can be 
excreted.  
Microsomal epoxide hydrolases are an important group of hydrolases covering a broad 
substrate specificity, including epoxide derivates of polycyclic aromatic hydrocarbons       
(e.g. derived from tobacco smoke), anticonvulsant drugs or steroids (19). They catalyze the 
hydrolysis of highly reactive epoxides (e.g. tobacco smoke-derived benzo[a]pyrene) to 
dihydrodiols, which however, can be metabolized into highly carcinogenic polycyclic 
hydrocarbon diol epoxides. Therefore, epoxide hydrolases may play a dual role in the 
(de)toxification of procarcinogens (20).  
NAD(P)H:quinone oxidoreductase 1 (NQO1), catalyzes the two-electron reduction of 
quinones (e.g. derived from tobacco smoke or red meat), quinine-imines or azo- and nitro 
compounds to hydroquinones and thereby prevents the generation of semiquinone free 
radicals and reactive oxygen species. However, not all hydroquinones are chemically stable 
and sometimes NQO1 activity may lead to more active products, and eventually this may 
result in the production of reactive oxygen species (17).  
Cytochrome P450-mediated oxidation of pre-carcinogens to their ultimate reactive 
metabolites is a well known mechanism in chemical-induced cancer. For example, CYP2E1 
catalyzes the oxidation of ethanol to its far more toxic metabolite acetaldehyde. CYP2E1 is 
also involved in the metabolism of benzene, aniline and several components of cigarette 
smoke, such as nitrosamines (21).  
The ADH gene family (ADH1-5) encodes enzymes that metabolize a wide variety of 
substrates, including ethanol, retinol, hydroxysteroids, and lipid peroxidation products (18). 
ADH3 plays a prominent role in the oxidation of ethanol to acetaldehyde in addition to the 
above-mentioned CYP2E1. At least 80% of the ingested ethanol is metabolized by ADH3 
(18).  
Overall, the enzymes mentioned above play an important role in the toxification and 
detoxification of tobacco smoke-derived compounds and alcohol, substrates that are relevant 
in colon carcinogenesis. Epidemiological studies showed that smoking of cigarettes is a risk 
factor for CRC with a long lag time of up to 35-40 years (22). Furthermore, a pooled analysis 
of 8 cohort studies revealed that that the consumption of alcohol was associated with an 
elevated risk for CRC, mainly at the highest levels of alcohol intake (6).  
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Polymorphic variations in these detoxification enzymes, at least in part, determine the rates of 
conversion of toxic or carcinogenic compounds. In the genes encoding for the enzymes 
mentioned above polymorphisms have been described (23-28) and some have been associated 
with increased CRC susceptibility (29). In Table I the genetic polymorphisms studied here, as 
well as their functional consequences and associations with CRC as published so far (30-36) 
are summarized.  
 
Table I. Polymorphic variants of the biotransformation enzymes investigated here and their association with CRC as found 
in earlier studies 
Gene Polymorphic variation a Effect on function (ref.) Association with CRC (ref.) 
EPHX1  
   exon 3 
Y113H 40% ↓ activity (23) ↑ risk (30); ↓ risk (31) 
EPHX1  
   exon 4 
H139R 25% ↑ activity (23) No association (30, 31) 
NQO1  
   exon 6 
P187S 3× ↓ or no activity (24) ↑ risk (32); no association (31, 33) 
CYP2E1 
   5’-flanking region 
-1293G;-1053C/-1293C;-1053T  
(c1/c2) 
↑ activity (25, 26) ↑ risk (34); no association (35) 
CYP2E1 
   intron 6 
7632T/7632A  
(D/C) 
↑ activity (27) No association (35) 
ADH3 
   exon 8 
I349V 2.5× ↓ activity (28) No association (36) 
a Bold characters indicate nucleotide or amino acid changes with respect to the most common allele. 
 
Overall, for the genetic polymorphisms studied here only a few studies were performed so far 
in association with CRC, and there was little consensus. Therefore, we studied the association 
between CRC and the above-mentioned genetic polymorphisms in a large study population of 
Dutch Caucasian CRC patients.  
 
Aim 
To determine whether genetic polymorphisms in EPHX1, NQO1, CYP2E1 or ADH3 may 
modulate the development of CRC, we genotyped 371 Caucasian patients with sporadic CRC 
and 415 Caucasian healthy controls. 
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Materials and Methods 
 
Patients and control subjects 
Selection of patients and controls has been described previously (37). Briefly, the sporadic 
CRC group consists of 371 patients and for comparison a control group of 415 healthy 
subjects was recruited in the Nijmegen area, The Netherlands, by advertisement in a local 
paper. All subjects studied were Caucasians of Dutch origin. 
 
Table II. Clinical characteristics of patients with sporadic CRC and controls 
Characteristics Group Controls (%) CRC patients (%) 
Number of subjects   415 371 
Age (years; mean ± SD)  42 ± 12 64 ± 11 a 
Gender Male 168 (40.5) 212 (57.1) a 
 Female 247 (59.5) 159 (42.9) 
Location tumour b Cecum  40/310 (12.9) 
 Ascending colon  22/310 (7.1) 
 Transverse colon  17/310 (5.5) 
    Proximal     89/324 (27.5) c 
 Descending colon  8/310 (2.6) 
 Sigmoid colon  85/310 (27.4) 
 Rectosigmoid junction  40/310 (12.9) 
 Rectum  98/310 (31.6) 
    Distal     235/324 (72.5) c 
Stage tumour d Dukes A  7/293 (2.4) 
 Dukes B  103/293 (35.2) 
    Dukes A/B     112/299 (37.5) e 
 Dukes C  81/293 (27.6) 
 Dukes D  102/293 (34.8) 
    Dukes C/D      187/299 (62.5) e 
a Controls versus CRC patients, P < 0.0001. 
b For 61 CRC cases, no information on the exact location of the tumour is available. 
c For some patients only proximal or distal location was reported in the medical files. 
d For 78 cases of CRC,  no information about the exact stage of the tumour is available. 
e For some patients only stage Dukes A/B or C/D was reported in the medical files. 
 
The diagnosis of colorectal cancer was based on histopathological investigation of tissue 
specimens by a pathologist. Cases were classified according to Dukes’ stages (A, B, C, D) 
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and according to location of the tumour in the large intestine as either proximal (cecum, 
ascending or transverse colon) or distal (descending colon, sigmoid, rectosigmoid junction or 
rectum). Patients had no (family) history of CRC and suspected cases of hereditary CRC 
syndromes (i.e. hereditary non-polyposis colorectal cancer or familial adenomatous 
polyposis) were excluded. Controls had to be at least 18 years of age and were excluded when 
they had a (family) history of CRC. The study was approved by the local medical ethical 
review committee and all subjects gave their written informed consent. Relevant data of 
patients and controls are summarized in Table II. 
 
Genotyping 
DNA was extracted from either whole blood (280 cases and 415 controls) or from normal 
colorectal mucosa (91 cases) as was described previously (37). Genetic polymorphisms were 
studied using polymerase chain reaction (PCR) followed by restriction fragment length 
polymorphism (RFLP) analyses, except for the polymorphism at codon 113 of EPHX1. The 
primers and restriction enzymes used for PCR-RFLP are shown in Table III. PCR-RFLP 
assays were adapted from methods described earlier and were used to identify the 
polymorphic variants of the following genes: EHPX1 exon 4 (30), NQO1 (38), CYP2E1      
5’-flanking region and intron 6 (39) and ADH3 (40).  
 
 
Table III. Primers, beacons and restriction enzymes used for genotyping analyses  
Gene Primers/beacons (5’-3’; F = forward, R = reverse) a Restriction enzyme 
EPHX1 codon 113 F: CAA CTC CAA CTA CCT GAA G-3’ 
R: TGA CAT ACA TCC CTC TCT G-3’ 
FAM: cgc gat GAT TCT CAA CAG ATA CCC TCA CTT CAA tcg cg 
HEX: cgc gat ATT CTC AAC AGA CAC CCT CAC TTC AAt cgc g 
- 
EPHX1 codon 139 F: ACA TCC ACT TCA TCC ACG T 
R: ATG CCT CTG AGA AGC CAT    
RsaI 
NQO1 codon 187 F: GAG ACG CTA GCT CTG AAC TGA T 
R: ATT TGA ATT CGG GCG TCT GCT G 
HinfI 
CYP2EI 5’-flanking region F: CCA GTC GAG TCT ACA TTG TCA 
R: TCA TTC TGT CTT CTA ACT GGC A 
PstI / RsaI 
CYP2EI intron 6 F: GCT CGT CAG TTC TGA AAG CAG 
R: GAG CTC TGA TGC AAG TAT CGC A 
DraI 
ADH3 codon 349 F: GCT TTA AGA GTA AAT ATT CTG TCC CC 
R: AAT CTA CCT CTT TCC GAA GC 
SspI 
a Bold characters indicate linkers attached to the beacons. 
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Yoshikawa et al. reported a silent substitution polymorphism (G to A) at codon 119 of the 
EPHX1 gene (41). This polymorphism may affect the accuracy of the codon 113 genotyping 
by PCR-RFLP (30), a method also used by us to analyse our samples. Therefore, we now also 
developed a dual-colour allele-specific discrimination assay for genotyping the polymorphism 
at codon 113 of the EPHX1 gene. EPHX1 genotypes were detected using the iCycler iQ 
Multicolour Real-Time Detection System (Bio-Rad Laboratories) using molecular beacons. 
PCR was performed with the forward primer 5’-CAA CTC CAA CTA CCT GAA G-3’ and 
the reverse primer 5’-TGA CAT ACA TCC CTC TCT G-3’ in the presence of the FAM-
labeled wild-type beacon (5’-cgc gat GAT TCT CAA CAG ATA CCC TCA CTT CAA tcg 
cg-3’) and the HEX-labeled mutant beacon (5’-cgc gat ATT CTC AAC AGA CAC CCT 
CAC TTC AAt cgc g-3’; see Table III). The 25 µl reaction mixture contained 200 ng of 
genomic DNA, 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100, 4 mM MgCl2, 
0.25 mM dNTPs, 50 ng of each primer, 200 nM of each beacon and 2.5 U Taq-DNA-
polymerase. The PCR conditions were 3 min at 95°C, then 40 cycles of 30 s at 95°C, 30 s at 
59°C and 30 s at 72°C. Fluorescent signals were measured at 59°C. Genotypes were assigned 
using the iCycler iQ Optical System Software version 3.1. At each PCR run, sterile H2O was 
substituted for genomic DNA and served as a negative control for amplification.  
 
Statistical analyses 
Differences between characteristics of patients and controls were analyzed with χ2 test and 
Student’s t-test. A P-value below 0.05 was considered significant. Among the control group, 
each polymorphism was tested whether it fitted the Hardy-Weinberg equilibrium. χ2 statistics 
were used to test for differences in the distribution of the genotypes between the two study 
groups. When one of the genotypes had expected counts of less then five, we used Fisher’s 
exact test.  Odds ratios (OR) with 95% confidence interval (95% CI) were calculated by 
logistic regression analyses for genotypes associated with normal enzyme activity (common 
genotype) versus genotypes associated with expected reduced or enhanced enzyme activity 
(heterozygous and homozygous variant genotypes). Finally, the Spearman rank coefficient of 
correlation was calculated for the association between the two EPHX1 polymorphisms and the 
CYP2E1 polymorphisms, respectively. All statistical analyses were performed with SAS 
(version 8.0; SAS Institute Inc., Cary, NC, USA.). 
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Results 
 
Characteristics of patients and controls 
Descriptive statistics of CRC patients and controls are given in Table II. The variables age 
and gender differed statistically significant among CRC patients and controls. The mean age 
for cases was 64 years and for controls 42 years (P < 0.0001), and 57.1% of cases was male 
versus 40.5% of controls (P < 0.0001). 
 
Polymorphisms in genes of detoxification enzymes 
Genotype distributions of the different detoxification enzymes investigated are summarized in 
Table IV. All polymorphisms investigated were in Hardy-Weinberg equilibrium. χ2- or 
Fisher’s exact test analyses revealed a significant difference for the investigated 
polymorphisms in NQO1 (P = 0.02) and CYP2E1 intron 6 (P = 0.004) between CRC patients 
and controls.  
 
In addition, genotypes were combined on the basis of an expected phenotype-genotype 
relationship (variant genotypes with reduced or enhanced enzyme activity versus genotypes 
with normal enzyme activity) and crude ORs were calculated. In comparison with healthy 
controls, CRC patients with variant NQO1 or CYP2E1 intron 6 genotypes were more common 
(1.5- or 2.2-fold, respectively), which was statistically significant. After adjustment for age 
and gender, the risk for CRC associated with variant NQO1 or CYP2E1 intron 6 genotypes 
was 1.6 (95% CI 1.03-2.4) or 1.8 (95% CI 0.88-3.8), respectively, implicating that only the 
association of CRC with the variant NQO1 genotypes was statistically significant.  
There were no statistically significant differences between cases and controls for the other 
genotype distributions investigated here (Table IV).  
 
In addition, the co-occurrence of the two polymorphisms in EPHX1 was investigated and no 
correlation was found. For the 5’-flanking region- and intron 6 CYP2E1 polymorphisms a 
correlation was observed in CRC patients (rs = 0.36, P < 0.01) as well as in controls (rs = 0.32, 
P < 0.01), meaning that these polymorphisms are usually linked on one allele.  
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Table IV. Distribution of genotypes of biotransformation enzymes in patients with CRC and controls 
Gene Genotype Controls  
(%) a 
CRC patients  
(%) a 
Crude OR  
(95%CI) b 
Adjusted OR  
(95%CI) c 
EPHX1 codon 113 Tyr/Tyr 194/391 (49.6) 185/365 (50.7)    
   Tyr/His 165 (42.2) 141 (38.6)   
 His/His 32 (8.2) 39 (10.7) 0.96 (0.72-1.3) 1.0 (0.70-1.5) 
EPHX1 codon 139 His/His 269/414 (65.0) 241/371 (65.0)   
   His/Arg 128 (30.9) 106 (28.6)   
 Arg/Arg 17 (4.1) 24 (6.5) 1.0 (0.75-1.3) 0.99 (0.66-1.5) 
NQO1 codon 187 Pro/Pro 292/415 (70.4) 225/369 (61.0) d   
   Pro/Ser 112 (27.0) 134 (36.3)   
 Ser/Ser 11 (2.7) 10 (2.7) 1.5 (1.1-2.0) e 1.6 (1.03-2.4) e 
CYP2E1 5’-flanking region c1c1 389/412 (94.4) 333/357 (93.3)   
   c1c2 21 (5.1) 23 (6.4)   
 c2c2 2 (0.5) 1 (0.3) 1.2 (0.68-2.2) 1.1 (0.48-2.4) 
CYP2E1 intron 6 DD 388/410 (94.6) 324/365 (88.8) f   
   DC 19 (4.7) 38 (10.4)   
 CC 3 (0.7) 3 (0.8) 2.2 (1.3-3.8) e 1.8 (0.88-3.8) 
ADH3 codon 349 Ile/Ile 144/385 (37.4) 113/320 (35.3)   
   Ile/Val 186 (48.3) 149 (46.6)   
 Val/Val 55 (14.3) 58 (18.1) 1.1 (0.80-1.5) 0.83 (0.54-1.3) 
a In both the CRC and control group there are some missing data because of insufficient amount of DNA or unsuccessful 
PCR.  
b Genotypes were combined on the basis of an expected phenotype-genotype relationship (heterozygous and homozygous 
variant genotypes with reduced or enhanced enzyme activity versus common genotypes with normal enzyme activity) and 
crude ORs were calculated.  
c OR adjusted for age and gender were calculated.  
d P = 0.02.  
e Statistically significant.  
f P = 0.004. 
 
Next, the occurrence of various combinations of EPHX1 codon 113 and codon 139 genotypes 
or imputed EPHX1 phenotypes were considered in CRC patients and controls (see Table V; 
classification of expected phenotypes was performed according to Ulrich et al. (42). Only the 
combination of homozygous variant codon 139 with any genotype of codon 113 of EPHX1 
revealed a statistically significant increased risk for CRC (OR 1.3, 95% CI 1.04-1.5). In 
addition, the codon 139 homozygous variant genotype, compared to most common genotype 
showed a slightly increased risk for CRC, although results were not statistically significant 
(OR 1.5, 95% CI 0.97-2.4).  
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Table V. Risk of CRC associated with EHPX1 genotypes and imputed EPHX1 phenotypes 
Gene a Cases/Controls b Adjusted OR (95%CI) c 
EPHX1 codon 113   
   Tyr/Tyr (MC) 185/194 1.0 (reference) 
   Tyr/His (heterozygous) 141/165 1.0 (0.69-1.6) 
   His/His (homozygous variant) 39/32 0.99 (0.71-1.4) 
EPHX1 codon 139   
   His/His (MC) 241/269 1.0 (reference) 
   His/Arg (heterozygous) 106/128 0.85 (0.56-1.3) 
   Arg/Arg (homozygous variant) 24/17 1.5 (0.97-2.4) 
Combined EPHX1 genotypes   
   MC/MC 119/130 1.0 (reference) 
   MC codon 113 / heterozygous codon 139 51/55 1.2 (0.64-2.2) 
   MC codon 139 / heterozygous codon 113 94/110 1.2 (0.90-1.5) 
   Double heterozygous 42/49 0.96 (0.77-1.2) 
   Homozygous variant codon 113 / MC or heterozygous codon 139 36/30 1.0 (0.85-1.2) 
   Homozygous variant codon 139 / any genotype codon 113 23/16 1.3 (1.04-1.5) d 
Imputed EPHX1 phenotypes   
   Rapid 67/63 1.5 (0.86-2.6) 
   Normal 160/178 1.0 (reference) 
   Slow 94/109 1.4 (0.86-2.4) 
   Very slow 25/14 1.2 (0.73-1.9) 
MC; most common.  
a Genotypes and phenotypes as classified by Ulrich et al. (42).  
b In both the CRC and control group there are some missing data because of insufficient amount of DNA or  
unsuccessful PCR.  
c OR adjusted for age and gender were calculated.  
d Statistically significant. 
 
 
We also investigated potential associations of genotype distributions of the different 
detoxification enzymes with clinical characteristics, such as tumour location and tumour stage 
(Table VI). These data revealed statistically significant associations of variant NQO1 
genotypes with distal CRC (adjusted OR 1.6, 95% CI 1.03-2.6) and of variant CYP2E1   
intron 6 genotypes and Dukes C/D CRC (adjusted OR 2.2, 95% CI 1.01-5.0). 
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Table VI. Distribution of genotypes of different biotransformation enzymes with respect to tumour location and tumour stage in patients 
with CRC  
Gene Genotype Proximal CRC (%) a Distal CRC (%) a CRC Dukes A/B (%) a CRC Dukes C/D (%) a 
EPHX1 codon 113 Tyr/Tyr 43/87 (49.4) 121/232 (52.2)  61/110 (55.5) 83/184 (45.1) 
   Tyr/His 33 (37.9) 89 (38.4) 37 (33.6) 82 (44.6) 
 His/His 11 (12.6) 22 (9.5) 12 (10.9) 19 (10.3) 
EPHX1 codon 139 His/His 52/89 (58.4) 160/235 (68.0) 76/112 (67.9) 125/187 (66.8) 
   His/Arg 34 (38.2) 59 (25.1) 28 (25.0) 53 (28.3) 
 Arg/Arg 3 (3.4) 16 (6.8) 8 (7.1) 9 (4.8) 
NQO1 codon 187 Pro/Pro 51/89 (57.3) b 146/233 (62.7) c, d 67/112 (59.8) 117/185 (63.2) 
   Pro/Ser 37 (41.6) 79 (33.9) 39 (34.8) 65 (35.1) 
 Ser/Ser 1 (1.1) 8 (3.4) 6 (5.4) 3 (1.6) 
CYP2E1  5’-flanking region c1c1 78/85 (91.8) 212/228 (93.0) 103/109 (94.5) 168/179 (93.8) 
   c1c2 6 (7.1) 16 (7.0) 5 (4.6) 11 (6.2) 
 c2c2 1 (1.1) 0 (0) 1 (0.9) 0 (0) 
CYP2E1 intron 6 DD 72/88 (81.8) e 210/231 (90.9)  95/111 (85.6) f 165/184 (89.7) c, d, g 
 DC 15 (17.1) 20 (8.7) 15 (13.5) 17 (9.2) 
 CC 1 (1.1) 1 (0.4) 1 (0.9) 2 (1.1) 
ADH3 codon 349 Ile/Ile 25/71 (35.2) 72/209 (34.4) 39/102 (38.2) 56/157 (35.7) 
   Ile/Val 29 (40.9) 103 (49.3) 48 (47.1) 72 (45.8) 
 Val/Val 17 (23.9) 34 (16.3) 15 (14.7) 29 (18.5) 
a (%: number/total); Among cases there are some missing data because of insufficient amount of DNA or unsuccessful PCR.  
b P = 0.02.  
c Genotypes were combined on the basis of an expected phenotype-genotype relationship (variant genotypes with reduced or enhanced 
enzyme activity versus genotypes with normal enzyme activity) and statistically significant ORs adjusted for age and gender were calculated.  
NQO1: Distal CRC 1.6 (1.03-2.6); CYP2E1 intron 6: CRC Dukes C/D 2.2 (1.01-5.0). 
d Statistically significant.  
e P < 0.0001.  
f P = 0.003. 
g P = 0.04. 
 
 
Discussion 
 
In the present study we investigated the relationship between sporadic CRC and 
polymorphisms in genes coding for EPHX1, NQO1, CYP2E1 and ADH3 that are all 
associated with functional changes in enzyme activity for substrates relevant in colon 
carcinogenesis. Up till now, controversial data have been provided by different studies 
investigating the EPHX1 Y113H polymorphism in relation to CRC (30, 31; see Table I). In 
the present study, no association between variant genotypes for the EPHX1 codon 113 
polymorphism and CRC risk was found. In accordance, three recent studies (43-45) found a 
similar association between this polymorphism and occurrence of colorectal adenomas. With 
respect to the EPHX1 codon 139 polymorphism, our results are similar to those of Harrison et 
  90
al. (30) and Sachse et al. (31). Furthermore, no association with tumour location or Dukes’ 
stage was found for both EPHX1 polymorphisms studied here, whereas Harrison et al. (30) 
showed the His113 allele to be present significantly more often in the left-sided colon cancer 
group compared with controls.  
It is unclear, whether the reported risk estimates by Harrison et al. were adjusted for any 
covariates, which may explain in part the discrepancy found for the codon 113 polymorphism 
in the various studies as discussed above. In addition, the genotype distribution for this 
polymorphism in the control subjects of Harrison et al. as calculated by us, was not in Hardy-
Weinberg equilibrium (χ2 = 4.2, P = 0.04). This deviation may be explained by a genotyping 
error, since Yoshikawa et al. (41) reported that the accuracy of the genotyping method for the 
EPHX1 codon 113 polymorphism as used by Harrison et al., might be influenced by a silent 
polymorphism in codon 119 (AAG119AAA). The reverse primer used for genotyping of the 
codon 113 polymorphism by the PCR-RFLP assay used by Harrison et al. includes this area. 
In Tyr113/His113 heterozygotes this primer mismatch may result in failure of the Tyr113 
allele to amplify, leading to a false genotype classification of His113/His113. Baxter et al. 
(46) and Gsur et al. (47) confirmed the existence of this codon 119 polymorphism in 
Caucasians. The presence of this polymorphism has serious consequences for the reliability of 
the conventional PCR-RFLP method. Baxter et al. and Gsur et al. reported that 37.8% and 
43.8%, respectively, of their heterozygotic controls were falsely classified as His113 
homozygotes. We therefore genotyped our patients and controls for the EPHX1 codon 113 
polymorphism by the allele-specific discrimination assay as described under Materials and 
Methods, as well as by the PCR-RFLP assay as described by Harrison et al. (30), and found 
that 50.7% of the heterozygotic patients and 64.8% of the heterozygotic controls were 
misclassified as His113 homozygotes (data not shown). In the present study, the genotype 
frequency of His113 homozygotes among controls was 8.2%, which is similar to frequencies 
reported in other studies on Caucasian populations that used allele-specific discrimination 
assays (42, 46-49). To our knowledge, the majority of previous studies on the EPHX1     
codon 113 polymorphism rates have been conducted using the PCR-RFLP assay (30, 31, 43, 
50) and consequently the validity of these studies must be questioned, especially when 
deviations from the Hardy-Weinberg equilibrium are present. To date, some studies have been 
published that used allele-specific discrimination assays for genotyping the EPHX1 codon 
113 polymorphism, and most studies contain data that obey the Hardy-Weinberg equilibrium, 
except for the recent study by Tranah et al. (45). Here, the reverse primer covers the silent 
polymorphism in codon 119, and similar to the conventional PCR-RFLP assay by Harrison et 
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al. (30), this may result in a primer mismatch and subsequently lead to a falsely high 
His113/His113 genotype rate of 17.1%.  
Based on the in vitro studies of Hassett et al. (23), we assumed that the alleles corresponding 
with the protein sequences EPHX1 113Y and 139R are associated with a higher total EPHX1 
enzyme activity. However, other polymorphic variants in the 5’-flanking promoter region of 
EPHX1 have been identified, which may also influence enzyme activity (51).  
 
Earlier studies (31-33; see Table I) reported contrary results on an association of CRC with 
the NQO1 P187S polymorphism. When combining genotypes with an expected reduced 
enzyme activity (heterozygous and homozygous Ser187 variants; ref. 24), we found an 
increased CRC risk (OR 1.6, 95% CI 1.03-2.4) associated with these variant genotypes, which 
was comparable with the OR reported by Lafuente et al. (OR 1.4, 95% CI 1.02-1.9; ref. 32). 
Furthermore, in contrast to Lafuente et al., we showed that this increased risk was seen 
particularly in patients with distal CRC (adjusted OR 1.6, 95% CI 1.03-2.6). Although a 
significant association between NQO1 genotypes and CRC risk was found by us and  
Lafuente et al. (32), two other studies did not find such an association (31, 33). Therefore, the 
contribution of the NQO1 polymorphism to the individual susceptibility to CRC remains 
unclear. 
 
Thus far, two studies investigated the CYP2E1 5’-flanking region polymorphisms in 
association with CRC (34, 35; see Table I). Like Butler et al. (35), we found no difference in 
genotype distribution in healthy controls compared to CRC patients. This suggests that 
individuals carrying the c2 alleles, encoding for more active enzymes do not have a higher 
risk for developing CRC. In the present study, the frequency of the c2 allele in healthy 
controls was 3%, which is similar to the frequencies reported in Caucasian control subjects of 
several other studies (35, 52-54). However, Kiss et al. (34) reported much higher c2 allele 
frequency in Hungarian control subjects (14%), which may explain the statistically significant 
difference in genotype distribution between cases and controls in this study. Inheritance of 
variant CYP2E1 intron 6 genotypes conferred a 2.2-fold risk for CRC, which was statistically 
significant when applying the crude data, but lost significance after adjustment for age and 
gender. This confirmed the results reported by Butler et al. (35; see Table I). However, the 
variant CYP2E1 intron 6 genotypes were associated significantly with Dukes C/D tumour 
stages (adjusted OR 2.2 95% CI 1.01-5.0) in this study. 
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Yet, only three studies on the relationship between ADH3 polymorphisms and colorectal 
neoplasia, adenomas (55, 56) or carcinomas (36; see Table I) have been published. Overall, 
these data suggest that the ADH3 polymorphisms do not confer a significant risk for 
colorectal neoplasia. We obtained similar results for this polymorphism and CRC risk. 
Frequencies of the Ile349 and Val349 alleles among controls were 62 and 38%, respectively, 
which are similar to frequencies reported in other Caucasian populations (36, 53, 55, 56). 
 
Our findings have to be viewed in the perspective of potential limitations. First, odds ratios 
can only be calculated correctly, when confounding factors, such as age, gender, diet and 
lifestyle factors, are taken into consideration. In this study we observed a statistically 
significant difference in age and gender between CRC patients and controls. By including 
both age and gender in the logistic regression analyses we corrected the calculated odds ratios 
for differences in these factors. This is necessary because the younger control subjects, in 
comparison to the CRC patients, have a shorter time of exposure to carcinogens and thus at 
the moment they reach the age of the CRC patients, some of them may also have developed 
CRC. It would be preferable to better match control and patient populations, but in daily 
practice this appeared very difficult to realize. Secondly, despite the fact that the present study 
is one of the largest studies in its sort so far, we realize that the sample size may be too small 
to perform extensive subgroup analyses, and we realize that the multiple comparisons we 
performed may increase the risk of chance findings. Therefore, it is important to verify results 
by other studies. Finally, for the participants of our study, no information was available on 
dietary habits, alcohol use and smoking patterns, which may also be confounding factors. 
Possibly some of the low-penetrance genes investigated here only contribute to CRC in 
combination with (some of) these dietary or lifestyle factors.  
 
Polymorphic variations in the detoxification enzymes may determine in part the conversion 
rates of toxic or carcinogenic compounds and thus may influence their levels in the 
gastrointestinal tract. We conclude that carriers of the low enzyme activity associated 
genotypes of NQO1 might be more prone to develop CRC. It is hard to estimate the actual 
impact of a respective 1.6-fold higher risk, because members of other detoxification enzymes 
may compensate reduced conversion rates. In addition, the combination of genetic 
polymorphisms in different enzymes may result in higher CRC risk as compared to a single 
polymorphism. Recently, Hou et al. (57) observed that polymorphisms in CYP1A1 (I462V) or 
NQO1 (P187S) were weakly associated with risk for colorectal adenoma. However, 
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individuals carrying the CYP1A1 Val462 and NQO1 Ser187 alleles showed an increased risk 
(OR 2.2, 95% CI 1.1-4.5), particularly among recent and heavy cigarette smokers. This 
finding points to involvement of several tobacco smoke-derived benzo[a]pyrene metabolic 
pathways in colorectal carcinogenesis. It is well known that phase II enzymes such as 
glutathione S-transferases (GSTs) and UDP-glucuronosyltransferases are also involved in the 
metabolism of tobacco smoke-derived benzo[a]pyrene. For example, GSTs catalyze the 
conjugation of glutathione to epoxides and diol-epoxide, which are formed in phase I 
reactions catalyzed by the enzymes under study here. Finally, (dietary) anticarcinogens are 
able to enhance the activity of detoxification enzymes and it is a challenge to investigate 
whether such anticarcinogens can reduce the number of patients with CRC in future.  
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Abstract 
 
Impaired metabolism of ingested toxic or carcinogenic compounds is a postulated mechanism 
underlying colorectal cancer (CRC). Furthermore, it is suggested that reactive oxygen species 
(ROS) may play a role in human cancer development. Polymorphic variations in NAD(P)H 
oxidase p22phox and paraoxonase 1 (PON1) enzyme activities may alter superoxide production 
or the rate of chemical metabolism, respectively and this may influence the risk for CRC. 
Therefore, this study was designed to determine whether distribution of polymorphisms in 
NAD(P)H oxidase p22phox and PON1 genes was different in sporadic CRC patients versus 
healthy controls. The study participants (365 cases and 354 controls) were all of Caucasian 
origin. NAD(P)H oxidase p22phox H72Y, and PON1  L55M and Q192R polymorphisms were 
genotyped by polymerase chain reaction, eventually followed by restriction-fragment-length-
polymorphism analyses. Comparison of CRC patients and controls revealed no significant 
differences in genotype distributions or allele frequencies for polymorphisms in the NAD(P)H 
oxidase p22phox and PON1 genes. Investigation of potential associations between the variant 
NAD(P)H oxidase p22phox or PON1 alleles and the clinical characteristics, tumour location or 
tumour stage, also did not reveal statistically significant associations. In conclusion, variant 
genotypes of NAD(P)H oxidase p22phox and PON1 do not contribute to the susceptibility of 
CRC. 
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Introduction 
 
The aetiology of colorectal cancer (CRC) remains elusive. It is estimated that up to 10% of 
CRC cases can be attributed to hereditary factors of high penetrance (1) leaving 
approximately 90% so-called sporadic CRC cases, which may be attributed to diet (2), 
lifestyle factors (3, 4) and genetic factors of low penetrance (5). Genetic predisposition to 
CRC may involve polymorphic variations in genes encoding for detoxification enzymes. 
Genetic variations in these enzymes may alter the conversion rate of toxic/carcinogenic 
compounds ingested by food, medication or lifestyle habits (e.g. smoking), which 
subsequently might influence the levels of these compounds in the colonic lumen or mucosa, 
possibly altering the risk for CRC. In addition, it is suggested that reactive oxygen species 
(ROS) may also play a role in human cancer development (6-8). ROS may induce cellular 
changes characteristic of those produced by known carcinogens (7). Phagocytosis by 
polymorphonuclear leukocytes results in the release of ROS, referred to as the respiratory 
burst, which plays an important role in host defence against certain micro-organisms. 
However, excessive generation of ROS by these phagocytes may cause harm to surrounding 
tissue and this may influence the risk for CRC (9). 
 
The NAD(P)H oxidase enzyme is involved in the production of large quantities of superoxide 
during the respiratory burst of activated phagocytes. However, not only phagocytes, but also 
non-phagocytic cells, such as endothelial cells, vascular smooth muscle cells, cultures of 
transformed colonic epithelial cells or primary colonic epithelial cells, may produce 
superoxide (10, 11). In non-phagocytic cells, superoxide has been suggested to act as a 
regulator of genes involved in proliferation, apoptosis and inflammation (12). NAD(P)H 
oxidase is a membrane bound enzyme complex, which consists of a transmembrane electron 
transporting component, comprising a catalytic subunit cytochrome b558, consisting of 
gp91phox and p22phox (13). In the p22phox gene a C242T polymorphism has been identified that 
substitutes histidine by tyrosine at codon 72 (11). This may result in 72H homozygotes with 
normal enzyme activity, and heterozygotes or 72Y homozygotes both with diminished 
enzyme activity (14). These variations in NAD(P)H oxidase p22phox genotypes eventually 
could lead to different amounts of superoxide in the colonic lumen or mucosa, which actually 
may influence the risk for CRC. 
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Paraoxonase 1 (PON1) is an esterase that is widely distributed among tissues such as liver, 
kidney and intestine, but also is present in blood plasma, where it is associated with high-
density lipoproteins (HDL; refs. 15, 16). The PON family (PON1-3) enzymes are hydrolases 
with a broad substrate specificity (17). The PON1 protein was identified first and, therefore, 
has been most studied. PON1 is a phase I detoxification enzyme that hydrolyzes 
organophosphates, such as the insecticides paraoxon and chlorpyriphos, and nerve agents 
such as sarin or soman (18). It also hydrolyzes aliphatic lactones, like dihydrocoumarin and 
homocysteine-thiolactone (19, 20). Furthermore, PON1 inactivates lipoxidation derivatives of 
low-density lipoprotein (LDL; refs. 15, 21, 22). In summary, PON1 can offer protection 
against toxic environmental agents, as well as endogenous products of oxidative stress. In the 
PON1 gene two common functional polymorphisms, L55M and Q192R, have been described, 
both of which may affect serum paraoxonase activity. PON1-55L is correlated with higher 
PON1 activity and mRNA levels than PON1-55M (23, 24), possibly caused by a decreased 
stability of the PON1-55M protein (25). The Q192R polymorphism results in substrate-
dependent differences in the kinetics of hydrolysis of various substrates. The PON1-192R 
allele is associated with a higher activity to hydrolyze paraoxon, whereas the efficiency to 
hydrolyze sarin, diazoxon or lactones was lower compared with the PON1-192Q allele (18, 
26). In addition, the Q192R polymorphism also alters the ability of the enzyme to protect 
LDL from oxidation, the PON1-192Q allele being most protective (27). Since PON is a HDL-
associated enzyme many studies have investigated the relationship between PON1 
polymorphisms and coronary heart disease (28) and atherosclerosis (29). Although PON is 
also known to play a role in the detoxification of toxic/carcinogenic compounds and, 
therefore, may influence susceptibility to cancer, data on its association with cancer are rare. 
Kerridge et al. (30) were the first to demonstrate an association between PON1 
polymorphisms and cancer in humans: the homozygous variant PON1-192R genotype was 
significantly more often present in non-Hodgkin’s lymphoma cases compared with control 
subjects. Furthermore, Akcay et al. found lower PON serum levels in patients with pancreatic 
(31) or gastric cancer (32) than in healthy controls, which suggests that PON may play a role 
in the aetiology of gastrointestinal cancer.  
 
Polymorphic variations in NAD(P)H oxidase p22phox and PON1 enzymes may alter 
superoxide production or conversion rates of toxic/carcinogenic compounds, respectively, and 
this may influence the risk for CRC. Therefore, this study was designed to determine whether 
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sporadic CRC patients have another distribution of polymorphisms in NAD(P)H oxidase 
p22phox and PON1 genes as compared to healthy controls.  
 
 
Materials and Methods 
 
Patients and control subjects 
Selection of patients and controls has been described previously (33). Briefly, the sporadic 
CRC group consists of 365 patients (209 males, 156 females; mean age 64 ± 11 years) and for 
comparison a control group of 354 healthy subjects (144 males, 210 females; mean age 43 ± 
13 years) was recruited by advertisement in a local paper. All subjects studied were 
Caucasians of Dutch origin. Relevant data of patients and controls are summarized in Table I. 
 
DNA isolation 
DNA was extracted from either whole blood (276 cases and 354 controls) or normal 
colorectal mucosa (89 cases), as described previously (33). Cases were classified according to 
Dukes’ stages (A, B, C, D) and according to location of the tumour in the large intestine as 
either proximal (cecum, ascending or transverse) or distal (descending, sigmoid, rectosigmoid 
junction or rectum).  
 
Genotyping 
The genetic polymorphisms in p22phox and PON1 genes were analyzed using polymerase 
chain reaction (PCR) followed by restriction-fragment-length-polymorphism (RFLP) 
analyses. Detection of the H72Y substitution in the p22phox gene was based on the method 
described by Inoue et al. (11). In short, the forward and reverse primers used were: 5’-TGC 
TTG TGG GTA AAC CAA GGC CGG TG-3’ and 5’-AAC ACT GAG GTA AGT GGG 
GGT GGC TCC TGT-3’, respectively. The PCR conditions were 5 min at 95ºC, then 35 
cycles of 30 s at 95ºC, 40 s at 58ºC, and 40 s at 72ºC, and finally an elongation step at 72ºC 
for 5 min. Digestion of the PCR product with the restriction enzyme RsaI was followed by 
separation on 2% agarose. A 348-bp fragment indicates the 72H-allele, whereas fragments of 
188- and 160-bp are indicative for the 72Y-allele.  
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Table I. Clinical characteristics of patients with sporadic CRC and controls 
Characteristics Group Controls (%) CRC patients (%) 
Number of subjects  354 365 
Age (years; mean ± SD)  43 ± 13 64 ± 11 a 
Gender Male 144 (40.7) 209 (57.3) a 
 Female 210 (59.3) 156 (42.7) 
Location tumour b Cecum  40/307 (13.0) 
 Ascending colon  22/307 (7.2) 
 Transverse colon  17/307 (5.5) 
    Proximal     88/319 (27.6) c 
 Descending colon  8/307 (2.6) 
 Sigmoid colon  84/307 (27.4) 
 Rectosigmoid 
junction 
 41/307 (13.4) 
 Rectum  95/307 (30.9) 
    Distal     231/319 (72.4) c 
Stage tumour d Dukes A  7/287 (2.4) 
 Dukes B  101/287 (35.2) 
    Dukes A/B     110/293 (37.5) e 
 Dukes C  79/287 (27.5) 
 Dukes D  100/287 (34.8) 
    Dukes C/D      183/293 (62.5) e 
a Controls versus CRC patients, P < 0.0001. 
b For 58 CRC cases, no information on the exact location of the tumour is available. 
c For some patients only proximal or distal location was reported in the medical files. 
d For 78 cases of CRC,  no information about the exact stage of the tumour is available. 
e For some patients only stage Dukes A/B or C/D was reported in the medical files. 
 
The polymorphisms in the PON1 gene corresponding with amino acid substitutions at the 
codons 55 and 192 were determined according to Humbert et al. (34). The forward and 
reverse primers used for detection of the L55M substitution were: 5’-GAA GAG TGA TGT 
ATA GCC CCA-3’ and 5’-TTT AAT CCA GAG CTA ATG AAA GCC-3’, respectively. The 
PCR conditions were 4 min at 95ºC, then 35 cycles of 30 s at 95ºC, 1 min at 56ºC, and 1 min 
at 72ºC, and finally an elongation step at 72ºC for 7 min. Digestion with NlaIII resulted in a 
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non-digested 170-bp PCR product indicative for the 55L-allele and 126- and 44-bp fragments 
for the 55M-allele.  
For detection of the Q192R substitution, we used the forward primer: 5’-TAT TGT TGC TGT 
GGG ACC TGA G-3’ and reverse primer: 5’-CAC GCT AAA CCC AAA TAC ATC TC-3’.  
Except for the annealing temperature, which was 54ºC for 1 min, similar PCR conditions 
were used as described for detection of the L55M substitution. Digestion with AlwI yielded a 
non-digested 99-bp fragment indicative for the 192Q-allele and 66- and 33-bp fragments for 
the 192R-allele. Digested PCR products of the two PON1 polymorphisms were separated on 
3% agarose and visualized using ethidium bromide. At each PCR run, sterile H2O was run in 
parallel with genomic DNA samples and served as negative control for amplification. 
 
Statistical analyses 
Differences between characteristics of patients and controls were analyzed with χ2 test and    
t-test. A P-value below 0.05 was considered significant. All genotypes investigated among 
controls were tested to find out whether they were distributed according to the Hardy-
Weinberg equilibrium. χ2 statistic was used to test for differences in genotype distribution and 
allele frequencies between the two study groups. Odds ratios (OR) with 95% confidence 
interval (95% CI) were calculated by logistic regression analyses, taking into account 
confounding factors such as age and gender. Finally, the Spearman rank coefficient of 
correlation was calculated for the association between the two PON1 polymorphisms. All 
statistical analyses were performed using SPSS (version 12.0; SPSS Inc., Chicago, USA). 
 
 
Results 
 
Descriptive statistics of CRC patients and controls are given in Table I. The mean age of CRC 
patients (64 ± 11 years) was higher compared to that of the control group (43 ± 13 years;       
P < 0.0001). Subsequently, there was a statistically significant difference in gender between 
CRC patients and healthy controls, with more female subjects in the control group                
(P < 0.0001). For all polymorphisms investigated, the distribution of the allele frequencies 
among the control subjects was tested and found to be in Hardy-Weinberg equilibrium. 
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No differences in genotype distribution were observed for the three polymorphisms 
investigated between CRC patients and controls (Table II). The allele frequencies also 
showed no statistical differences between the two study groups (Table III).  
 
Table II. Distribution of p22phox and PON1 genotypes in patients with CRC and controls 
Gene Genotype Controls  
(%) a 
CRC patients  
(%) a 
Crude OR  
(95%CI) b 
Adjusted OR  
(95%CI) c 
p22phox HH 169/336 (50.3) 177/365 (48.5)   
 HY 137 (40.8) 148 (40.5)   
 YY 30 (8.9) 40 (11.0) 1.1 (0.80-1.4)  1.2 (0.80-1.8)  
PON1-55 LL 140/352 (39.8) 139/364 (38.2)   
 LM 162 (46.0) 166 (45.6)   
 MM 50 (14.2) 59 (16.2) 1.1 (0.79-1.4) 1.1 (0.73-1.6) 
PON1-192 QQ 158/295 (53.6) 180/354 (50.8)   
 QR 120 (40.7) 150 (42.4)   
 RR 17 (5.8) 24 (6.8) 1.1 (0.82-1.5) 1.1 (0.76-1.7) 
a In both the CRC and control group there are some missing data because of insufficient amount of  
DNA or unsuccessful PCR. 
b Genotypes were combined on the basis of an expected phenotype-genotype relationship (variant  
genotypes with reduced or enhanced enzyme activity versus genotypes with normal enzyme activity)  
and crude OR were calculated. Starting from paraoxon as substrate, phenotype-genotype relationships  
for the PON1 polymorphisms were estimated (23).  
c OR adjusted by age and gender were calculated. 
 
Table III. Allele frequencies of p22phox and PON1 in patients with CRC and controls 
Alleles Controls  
(number/total) a 
CRC patients  
(number/total) a 
Crude OR  
(95% CI) b  
Adjusted OR  
(95% CI) c 
p22phox 72H 0.71 (475/672) 0.69 (502/730)   
p22phox 72Y 0.29  0.31 1.1 (0.87-1.4) 1.1 (0.93-1.3) 
PON1 55L 0.63 (442/704) 0.61 (444/728)   
PON1 55M 0.37 0.39 1.1 (0.87-1.3) 1.1 (0.94-1.2) 
PON1 192Q 0.74 (436/590) 0.73 (510/708)   
PON1 192R 0.26 0.27 1.1 (0.86-1.4) 1.1 (0.91-1.3) 
a In both the CRC and control group there are some missing data because of insufficient amount of  
DNA or unsuccessful PCR. 
b Crude OR were calculated. 
c OR adjusted by age and gender were calculated. 
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We also investigated potential associations between allele frequencies of the detoxification 
enzymes and clinical characteristics of the patients, such as tumour location and tumour stage, 
and results are summarized in Table IV. These data only reveal a borderline association of the 
variant PON1-55M allele with distal CRC, age- and gender-adjusted OR 1.1, 95% CI 0.98-
1.3. No relationship was found between allele frequencies of the investigated enzymes and 
tumour stage. 
 
Table IV. Allele frequencies of p22phox and PON1 with respect to tumour location and tumour stage 
in patients with CRC  
Gene Proximal CRC 
(number/total) a 
Distal CRC  
(number/total) a 
CRC Dukes A/B 
(number/total) a 
CRC Dukes C/D 
(number/total) a 
p22phox 72H 0.67 (117/176) 0.70 (321/462) 0.70 (154/220) 0.68 (250/366) 
p22phox 72Y 0.33 0.30 0.30 0.32 
PON1 55L 0.63 (111/176) 0.59 (273/460) b 0.61 (134/220) 0.64 (235/366) 
PON1 55M 0.37 0.41 0.39 0.36 
PON1 192Q 0.71 (120/168) 0.74 (331/450) 0.72 (157/218) 0.73 (257/354) 
PON1 192R 0.29 0.26 0.28 0.27 
a There are some missing data because of insufficient amount of DNA or unsuccessful PCR. 
b OR adjusted by age and gender were calculated. PON1-55: Distal CRC 1.1 (0.98-1.3). 
 
Finally, the co-occurrence of the PON1-55 and PON1-192 polymorphisms was investigated. 
A negative correlation was found in both patients (rs = -0.29, P < 0.01) and controls              
(rs = -0.37, P < 0.01). Thus, the PON1-55M and PON1-192Q polymorphisms, both associated 
with low enzyme activity, are usually linked on one allele. This combination of PON1 
polymorphisms was not distributed differently between CRC patients and healthy controls. 
 
 
Discussion 
 
It is generally accepted that inter-individual differences in genetic factors of low penetrance 
and environmental exposures may influence the risk for CRC (35). Polymorphisms in genes 
encoding for detoxification enzymes may be of importance in susceptibility to toxic or 
carcinogenic environmental chemicals (5, 36). In addition, there is increasing evidence that 
ROS may also play a role in human cancer development (6-8).  To investigate the role of 
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NAD(P)H oxidase and paraoxonase enzymes in colorectal carcinogenesis, we determined the 
frequencies of NAD(P)H oxidase p22phox and PON1 gene polymorphisms in healthy controls 
and patients with sporadic CRC. The observed frequencies of the variants of p22phox and 
PON1 in our control population are in full agreement with the corresponding data from 
several other studies (14, 17, 30, 37, 38).  
 
Perner et al. (10) concluded that superoxide, released in epithelial cells isolated from the 
normal human colon by NAD(P)H oxidases expressing the p22phox subunit, can contribute to 
the maintenance of normal colonic barrier. Knowing this, it may be hypothesized that 
polymorphisms in NAD(P)H oxidase p22phox can contribute to an increased risk of colon 
cancer, but the results of this study do not confirm this hypothesis. The p22phox-72Y 
homozygotes, however, may have only diminished and not a complete loss of enzyme activity 
(14), and this reduced enzyme activity can still be sufficient to maintain the normal colonic 
barrier. 
 
Since, it has been demonstrated that polymorphisms affecting amino acid substitutions at 
positions 55 and 192 are associated with marked alterations of PON1 serum concentrations 
(23, 24) and PON1 serum levels were reported to modulate susceptibility towards 
gastrointestinal cancers (31, 32), we investigated the relationship between PON1 
polymorphisms and CRC. No differences were observed for genotype distributions and allele 
frequencies between patients and controls, except for a trend towards a slightly increased risk 
for distal CRC in individuals bearing the PON1-55M allele. The PON1-55M variant is 
associated with a reduced enzyme activity (23, 24), which could mean that the conversion rate 
of carcinogenic compounds is decreased and that these compounds may accumulate in the 
colonic lumen. Nevin et al. (16) reported that the PON1 genotype accounts for 76% of the 
variation in serum PON enzyme activity level. In addition, PON1 serum levels are modulated 
by disease state, dietary-, lifestyle- and environmental factors and, therefore, may vary up to 
13-fold between individuals (17, 39). Moreover, human studies characterizing the PON1 
polymorphisms have indicated the importance of estimating the PON1 status (i.e. genotype 
and phenotype taken together) rather than genotyping alone (40). Unfortunately, no serum 
was available from the majority of our patients, so we were unable to measure serum PON1 
enzyme activities.  
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Our findings have to be viewed in the perspective of potential limitations. Odds ratios can 
only be calculated correctly when confounding factors, such as age, gender, diet and other 
lifestyle factors are taken into consideration. In this study we observed a statistically 
significant difference in age and gender between CRC patients and controls. By including 
both age and gender in the logistic regression analyses, we corrected the calculated odds 
ratios for differences in these factors. This is necessary because the younger control subjects, 
in comparison to the CRC patients, have a shorter time of exposure to carcinogens and, thus, 
at the moment they reach the age of the CRC patients, some of them may also have developed 
CRC. It would be preferable to better match control and patient populations, but in practice 
this appeared very difficult to realize. In this study, no information was available on the 
dietary habits, alcohol use and smoking patterns of both patients and controls, which may also 
be confounding factors. Possibly some of the low-penetrance genes investigated here only 
contribute to CRC in combination with (some of) these dietary or lifestyle factors. 
In conclusion, no association was found between polymorphic variations in NAD(P)H oxidase 
p22phox and PON1 genes and the risk for sporadic CRC.  
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Each day the colon is exposed to a large variety of ingested toxic or carcinogenic compounds. 
Metabolism of these compounds often requires modification by detoxification enzymes before 
they can be excreted from the body. Genetic polymorphisms in detoxification enzymes may 
result in altered enzyme activities, which may have consequences for detoxification (1). Apart 
from the diet, variations in enzyme activities might influence the levels of toxic or 
carcinogenic compounds in the colon. Therefore, genetic polymorphisms in detoxification 
enzymes could contribute to individual susceptibility to colorectal cancer (CRC).  
 
Recently, we evaluated the effects of genetic polymorphisms in different families of 
detoxification enzymes. We found that the risk for sporadic CRC may be modulated by UDP-
glucuronosyltransferase 1A6 (UGT1A6), UGT1A7 or NAD(P)H:quinone oxidoreductase 1 
(NQO1) polymorphisms. No associations were found for genetic polymorphisms in UGT1A1, 
UGT1A8, glutathione S-transferases (GSTA1, GSTM1, GSTP1, GSTT1), microsomal epoxide 
hydrolase (exon 3 or exon 4 of EPHX1), NAD(P)H oxidase p22phox, paraoxonase 1 (codon 55 
or 192 of PON1), alcohol dehydrogenase (ADH3) and cytochrome P450 2E1 (5’-flanking 
region or intron 6 of CYP2E1; refs. 2-4).  
 
Two meta-analyses (5, 6) summarized the inconsistent results that have been reported by 
previous case-control studies on genetic polymorphisms in detoxification enzymes and 
sporadic CRC susceptibility. For example, most studies investigating the relationship between 
the GSTM1 polymorphism and CRC found no association, however two studies revealed a 
strong statistically significant association between the GSTM1 null genotype and CRC risk.   
A possible reason for this inconsistency is that a single polymorphism may only have a weak 
effect, while CRC susceptibility may be strongly associated with a combination of 
polymorphisms at multiple gene loci. In our earlier studies we investigated the effect of a 
single polymorphism (2-4). We now studied whether the simultaneous occurrence of different 
genetic polymorphisms in the detoxification enzymes as mentioned above, might alter the risk 
for sporadic CRC. Therefore, we assessed whether combinations of polymorphisms in 
detoxification enzymes could be found more often in patients with sporadic CRC than in 
healthy controls. Individuals were classified according to the number of variant high-risk 
genotypes as follows: 0, reference group with no high-risk genotypes; 1, individuals with one 
of the high-risk genotypes; 2, individuals with two of the high-risk genotypes; etcetera. Age 
and gender adjusted odds ratios (OR) with 95% confidence intervals (CI) were estimated by 
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logistic regression analysis. All statistical analyses were performed with SPSS (version 12.0; 
SPSS Inc., Chicago, USA).  
 
So far, just a few studies have evaluated combinations of genetic polymorphisms in 
detoxification enzymes for a possible association with sporadic CRC. These studies only 
report on the combination 2 or 3 genetic polymorphisms. In a study by Kiss et al. (7), 
combined analysis of CYP1A1, CYP2E1 (5’-flanking region) and GSTM1 polymorphisms 
showed that individuals carrying all the three high-risk alleles have an increased risk for 
sporadic CRC (OR = 4.6, 1.2-25.7). In the present study, evaluation of the combination of 
CYP2E1 (5’-flanking region) and GSTM1 polymorphisms did not reveal an association 
between high-risk genotypes and sporadic CRC (see Table I). We also tested different 
combinations of polymorphisms in GST-isoenzymes (see Table I). No significant associations 
were found for any of the GST-combinations, which confirmed the results from previous 
studies on GSTM1/GSTP1- (8, 9), GSTM1/GSTT1- (9-12) and GSTP1/GSTT1-combinations 
in Caucasian CRC patients and control subjects (9). 
 
Table I. Combinations of genetic polymorphisms in detoxification enzymes that have been studied previously among 
sporadic CRC patients and controls: results of our recent study  
Number of polymorphisms Controls Sporadic CRC Adjusted OR 95% CI 
No. of CYP2E1 5’-flanking region and GSTM1 variants (ref. 7) 
0 
1 
2 
 
202/412 
195 
15 
 
167/356 
180 
9 
 
1 
0.86 
0.53 
 
Reference 
(0.57-1.3) 
(0.17-1.6) 
No. of GSTM1 and GSTP1 variants (refs. 8, 9) 
0 
1 
2 
 
90/414 
205 
119 
 
79/368 
182 
107 
 
1 
1.0 
0.89 
 
Reference 
(0.61-1.8) 
(0.67-1.2) 
No. of GSTM1 and GSTT1 variants (refs. 9-12) 
0 
1 
2 
 
179/415 
200 
36 
 
150/370 
184 
36 
 
1 
1.1 
0.79 
 
Reference 
(0.70-1.6) 
(0.55-1.1) 
No. of GSTP1 and GSTT1 variants (ref. 9) 
0 
1 
2 
 
148/414 
223 
43 
 
123/369 
206 
40 
 
1 
1.2 
0.85 
 
Reference 
(0.81-1.9) 
(0.60-1.2) 
 
Next, we considered the polymorphisms in the genes of detoxification enzymes that catalyze 
the same type of metabolic reaction to evaluate the combined effects. CYP2E1 and ADH3 
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both catalyze the oxidation of ethanol. The combination of genetic polymorphisms in these 
enzymes revealed that with an increasing number of variant genotypes the risk for sporadic 
CRC also increased in comparison with individuals that carry no variant genotypes (see Table 
II). After evaluation of combinations of EPHX1 and PON1 polymorphisms, enzymes that 
both catalyze hydrolysis reactions, no significant associations between variant genotypes and 
the CRC risk were observed (see Table II).  
 
Table II. Combination of genetic polymorphisms in phase I detoxification enzymes among sporadic CRC patients and controls 
Number of polymorphisms Controls Sporadic CRC Adjusted OR 95% CI 
No. of CYP2E1 5’-flanking region or intron 6 and AHD3 variants 
0 
1 
2 
3 
 
216/383 
151 
13 
3 
 
168/319 
129 
18 
4 
 
1 
1.3 
2.7 
- 
 
Reference 
(0.86-2.0) 
(0.97-7.4) 
- 
No. of EPHX1 exon 3 or exon 4 and PON1-55 or -192 variants 
0 
1 
2 
3 
4 
 
18/191 
47 
67 
51 
8 
 
13/223 
58 
78 
60 
14 
 
1 
0.97 
0.76 
0.95 
1.1 
 
Reference 
(0.32-2.9) 
(0.26-2.3) 
(0.31-3.0) 
(0.22-5.5) 
-, Not enough data to calculate an odds ratio 
 
Table III shows the combined effects of polymorphisms in genes encoding for different GST-
isoenzymes, which catalyze the conjugation of glutathione to ingested agents. No association 
was found for the number of genetic polymorphisms and CRC risk.  
  
Table III. Combination of genetic polymorphisms in phase II detoxification enzymes among sporadic CRC patients and controls 
Number of polymorphisms Controls Sporadic CRC Adjusted OR 95% CI 
No. of GSTA1, GSTM1, GSTP1 and GSTT1 variants 
0 
1 
2 
3 
4 
 
27/410 
132 
147 
93 
11 
 
28/368 
102 
151 
72 
15 
 
1 
1.3 
1.2 
0.95 
0.93 
 
Reference 
(0.51-3.3) 
(0.76-1.8) 
(0.72-1.3) 
(0.65-1.3) 
No. of UGT1A1, UGT1A6, UGT1A7 and UGT1A8 variants 
0 
1 
2 
3 
4 
 
42/390 
90 
63 
191 
4 
 
27/359 
85 
74 
170 
3 
 
1 
1.9 
1.9 
2.6 
- 
 
Reference 
(0.93-4.0) 
(0.90-4.1) 
(1.3-5.5) 
- 
-, Not enough data to calculate an odds ratio 
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UGTs catalyze the conjugation of glucuronic acid to ingested compounds. We found that the 
risk for CRC increased with the number of variant UGT genotypes. The ORs were 1.9, 1.9 
and 2.6 in individuals with one, two or three variant genotypes, respectively (see Table III). 
However, note that only individuals carrying three variant genotypes have a statistically 
higher risk for CRC. 
From our recent studies (2-4), in which we investigated single polymorphisms, we concluded 
that UGT1A6, UGT1A7 or NQO1 polymorphisms might modulate the risk for sporadic CRC. 
Now, we also examined the combination of these three polymorphisms (see Table IV). 
Individuals carrying all three variant genotypes had a statistically increased risk for CRC (OR 
3.0, 1.3-6.8) compared with the reference group (no variant genotypes).  
 
Table IV. Combination of genetic polymorphisms in detoxification enzymes among patients with sporadic  
CRC and controls 
Number of polymorphisms Controls Sporadic CRC Adjusted OR 95% CI 
No. of UGT1A6, UGT1A7 and NQO1 variants 
0 
1 
2 
3 
 
29/403 
104 
203 
67 
 
27/359 
74 
164 
94 
 
1 
1.1 
1.7 
3.0 
 
Reference 
(0.51-2.3) 
(0.78-3.6) 
(1.3-6.8) 
Combination of all polymorphisms investigated;  
genetic polymorphisms that contribute the most to CRC risk 
NQO1 
UGT1A7 
CYP2E1 intron 6 
   
 
1.5 
2.1 
3.2 
 
 
(0.95-2.5) 
(0.96-4.6) 
(1.3-7.9) 
-, Not enough data to calculate an odds ratio 
 
Finally, all investigated genetic polymorphisms as well as age and gender, were 
simultanenously entered in a backward conditional logistic regression analysis, to determine 
which polymorphisms contribute most to CRC risk. The NQO1, UGT1A7 and CYP2E1 
(intron 6) polymorphisms appeared in the last step model, corresponding odds ratios are 
presented in Table IV. 
 
These data indicate that these polymorphisms contributed the most to sporadic CRC risk. In 
contrast with the results obtained from our recent study (2), in which we investigated single 
polymorphisms, the UGT1A6 polymorphism does not seem to modulate the risk for sporadic 
CRC, whereas the contribution of the CYP2E1 (intron 6) polymorphism was highly 
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significant now. Earlier (3), the CYP2E1 (intron 6) polymorphism did not show an association 
with overall sporadic CRC (adjusted OR 1.8, 0.88-3.8), however it showed a statistically 
significant association with Dukes C/D stages of CRC (adjusted OR 2.2, 1.01-5.0). 
 
Some limitations have to be considered in this study, including false positive results arising 
from multiple comparisons and the great difference in mean age of the CRC patients and 
controls.  
 
Table V. Genetic polymorphisms in detoxification enzymes and sporadic CRC risk; whole study versus  
age- and gender-matched group 
 Controls / CRC patients Age and gender matched controls and CRC patients 
Number of subjects 415 / 371 140 / 140 
Mean age (years) 42 / 64 55 / 55 
Gender (%) Male: 40.5 / 57 48 / 48 
 Female: 59.5 / 43 52 / 52 
Gene Adjusted OR (95%CI)  
for age and gender 
OR (95%CI) 
for age and gender matched controls and patients 
UGT1A1 1.2 (0.83-1.8) 1.5 (0.91-2.4) 
UGT1A6 1.5 (1.03-2.3) a 1.6 (1.01-2.6) a 
UGT1A7 2.4 (1.3-4.6) a 2.5 (1.2-5.2) a 
UGT1A8 0.69 (0.30-1.6) 0.47 (0.14-1.6) 
GSTA1 0.80 (0.54-1.2) 0.67 (0.41-1.1) 
GSTM1 0.81 (0.54-1.2) 0.66 (0.41-1.1) 
GSTP1 0.93 (0.62-1.4) 0.95 (0.59-1.5) 
GSTT1 1.0 (0.64-1.7) 0.73 (0.40-1.3) 
EPHX1 codon 113 1.0 (0.70-1.5) 0.86 (0.53-1.4) 
EPHX1 codon 139 0.99 (0.66-1.5) 1.0 (0.64-1.7) 
NQO1 1.6 (1.03-2.4) a 1.6 (0.97-2.7) 
CYP2E1 5’-flanking region 1.1 (0.48-2.4) 1.4 (0.56-3.7) 
CYP2E1 intron 6 1.8 (0.88-3.8) 1.8 (0.80-4.4) 
ADH3  0.83 (0.54-1.3) 0.77 (0.46-1.3) 
p22phox 1.2 (0.80-1.8) 1.2 (0.73-1.9) 
PON1 codon 55 1.1 (0.73-1.6) 1.1 (0.67-1.8) 
PON1 codon 192 1.1 (0.76-1.7) 0.99 (0.58-1.7) 
a Statistically significant. 
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By including age in the logistic regression analyses we corrected the calculated odds ratios for 
this factor. This is necessary because the younger control subjects, in comparison to the CRC 
patients, have a shorter time of exposure to carcinogens and thus at the moment they reach the 
age of the CRC patients, some of them may also have developed CRC. However, we also 
compared the genotype distributions of the investigated polymorphism in 140 age- and 
gender-matched case-control pairs, which were selected from the whole study group. Highly 
similar odds ratios with 95% CI were found between these two study groups (see Table V). 
 
In conclusion, these findings suggest that UGT1A6, UGT1A7, NQO1 and CYP2E1 (intron 6) 
polymorphisms, which are associated with altered detoxification capacity, may modulate the 
susceptibility of sporadic CRC. In future, studies should be performed that examine the exact 
role of the enzymes involved (UGT1A6, UGT1A7, NQO1 and CYP2E1) and try to define the 
substrates of these enzymes, which are contributing to development of CRC. In this way the 
mechanism of colorectal carcinogenesis could be unravelled. In addition, studies on 
enhancement of the disturbed enzyme activity of the above enzymes could lead to reduction 
of the CRC cases.   
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Abstract 
 
It is hypothesized that excessive generation of reactive oxygen species (ROS) by phagocytes 
or leakage from mitochondria may harm key genes or proteins responsible for intestinal cell 
homeostasis. This may initiate the multistage process of colon cancer development. The 
present study investigates whether ROS production by whole blood may contribute to the 
aetiology of colorectal cancer (CRC). Whole blood oxygen radical production was measured 
by luminol-enhanced chemiluminescence and performed in fourfold with and without the 
stimuli phorbol 12-myristate 13-acetate (PMA) and serum-treated zymosan (STZ). We 
evaluated patients (i) with a history of sporadic CRC at least 3 month after surgery, (ii) who 
are hereditary non-polyposis colorectal cancer (HNPCC) gene carriers and (iii) with familial 
adenomatous polyposis (FAP). For each patient group (n = 20) an age- and gender-matched 
healthy control group was measured. Unstimulated and PMA-stimulated values for maximal 
oxygen radical production were significantly higher in patients with sporadic CRC in 
comparison to controls (P = 0.01 and P = 0.04, respectively). Furthermore, trends toward 
higher unstimulated and PMA-stimulated area under the curve chemiluminescence were seen 
in CRC patients compared with controls (P = 0.08 and P = 0.09, respectively). In patients 
with HNPCC or FAP, unstimulated, PMA- or STZ-stimulated chemiluminescence did not 
differ as compared to their control groups. In conclusion, whole blood oxygen radical 
production was higher in patients with a history of sporadic CRC, in comparison with age- 
and gender-matched controls, which indicates that ROS may play a role in the aetiology of 
sporadic CRC.  
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Introduction 
 
Cancer development is a multistage process. The cascade of molecular and cellular changes 
that occurs during the process of carcinogenesis can be mediated by a variety of endogenous 
and environmental factors (1, 2). It is suggested that reactive oxygen species (ROS) may play 
a role in human cancer development (1, 3, 4). Sources of ROS may be both exogenous (drugs, 
ozone, radiation) and endogenous (NO, phagocytes, leakage from mitochondria; ref. 1). In a 
recent review, Klaunig and Kamendulis (1) described the involvement of ROS in the various 
stages (initiation, promotion, progression) of the process of carcinogenesis. 
 
In healthy individuals, the generation of ROS seems to be counterbalanced by the antioxidant 
defence, which is recruited either from endogenous sources (glutathione, cysteine, uric acid, 
bilirubin, etc.) or from the diet (vitamins A, C and E; refs. 5, 6). An imbalance between ROS 
and antioxidant defences in favour of the former creates oxidative stress (6, 7). This may 
occur when the antioxidant levels are low/depleted and when the formation of ROS is high. 
Severe oxidative stress may affect a variety of metabolic processes. For example, ROS can 
cause structural alteration in DNA and may affect cytoplasmic and nuclear signal transduction 
pathways (4). Furthermore, ROS can modulate the activity of the proteins that respond to 
stress and which regulate genes that are involved in cell proliferation, differentiation, and 
apoptosis (4).  
 
Although it is clear that ROS may induce cellular changes similar to those produced by 
known carcinogens (4), the precise mechanisms remain unclear. For instance it is suggested 
that overproduction of ROS, such as superoxide and hydrogen peroxide, by 
polymorphonuclear leukocytes might sometimes initiate carcinogenesis (8). Phagocytosis by 
polymorphonuclear leukocytes results in the release of ROS, referred to as the respiratory 
burst, which plays an important role in host defence against certain micro-organisms. 
Excessive generation of ROS by these phagocytes may cause harm to surrounding tissue (8). 
When key genes or proteins responsible for intestinal cell homeostasis are targeted, dysplasia 
and subsequent development of adenoma or carcinoma may occur.  
 
Data on a role for ROS in the pathogenesis of colorectal cancer (CRC) are accumulating. 
Recently, Schmielau and Finn (9) reported that patients with advanced cancer of the colon, 
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pancreas, or breast showed signs of extensive granulocyte activation with release of ROS. In 
addition, these patients had elevated plasma levels of isoprostane, a product of lipid oxidation 
and a marker for oxidative stress. In addition, Gackowski et al. (10) observed that the levels 
of 8-oxo-2’-deoxyguanosine, a typical product of ROS-induced DNA base modification, were 
significantly higher in lymphocytes of patients with CRC in comparison to control subjects. 
Furthermore, they also found lower antioxidant plasma levels in patients with CRC in this 
study. They hypothesized that severe oxidative stress resulting in the production of ROS is 
responsible for this consumption of the antioxidant vitamins, creating a pro-oxidant 
environment in the blood of CRC patients. However, it is also possible that this pro-oxidant 
environment is characteristic for advanced stages of colon cancer and that oxidative stress is a 
result of the disease itself. Oldenburg et al. (11) demonstrated that whole blood ROS 
production was significantly higher in patients with inflammatory bowel disease compared to 
healthy volunteers. Additionally, inflammatory bowel disease has been associated with 
increased risk for colon cancer (12, 13). Furthermore, Keshavarzian et al. (14) found that 
normal-appearing rectal mucosa of patients with a history of CRC was able to produce higher 
levels of luminol-enhanced chemiluminescence than corresponding mucosa of control 
subjects.  
 
 
Aim 
The aim of this study was to investigate whether ROS production by whole blood plays a role 
in the aetiology of CRC. Oxygen radical production can be measured by means of the 
luminol-enhanced chemiluminescence technique and can be performed on isolated 
neutrophils as well as in whole blood, the latter due to the high sensitivity of this technique 
(15-17). We measured oxygen radical production using luminol-enhanced chemiluminescence 
with or without the stimuli phorbol 12-myristate 13-acetate (PMA) and serum treated 
zymosan (STZ), in whole blood from patients with a history of sporadic CRC or at risk for 
CRC (hereditary non-polyposis colorectal cancer (HNPCC) gene carriers or familial 
adenomatous polyposis (FAP)) and healthy control subjects. 
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Materials and methods 
 
Patients and control subjects 
Patients with a history of sporadic CRC (n = 20), gene carriers for HNPCC (n = 20), and 
patients with FAP (n = 20) were recruited at the Departments of Gastroenterology and 
General Surgery, University Medical Centre, Nijmegen, The Netherlands, from July 2003 
until July 2004. In the patients with a history of sporadic CRC (n = 20) tumours were located 
in the cecum (n = 7), in the descending colon (n = 3), in the sigmoid (n = 4), in the 
rectosigmoid junction (n = 1), or in the rectum (n = 5). Cancer diagnosis was confirmed after 
histopathological investigation by a pathologist, and cases were classified according to 
Dukes’ stages (A = 1, B = 11, C = 7, D = 1). These patients underwent surgery at least 3 
months before blood sampling, and patients did not receive any adjuvant chemotherapy at the 
time of blood sampling. None of the CRC patients has had a previous tumour elsewhere. 
HNPCC patients were classified according to the Amsterdam Criteria (18). All HNPCC 
patients were mismatch repair gene mutation carriers (10 MLH-1, 8 MSH-2, 2 MSH-6). FAP 
patients were diagnosed as having more than 100 colorectal adenomatous polyps and 
belonged to typical FAP families or were gene carriers. Healthy volunteers, who served as 
controls, were recruited from the Nijmegen area, by advertisement in a local paper. Controls 
had to be at least 18 years of age and were excluded when they had a (family) history of CRC. 
Patients and controls were matched for age and gender in order of inclusion in the study. All 
subjects were Caucasians of Dutch origin. Data on smoking habits and alcohol consumption 
for patients and controls were obtained from the medical files and a questionnaire, 
respectively. It is known that antioxidants may influence ROS levels. Unfortunately, no 
information on the use of antioxidants could be obtained from the medical file of most of the 
patients and therefore we were not able to account for this factor. The local medical ethical 
review committee approved the study and all subjects gave their written informed consent. 
 
Materials 
Reagents were from Sigma Chemicals (St Louis, MO), unless stated otherwise. Stock 
solutions of PMA (0.1 mg/ml DMSO) and ammonium persulfate (APS; 10% in phosphate-
buffered saline (PBS)) were stored at -20ºC until use. STZ (10 mg/ml 0.9% NaCl) was 
prepared as described (19) and stored at -80ºC until use. Hank’s balanced salt solution 
(HBSS) was from Life Technologies Ltd. (Paisley, Scotland). PBS (pH 7.4) contained Na+ 
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163.9 mmol/l, Cl- 140.3 mmol/l, HPO42- 10.9 mmol/l, and H2PO4- 1.8 mmol/l. A stock 
solution of luminol (10 mmol/l in DMSO) was kept in the dark at room temperature.  
 
Procedures and assays 
Whole blood was obtained from each subject by venapuncture in sterile vacutainer tubes 
anticoagulated with lithium-heparin (chemiluminescence) or EDTA (leukocyte count and 
differentiation). Within 1 h after blood sample collection an ex vivo whole blood 
chemiluminescence assay was performed in 96-wells plates at 37ºC using an automated 
LB96V Microlumat Plus Luminometer (EG&G Berthold, Vilvoorde, Belgium). Briefly, 
heparin blood was diluted 1:100 in HBSS and 200 µl of this diluted blood was added to each 
well. Luminol-enhanced chemiluminescence was measured with or without the stimuli PMA 
(receptor-independent) or STZ (receptor-dependent). Twenty microlitres of PMA (0.5 µg/ml 
final) or STZ (1 mg/ml final) was added to each well. As internal standard 0.1% APS in PBS 
(stock 1:100 diluted) was run simultaneously. Each measurement was performed in fourfold. 
To each well, containing either whole blood or APS, 20 µl of 1 mmol/l luminol (stock 1:10 
diluted in HBSS supplemented with 0.5% (w/v) bovine serum albumin) was added. 
Chemiluminescence was monitored every 145 s for 1 h and maximal oxygen radical 
production (relative light units (RLU)/s) and area under the curve (AUC) in this period (RLU) 
were calculated. Data were analyzed with Winglow (EG&G Berthold) software. Afterwards, 
these data were corrected for the unstimulated chemoluminescence and values were expressed 
as RLU per neutrophil.  
 
 
Statistical analyses  
Differences between characteristics of patients and controls were analyzed with the Wilcoxon 
rank-sum test or χ2 test. A P-value below 0.05 was considered significant. The Wilcoxon 
rank-sum test was used to assess statistical significance of differences between control and 
treatment groups. In addition, Kruskal-Wallis ANOVA was performed to assess statistical 
significance in chemiluminescence values between the three control groups. Values are given 
as median and range unless stated otherwise. All statistical analyses were performed using 
SPSS (version 12.0; SPSS Inc., Chicago, USA). 
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Results 
 
Characteristics of the three study and control groups are given in Table I. Age, gender, and 
leukocyte and neutrophil counts did not differ significantly between each patient and 
corresponding control group.  
 
Table I. Characteristics of patients and controls 
Characteristic Group Sporadic CRC  HNPCC gene-carrier  FAP  
  Controls  Cases a Controls Cases a Controls Cases a 
Age [years]             
(range) 
 55 
(46-71) 
61  
(46-76) 
43 
(26-56) 
42 
(27-55) 
44 
(21-64) 
42 
(19-64) 
Gender (%) Female 9 (45) 8 (40) 11 (55) 12 (60) 8 (40) 8 (40) 
 Male 11 (55) 12 (60) 9 (45) 8 (40) 12 (60) 12 (60) 
Smoking (%) No 7 (35) 8 (40) 9 (45) 5 (25) 10 (50) 4 (20) 
 Yes 5 (25) 4 (20) 5 (25) 2 (10) 7 (35) 4 (20) 
 Stopped 8 (40) 3 (15) 6 (30) - 3 (15) 1 (5) 
 Unknown - 5 (25) - 13 (65) - 11 (55) 
Alcohol (%) No 11 (55) 5 (25) 7 (35) 5 (25) 8 (40) 3 (15) 
 Yes b 9 (45) 8 (40) 13 (65) - 12 (60) 5 (25) 
 Stopped - 2 (10) - 1 (5) - - 
 Unknown - 5 (25) - 14 (70) - 12 (60) 
Leukocyte count [*109/l]  
(range) 
 6.7 
(5.1-8.9) 
6.1 
(4.0-10.0) 
5.9  
(4.0-9.6) 
6.3  
(3.3-10.0) 
7.0  
(4.0-10.0) 
6.3  
(3.1-11.0) 
Neutrophil count [*109/l]  
(range) 
 4.1  
(3.0-6.2) 
4.0 
(2.0-7.3) 
3.6  
(2.0-5.8) 
4.0 
(1.7-7.7) 
4.4  
(2.0-7.0) 
4.2 
(1.9-8.5) 
a In all patient groups there were missing data on smoking and/or alcohol consumption, because lack of information on these 
lifestyle habits in the medical files. 
b Alcohol consumption less than 60 g (females) or 80 g (males) of ethanol per day. 
 
Data on whole blood oxygen radical production are summarized in Table II. Unstimulated and 
PMA-stimulated values for maximal oxygen radical production were significantly higher in 
patients with sporadic CRC in comparison to controls (P = 0.01 and P = 0.04, respectively). 
Furthermore, trends toward higher unstimulated and PMA-stimulated AUC 
chemiluminescence were seen in the CRC patient group compared with the control group     
(P = 0.08 and P = 0.09, respectively). After stimulation with STZ no differences in either 
maximal or AUC chemiluminescence were observed in sporadic CRC patients compared to 
control subjects.  
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Table II. Whole blood oxygen radical production in patients with a history of/at risk for CRC and controls  
Chemiluminescence Stimulus Sporadic CRC HNPCC gene-carrier FAP 
  Controls  Cases Controls Cases Controls Cases 
Maximal - 60  
(25-100) 
75 b 
(33-180) 
60  
(25-105) 
70 
(28-155) 
60  
(29-105) 
65  
(35-150) 
 PMA a 75  
(3-180) 
115 c 
(20-195) 
100 
(25-475) 
90 
(26-195) 
70 
(2-475) 
85  
(47-195) 
 STZ a 225  
(34-440) 
235 
(70-420) 
240 
(55-415) 
265 
(155-330) 
220 
(38-440) 
235 
(155-446) 
AUC - 160 
(70-270) 
195 d 
(100-350) 
180  
(70-310) 
185 
(75-375) 
170 
(85-290) 
165  
(80-365) 
 PMA a 145  
(10-435) 
185 e 
(45-290) 
155 
(40-435) 
190 
(105-305) 
160 
(5-325) 
155 
(100-295) 
 STZ a 555  
(70-1065) 
605  
(185-1070) 
545 
(105-980) 
645 
(430-890) 
535 
(80-1065) 
600 
(395-940) 
Data were measured in fourfold and are given as median (range) in *10-6 RLU/s/neutrophil or *10-3 RLU/neutrophil  
for maximal and AUC values, respectively. 
a Data were corrected for unstimulated measurements. Controls versus patients with a history of CRC: b P = 0.01,  
c P = 0.04, d P = 0.08, e P = 0.09. 
 
Unstimulated, PMA-stimulated or STZ-stimulated maximal and AUC chemiluminescence did 
not differ between HNPCC gene carriers or FAP patient groups and their corresponding 
control groups. In addition, Kruskal-Wallis analyses revealed no statistically significant 
differences between the chemiluminescence values (unstimulated, PMA and STZ) of the three 
control groups (maximal, P = 0.60, 0.62 and 0.98, respectively; AUC, P = 0.38, 0.84 and 1.0, 
respectively). Chemiluminescence parameters showed no significant differences between 
females and males in each patient and control group. Within-run coefficients of variation for 
the internal standard (APS) were 3.3% for maximal and 1.8% for AUC chemiluminescence. 
Day-to-day coefficients of variations for the APS internal standard were 13.5% for maximal 
and 8.5% for AUC chemiluminescence.  
 
 
Discussion 
 
Evidence for a role of ROS in the pathogenesis of CRC is accumulating (9-11, 13, 14). The 
aim of this study was to investigate whether oxygen radical production by peripheral whole 
blood may contribute to the aetiology of CRC. By measuring luminol-enhanced 
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chemiluminescence in whole blood of healthy controls and patients with a history of CRC, 
HNPCC gene carriers, or patients with FAP, whole blood oxygen radical production could be 
calculated. Both unstimulated and PMA-stimulated oxygen radical production was higher in 
patients with a history of CRC, whereas no differences were observed between patients at risk 
for CRC due to hereditary syndromes like HNPCC and FAP, compared to age- and gender-
matched healthy control subjects. These data correspond with the results reported by 
Keshavarzian et al. (14), who found that normal-appearing rectal mucosa of patients with a 
history of CRC was able to produce higher levels of luminol-enhanced chemiluminescence 
than corresponding mucosa of healthy control subjects. This finding is more or less similar to 
our observation that whole blood unstimulated chemiluminescence values were higher in 
patients with a history of CRC compared to healthy controls. The colon is an organ with an 
intensive blood supply and therefore ROS produced by mucosal biopsies may originate partly 
from the neutrophils present in the blood vessels. However, Perner et al. (20) observed that 
primary colonic epithelial cells, isolated from mucosal biopsies, produced superoxide. 
Furthermore, they found that mRNA coding for the catalytic subunits of NAD(P)H oxidase, 
Nox1 and p22phox, was detected in these cells. This finding was confirmed by Geiszt et al., 
who observed high Nox1 expression in the entire colon and rectum (21). They also showed 
that Nox1 interacts with phagocytic oxidase components, such as p22phox, p47phox, or p67phox, 
and observed a significant dependence on PMA stimulation for superoxide production (21). 
This raises the possibility of a functional homology between the phagocytic and intestinal 
oxidase enzymes (22). Phagocytic NAD(P)H oxidase (gp91phox) plays an important role in the 
host defence against a broad range of micro-organisms by production of ROS, whereas 
intestinal NAD(P)H oxidase (Nox1) may provide an oxidative host defence barrier against 
intestinal pathogens in particular. 
 
Phagocyte activation is necessary to elicit its effector functions and can be induced by several 
agents in a distinctive manner. The phorbol ester PMA and STZ, i.e. yeast particles opsonized 
with both IgG and C3 complement fragments, are the most frequently used agents in studies 
assessing neutrophil functions. PMA crosses the cellular membrane and binds directly to and 
activates protein kinase C (receptor-independent). This results in phosphorylation and 
translocation of the cytosolic NAD(P)H oxidase components, which in turn mediates the 
reduction of oxygen to form several ROS (23, 24). STZ comprises a particulate stimulus that 
binds to membrane complement receptors or Fcγ receptors on neutrophils. After binding to 
these receptors, the STZ particles are ingested and concomitantly this leads to respiratory 
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burst and degranulation (25). The present study showed a higher PMA-stimulated oxygen 
radical production in patients with a history of sporadic CRC, compared to healthy controls. 
This suggests that the receptor-independent activation of neutrophils differs between these 
groups. In patients with a history of CRC, PMA homologous stimuli may provoke a reaction 
that results in a higher production of ROS; eventually this may be harmful to the surrounding 
tissue and may have contributed to the development of CRC.  
 
Next, the question may arise as to why patients eventually do develop colon cancer as a result 
of overproduction of ROS and not all other kinds of cancer. This could be explained by the 
characteristics of the colonic mucosa, being a highly proliferative tissue with a high load of 
toxic or carcinogenic compounds and low levels of protecting enzymes (26, 27).   
 
Wyche et al. (28) reported that a functional polymorphism in codon 72 of the gene encoding 
for the NAD(P)H subunit p22phox results in a 30% reduction in respiratory burst after PMA 
stimulation, suggesting decreased activity of the NAD(P)H oxidase. These variations in 
NAD(P)H oxidase p22phox genotypes eventually could lead to different amounts of ROS in the 
colonic mucosa, which actually may influence the risk for CRC. However, in a case-control 
study performed by us, genotyping of this p22phox codon 72 polymorphism in 365 sporadic 
CRC cases and 354 healthy controls revealed no association between this polymorphism and 
risk for CRC (29). 
 
In patients with HNPCC or FAP, unstimulated, PMA-stimulated or STZ-stimulated 
chemiluminescence did not differ as compared to the corresponding control groups, whereas 
unstimulated or PMA-stimulated values were significantly higher in sporadic CRC patients in 
comparison to their controls. This difference between patients with HNPCC or FAP versus 
patients with sporadic CRC could be explained by the fact that a genetic factor of high 
penetrance is responsible in HNPCC or FAP, whereas such a driving factor is missing in 
sporadic CRC patients. However, in the latter group, ROS could be a factor of importance in 
the process of carcinogenesis, as revealed by our findings. In contrast to the sporadic CRC 
group, HNPCC or FAP patients did not have had a resection for a tumour in the colon, and it 
would be worthwhile to also investigate the ROS production in patients with HNPCC or FAP 
after development of a colon tumour; however such patients are not available to us at this 
moment. 
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In our three patient groups there were some missing data on smoking and/or alcohol 
consumption, because no information on these lifestyle habits was reported in the medical 
files. Therefore, and also because of the small groups tested, no estimation could be made of 
the influence of these smoking and drinking habits on the oxygen radical production. 
Kopprasch et al. (16) reported that smoking of 10 or more cigarettes per day had no effect on 
phagocyte oxygen radical production. In addition, Lafuente et al. (15) found no difference in 
basal chemiluminescence values between smokers and non-smokers; however, healthy 
smokers showed a significantly higher PMA-stimulated chemiluminescence when compared 
with non-smokers. Furthermore, the use of antioxidants could contribute to the differences 
between the groups. Unfortunately, however, we do not have information on the use of 
antioxidants. It seems not very likely, however, that individuals in one study group (sporadic 
CRC) are far more deficient in antioxidants as compared to the individuals in the other study 
groups. 
 
Luminol-enhanced chemiluminescence is an accepted and reliable means of estimating 
oxygen radical production, and its measurement can be performed in isolated neutrophils as 
well as in whole blood (15-17). Kopprasch et al. (16) compared both methods and enumerated 
their advantages and disadvantages. In short, the time required to separate neutrophils, the risk 
of cell priming during the separation procedure, and the relatively large amounts of blood 
needed are considered major limitations of chemiluminescence measurements with isolated 
neutrophils. The whole blood assay has the advantage of avoiding neutrophil pro-activation 
during the purification process. Furthermore, measurement in whole blood allows monitoring 
of cellular responses in an environment more closely resembling the in vivo situation than 
analysis of isolated neutrophils. On the other hand, the whole blood chemiluminescence assay 
is flawed due to light quenching by erythrocytes or plasma proteins (decreased sensitivity), 
whereas production of ROS by other cells than neutrophils, like monocytes and platelets, may 
occur. Egger et al. (30) investigated the changes in neutrophil function in whole blood 
induced by storage time, temperature, and agitation. They recommend that blood samples 
should be processed carefully without mechanical stress, however blood samples can be 
handled at room temperature. These criteria were taken into consideration before performing 
our whole blood chemiluminescence assay.  
In conclusion, whole blood oxygen radical production was higher in patients with a history of 
CRC, in comparison with age- and gender-matched healthy controls, which may indicate a 
role for ROS in the aetiology of sporadic CRC. 
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Colorectal cancer (CRC) is one of the most common forms of cancer in Western societies and 
shows a 20-fold geographic variation in incidence worldwide. In The Netherlands, cancer 
incidence rates in women are highest for breast cancer followed by CRC, whereas in men 
CRC cancer incidence rates are third highest after lung and prostate cancer. The aetiology of 
CRC is complex and involves genetic (high- and low-penetrance) as well as lifestyle factors 
(dietary habits, alcohol use, smoking). It is now generally accepted that a time-dependent 
accumulation of mutations in genes involved in the regulation of cell proliferation and cell 
death (apoptosis) results in the transformation of normal colonic epithelium into 
hyperproliferative tissue, adenoma, and finally eventually in carcinoma. Epidemiological 
studies have revealed that the worldwide variation in CRC incidence is strongly related to 
differences in dietary habits and lifestyle factors. Consumption of a typical Western-style diet, 
which is characterized by high intake of red meat, (saturated) fat and alcohol, and a low intake 
of fresh vegetables, fruits and calcium, is associated with a high risk for CRC. It is assumed 
that the Western-style diet contains more harmful and carcinogenic compounds as compared 
to the diets containing more fruits and vegetables. Humans however, possess a highly 
efficient system of defence against such harmful compounds and detoxification enzymes, 
such as glutathione S-transferases (GSTs) and UDP-glucuronosyltransferases (UGTs), play an 
important role in detoxification. However, when the detoxification capacity of the colon is 
insufficient to deal with the daily load of toxic or carcinogenic compounds, this may lead to 
DNA mutations and damage of cells and ultimately to the development of CRC. 
 
In Chapter 1 a general introduction is presented and the objectives of the thesis are 
summarized as follows: 1) to investigate the modulation of rat hepatic and intestinal UGTs by 
anticarcinogens, 2) to study whether genetic polymorphisms in detoxification enzymes may 
modulate the risk for CRC, and 3) to elucidate whether neutrophil oxygen radical production 
may contribute to the aetiology of CRC. 
 
In the Chapters 2.1 and 2.2 the effects of potential anticarcinogens on rat hepatic and 
intestinal UGT enzyme activities are described. As a representative of cruciferous vegetables 
we supplemented the standard diet with Brussels sprouts. In addition, the following 
compounds, present in the digestive tract after consumption of cruciferous vegetables        
(e.g. Brussels sprouts and broccoli), were studied: indole-3-carbinol, compound 30                
(a sulforaphane analog), phenethylisothiocyanate (PEITC; all glucosinolate hydrolysis 
products) and oltipraz (a substituted dithiolthione). Furthermore, we studied the following 
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non-nutritive dietary anticarcinogens: ellagic acid, ferulic acid, quercetin, α-angelicalactone, 
tannic acid, coumarin, fumaric acid, curcumin, flavone, D-limonene and the carotenoids       
α-tocopherol and β-carotene (all naturally occurring component of vegetables and fruits). 
Most anticarcinogens studied were shown to enhance UGT enzyme activity at one or more 
sites in the gastrointestinal tract. In the liver, the most striking enhancement of                       
4-methylumbelliferone (MUB) UGT enzyme activity was seen after supplementation of the 
diet with flavone (10.6×), coumarin (6.2×), α-angelicalactone (4.2×) or D-limonene (3.2×).  
Curcumin was the most potent compound in the colon, enhancing 4-MUB UGT enzyme 
activity 3.1-fold, followed by coumarin (2.7×), quercetin and α-angelicalactone (both 2.2×). 
In the small intestine, curcumin showed the largest effect on 4-MUB UGT enzyme activity 
(3.2×, 4.3× and 6.1× in the proximal, mid and distal part, respectively). No statistically 
significant changes in 4-MUB UGT enzyme activities were found with tannic acid,               
α-tocopherol, β-carotene and indole-3-carbinol in all organs investigated. Since humans may 
be exposed to mixtures of anticarcinogens in their diets, it may be worthwhile to study 
combinations of such compounds in laboratory animals in order to learn more on possible 
additional effects. Therefore, we conducted a dose-dependent combination study with           
α-angelicalactone and flavone in rats, as described in Chapter 2.1. UGT enzyme activity was 
increased most in rats that were fed the highest dose of α-angelicalactone, flavone or the 
combination of both compounds. In addition, dietary administration of α-angelicalactone and 
flavone, even at relatively low concentrations, may exert anticarcinogenic effects in the liver 
and to a lesser extent in the small- and large intestine by enhancing UGT detoxification 
activity. Exposure to the combination of both compounds showed additional effects on UGT 
enzyme activity. From these studies it may be concluded that dietary anticarcinogens may 
exert their chemopreventive effects in the gastrointestinal tract of the rat by enhancing UGT 
enzyme activity. Enhancement of UGT enzyme activity might lead to a more efficient 
elimination of carcinogens. The combined effect of dietary anticarcinogens may therefore 
contribute to the prevention of cancer in the gastrointestinal tract. In Chapter 2.2 also another 
class of anticarcinogens was studied; the nonsteroidal anti-inflammatory drugs (NSAIDs). 
NSAIDs have been shown to inhibit the process of carcinogenesis in laboratory animals as 
well as in humans. After supplying NSAIDs to the diet of rats, enhancement of small 
intestinal UGT enzyme activity was mainly observed in the proximal part by ibuprofen and 
indomethacin. In addition, ibuprofen was also able to enhance large intestinal UGT enzyme 
activity. However, none of the NSAIDs had a significant effect on hepatic UGT enzyme 
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activity. The enhancement of UGT activity in the upper part of the gastrointestinal tract, 
resulting in a more efficient detoxification, may directly contribute to the tumor preventing 
properties of NSAIDs in this part of the gastrointestinal tract. However, organs such as the 
colon could also benefit from a more efficient detoxification in the proximal part of the 
gastrointestinal tract, since lower concentrations of carcinogens may reach the colon. 
 
The Chapters 3.1 to 3.4 are focussed on the possible role of genetic polymorphisms in 
detoxification enzymes in the aetiology of sporadic CRC. Therefore, the possible association 
between genetic polymorphisms in detoxification enzymes and predisposition to sporadic 
CRC are studied. UDP-glucuronosyltransferases (UGTs) and glutathione S-transferases 
(GSTs) are important detoxification enzymes (Chapter 3.1). The genetic polymorphisms in 
the different UGT- and GST-isoenzymes (UGT1A1, UGT1A6, UGT1A7, UGT1A8, GSTA1, 
GSTM1, GSTP1, GSTT1) as studied here, may result in lower enzyme activities and 
subsequent less efficient conversion of toxic or carcinogenic compounds. After adjustment for 
age and gender, polymorphic variants in the UGT1A6 and UGT1A7 genes were found 
significantly more often in patients with CRC (n = 371) as compared to healthy controls       
(n = 415), indicating that the presence of these polymorphic variants may contribute to 
development of sporadic CRC. In Chapter 3.2 the contribution of genetic polymorphisms in 
other enzymes that may be involved in detoxification of CRC related carcinogens, being: 
microsomal epoxide hydrolase (EPHX1), NAD(P)H:quinone oxidoreductase (NQO1), 
cytochrome P450 2E1 (CYP2E1) and alcohol dehydrogenase (ADH3) is described. Genetic 
polymorphisms in EPHX1, CYP2E1 and ADH3 occurred equally frequent in patient and 
control groups. Polymorphic NQO1 variants however, were found significantly more often in 
patients with sporadic CRC. The presence of variant NQO1 alleles may result in a reduced or 
complete loss of enzyme activity and consequently to a partly deficient detoxification. 
Therefore, the presence of these polymorphic variants may contribute to the development of 
sporadic CRC. The study in Chapter 3.3 was performed to investigate the possible 
association between genetic polymorphisms in NAD(P)H oxidase p22phox or paraoxonase 1 
(PON1) and sporadic CRC. Similar distributions of the p22phox and PON1 genotypes are 
present in healthy control subjects and patients with sporadic CRC, suggesting that these 
polymorphisms are not associated with sporadic CRC. Based on the results of these studies, 
we conclude that individuals carrying the low enzyme activity associated genotypes of 
UGT1A6, UGT1A7 or NQO1 might be more prone to develop sporadic CRC. Chapter 3.4 
describes the results of combinations of polymorphisms in the genes of detoxification 
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enzymes as studied in the Chapters 3.1 to 3.3. The number of genetic polymorphisms in 
detoxification enzymes may influence the occurrence of sporadic CRC. When considering all 
investigated polymorphisms, the NQO1, UGT1A7 and CYP2E1 (intron 6) polymorphisms 
contributed most to the risk for sporadic CRC. Summarizing, this suggests that impairment in 
detoxification of toxic or carcinogenic compounds as a result of genetic polymorphisms in 
NQO1, UGT1A6, UGT1A7 and CYP2E1 may contribute to the aetiology of sporadic CRC. 
 
Chapter 4 reports on a study on neutrophil oxygen radical production in individuals at risk 
for CRC. Oxygen radical production was measured in whole blood from patients with (i) a 
history of sporadic CRC, (ii) who are hereditary non-polyposis colorectal cancer (HNPCC) 
gene carriers and (iii) with familial adenomatous polyposis (FAP), and also in age- and 
gender-matched controls. Whole blood oxygen radical production was significantly higher in 
patients with a history of sporadic CRC in comparison with the age- and gender-matched 
controls, whereas oxygen radical production did not differ between HNPCC or FAP patients 
and their corresponding control groups. These data indicate that ROS might play a role in the 
aetiology of sporadic CRC.  
 
In summary, we may conclude that anticarcinogens, components of fruit and vegetables, and 
to a lesser extent NSAIDs can induce rat hepatic and intestinal UGT enzyme activities. This 
enhancement in UGT enzyme activity may lead to a more efficient detoxification of toxins 
and carcinogens and subsequently this might inhibit carcinogenesis. It also seems worthwhile 
to study the combined effect of dietary anticarcinogens, since additional or even synergistic 
effects may occur. The significance of the results in animal studies should be verified in 
human intervention studies.  
Furthermore, a possible modulating effect on the risk for sporadic CRC might be due to 
polymorphic variations in detoxification enzymes, in particular NQO1, UGT1A6, UGT1A7 
and CYP2E1 (intron 6), which may result in an activation or impaired deactivation of toxic 
compounds. 
At last, we showed by measuring whole blood oxygen radical production in patients with a 
history or at risk for CRC and age- and gender-matched controls, that oxidative stress might 
be involved in the aetiology of sporadic CRC.  
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Dikke darmkanker is een van de meest voorkomende vormen van kanker in de Westerse 
wereld en wereldwijd is er een 20-voudige geografische variatie in incidentie te zien. In 
Nederland, is de incidentie van kanker bij vrouwen het hoogst voor borstkanker, gevolgd door 
dikke darmkanker, terwijl bij mannen dikke darmkanker het op drie na vaakst voorkomt, na 
long- en prostaatkanker. De etiologie van dikke darmkanker is complex en betreft zowel 
genetische- als leefstijl factoren (voedingsgewoonten, alcohol consumptie, roken). Algemeen 
wordt erkend dat een tijdsafhankelijke opeenhoping van mutaties in genen betrokken bij de 
regulatie van celproliferatie en celdood (apoptose) resulteert in de overgang van normaal 
dikke darmepitheel naar hyper-proliferatief weefsel, adenoom en uiteindelijk carcinoom. 
Epidemiologische studies hebben laten zien dat de wereldwijde variatie in de incidentie van 
dikke darmkanker sterk gerelateerd is aan verschillen in voedingsgewoonten en leefstijl 
factoren. De consumptie van een typisch Westers dieet, dat wordt gekarakteriseerd door een 
hoge inname van rood vlees, (verzadigd) vet en alcohol en een lage inname van verse groeten, 
fruit en calcium, wordt geassocieerd met een hoog risico op dikke darmkanker. Verder wordt 
verondersteld dat het Westers dieet meer schadelijke en kankerverwekkende (carcinogene) 
stoffen bevat in vergelijking met voeding die meer groeten en fruit bevat. Mensen bezitten 
echter een zeer efficiënt afweersysteem tegen zulke schadelijke stoffen en vooral 
ontgiftingsenzymen zoals glutathion S-transferasen (GST) en UDP-glucuronosyltransferasen 
(UGT) spelen een belangrijke rol in de ontgifting. Echter, wanneer de ontgiftingscapaciteit 
van de dikke darm tekortschiet om de dagelijkse belasting van toxische en 
kankerverwekkende stoffen te kunnen opvangen, kan dit leiden tot celschade en uiteindelijk 
tot het ontstaan van dikke darmkanker.  
 
In Hoofdstuk 1 wordt een algemene introductie gegeven en worden de doelen van dit 
proefschrift als volgt samengevat: 1) onderzoek naar de modulering van lever- en darm UGT 
door anticarcinogenen in de rat, 2) bestuderen of genetisch polymorfismen in 
ontgiftingsenzymen het risico op dikke darmkanker kunnen beïnvloeden, en 3) onderzoek 
naar de rol van zuurstof radicaal productie door neutrofielen in de etiologie van dikke 
darmkanker. 
 
In de Hoofdstukken 2.1 en 2.2 worden de effecten van potentiële anticarcinogenen op de 
lever- en darm UGT enzymactiviteit van ratten beschreven. Als modeldieet voor crucifere 
(kruisbloemige) groenten hebben we aan het standaard ratten dieet spruitjes toegevoegd. 
Daarnaast werden de volgende stoffen bestudeerd, die ontstaan in het spijsverteringskanaal na 
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consumptie van crucifere groenten zoals spruitjes, bloemkool, broccoli etc.: indole-3-carbinol, 
compound 30 (een synthetisch analoog van sulforaphaan), phenethylisothiocyanaat (PEITC) 
en oltipraz (een gesubstitueerde dithiolthion). Bovendien bestudeerden we de volgende non-
nutriënten en potentiële anticarcinogenen in voeding: de carotenoïden α-tocopherol (vitamine 
E) en β-caroteen (een voorloper van vitamine A), ellaginezuur, ferulinezuur, quercetine,       
α-angelicalacton, tanninezuur, coumarine, fumaarzuur, curcumine, flavon en D-limoneen 
(allemaal natuurlijk voorkomende componenten uit groenten en fruit). De meeste 
anticarcinogenen lieten op een of meer plaatsen van het maag-darmkanaal een verhoging van 
UGT enzymactiviteit zien. In de lever was de meest opvallende verhoging van                       
4-methylumbelliferon (MUB) UGT enzymactiviteit te zien na toevoeging van flavon (10,6×), 
coumarine (6,2×), α-angelicalacton (4,2×) of D-limoneen (3,2×) aan het dieet. Curcumine was 
de meest potente component in de dikke darm en verhoogde de 4-MUB UGT enzymactiviteit 
3,1 keer, gevolgd door coumarine (2,7×), quercetine en α-angelicalacton (beide 2,2×). In de 
dunne darm liet curcumine het grootste effect op 4-MUB UGT enzymactiviteit zien (3,2×, 
4,3× en 6,1× respectievelijk in het proximale, middelste en distale deel). Er werden geen 
statistisch significante veranderingen gezien in de 4-MUB UGT enzymactiviteit met 
tanninezuur, α-tocopherol, β-caroteen en indole-3-carbinol in alle bestudeerde organen. 
Aangezien mensen aan een mix van anticarcinogenen (aanwezig in hun voeding) kunnen 
worden blootgesteld, is het de moeite waard om de combinatie van zulke stoffen te bestuderen 
in proefdieren, zodat meer inzicht wordt verkregen in mogelijk elkaar versterkende effecten 
van de afzonderlijke componenten. Daarom hebben we een dosis-afhankelijke 
combinatiestudie met α-angelicalacton en flavon uitgevoerd in ratten, zoals beschreven staat 
in Hoofdstuk 2.1.  De UGT enzymactiviteit werd het meest verhoogd in ratten die de hoogste 
dosis α-angelicalacton, flavon of de combinatie van beide stoffen gevoerd kregen. Bovendien 
kon toediening van α-angelicalacton en flavon via de voeding, zelfs bij relatief lage 
concentraties, anticarcinogene effecten teweegbrengen in de lever en in mindere mate in de 
dunne- en dikke darm, door een verhoging van de UGT ontgiftingsactiviteit. Blootstelling aan 
de combinatie van beide stoffen liet additionele effecten zien op de UGT enzymactiviteit. Uit 
deze studies kan geconcludeerd worden dat anticarcinogenen in voeding hun beschermende 
effecten op het maag-darmkanaal van de rat kunnen uitoefenen door verhoging van de UGT 
enzymactiviteit. De verhoging van de UGT enzymactiviteit zou kunnen leiden tot een 
efficiëntere afbraak en uitscheiding van carcinogenen. Het gecombineerde effect van 
anticarcinogenen in voeding kan derhalve bijdragen aan de preventie van kanker van het 
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maag-darmkanaal. In Hoofdstuk 2.2 werd ook een andere klasse van anticarcinogenen 
bestudeerd, de niet-steroïde anti-ontstekingsmiddelen (nonsteroidal anti-inflammatory drugs, 
NSAIDs). NSAIDs hebben laten zien dat ze zowel in proefdieren als mensen het proces van 
kankervorming (carcinogenese) kunnen remmen. Na het toevoegen van NSAIDs aan het dieet 
van ratten werd met name in het proximale deel van de dunne darm een verhoging van de 
UGT enzymactiviteit gezien bij ibuprofen en indomethacine. Bovendien was ibuprofen ook in 
staat om de UGT enzymactiviteit in de dikke darm te verhogen. Echter, geen enkel NSAID 
had een significant effect op de UGT enzymactiviteit in de lever. De verhoging van de UGT 
enzymactiviteit in het bovenste gedeelte van het maag-darmkanaal, resulterend in een 
efficiëntere ontgifting, kan direct bijdragen aan de tumor preventieve eigenschappen van 
NSAIDs in dit deel van het maag-darmkanaal. Echter, organen zoals de dikke darm, zouden 
ook van een efficiëntere ontgifting in het proximale deel van het maag-darmkanaal kunnen 
profiteren, aangezien lagere concentraties aan carcinogenen de dikke darm zouden kunnen 
bereiken.  
 
De Hoofdstukken 3.1 tot en met 3.4 concentreren zich op de mogelijke rol van genetische 
polymorfismen in ontgiftingsenzymen bij het ontstaan van sporadische dikke darmkanker. 
Daarom wordt de mogelijke associatie tussen genetische polymorfismen in 
ontgiftingsenzymen en aanleg voor sporadische dikke darmkanker bestudeerd. UDP-
glucuronosyltransferases (UGTs) en glutathion S-transferases (GSTs) zijn belangrijke 
ontgiftingsenzymen (Hoofdstuk 3.1). De genetische polymorfismen in de verschillende 
UGT- en GST-isoenzymen (UGT1A1, UGT1A6, UGT1A7, UGT1A8, GSTA1, GSTM1, 
GSTP1, GSTT1) zoals hier bestudeerd werden, kunnen resulteren in een lagere 
enzymactiviteit en vervolgens in een minder efficiënte omzetting van toxische of carcinogene 
stoffen. Na correctie voor leeftijd en geslacht, werden polymorfe varianten in de UGT1A6 en 
UGT1A7 genen significant vaker gevonden in patiënten met dikke darmkanker (n = 371) in 
vergelijking met gezonde controles (n = 415), wat er op wijst dat de aanwezigheid van deze 
polymorfe varianten kan bijdragen aan de ontwikkeling van sporadische dikke darmkanker. In 
Hoofdstuk 3.2 wordt de bijdrage van genetische polymorfismen in andere enzymen, die bij 
ontgifting van dikke darmkanker-gerelateerde carcinogenen betrokken kunnen zijn, zoals 
microsomaal epoxide hydrolase (EPHX1), NAD(P)H:quinone oxidoreductase (NQO1), 
cytochroom P450 2E1 (CYP2E1) en alcohol dehydrogenase (ADH3) beschreven. Genetische 
polymorfismen in EPHX1, CYP2E1 en ADH3 kwamen even vaak voor in de patiënten en 
controles. Echter, de polymorfe NQO1 varianten werden significant vaker gevonden in 
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patiënten met sporadische dikke darmkanker. De aanwezigheid van variante NQO1 allelen 
kan resulteren in verlaagde of compleet verlies van enzymactiviteit en dus in een gedeeltelijk 
deficiënte ontgifting en de aanwezigheid van deze polymorfe varianten zou dus kunnen 
bijdragen aan de ontwikkeling van sporadische dikke darmkanker. De studie in Hoofdstuk 
3.3 werd uitgevoerd om de mogelijke associatie tussen genetische polymorfismen in 
NAD(P)H oxidase p22phox of paraoxonase 1 (PON1) en sporadische dikke darmkanker te 
onderzoeken. Vergelijkbare verdelingen van de p22phox en PON1 genotypen waren aanwezig 
in gezonde controle personen en patiënten met sporadische dikke darmkanker, dit suggereert 
dat deze polymorfismen geen rol spelen bij het ontstaan van sporadische dikke darmkanker. 
Gebaseerd op de resultaten van deze studies kunnen we concluderen dat personen, die de met 
lagere enzymactiviteit geassocieerde genotypen van UGT1A6, UGT1A7 of NQO1 dragen 
meer aanleg zouden kunnen hebben voor het ontwikkelen van sporadische dikke darmkanker. 
Hoofdstuk 3.4 beschrijft de resultaten van combinaties van polymorfismen in de genen van 
ontgiftingsenzymen zoals bestudeerd in de Hoofdstukken 3.1 tot en met 3.3. Het aantal 
genetische polymorfismen in ontgiftingsenzymen zou het voorkomen van sporadische dikke 
darmkanker kunnen beïnvloeden. Wanneer we met alle onderzochte polymorfismen rekening 
houden, dragen de NQO1, UGT1A7 en CYP2E1 (intron 6) polymorfismen het meest bij aan 
het risico op sporadische dikke darmkanker. Samenvattend suggereert dit dat de insufficiënte 
ontgifting van toxische of carcinogene stoffen ten gevolge van genetische polymorfismen in 
NQO1, UGT1A6, UGT1A7 en CYP2E1 kan bijdragen aan de etiologie van sporadische dikke 
darmkanker. 
 
Hoofdstuk 4 rapporteert over een studie naar neutrofiel zuurstof radicaal productie in 
personen met een hoger risico op dikke darmkanker. Zuurstof radicaal productie werd 
gemeten in volbloed van patiënten i) met een geschiedenis van sporadische dikke 
darmkanker, ii) die gendrager zijn van het erfelijk non-polyposis colorectaal kanker (HNPCC) 
syndroom en iii) met het familiair adenomateuze polyposis syndroom (FAP), en ook in 
corresponderende, voor leeftijd- en geslacht-gematchte controles. De volbloed zuurstof 
radicaal productie was significant hoger in patiënten met een geschiedenis van sporadische 
dikke darmkanker in vergelijking met de voor leeftijd- en geslacht-gematchte controles, 
terwijl de zuurstof radicaal productie niet verschilde tussen HNPCC of FAP patiënten en hun 
overeenkomstige controle groepen. Deze data wijzen er op dat reactieve zuurstof radicalen 
een rol zouden kunnen spelen in de etiologie van sporadische dikke darmkanker. 
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Samenvattend kunnen we concluderen dat anticarcinogenen, componenten uit groenten en 
fruit en in mindere mate NSAIDs, de lever- en darm UGT enzymactiviteit kunnen induceren 
in ratten. Deze verhoging van de UGT enzymactiviteit kan leiden tot een efficiëntere 
ontgifting van toxische en carcinogene stoffen wat vervolgens de carcinogenese zou kunnen 
remmen. Het lijkt ook zinvol om de gecombineerde effecten van anticarcinogenen in voeding 
te bestuderen, aangezien er additionele en zelfs synergistische effecten kunnen optreden. De 
betekenis van de resultaten uit dierstudies zouden echter geverifieerd moeten worden via 
humane interventie studies.  
Een mogelijk modulerend effect op het risico voor het ontstaan van sporadische dikke 
darmkanker zou veroorzaakt kunnen worden door variaties in de genen coderend voor 
ontgiftingsenzymen, in het bijzonder NQO1, UGT1A6, UGT1A7 en CYP2E1 (intron 6), die 
kunnen resulteren in een activatie of verminderde de-activatie van toxische en carcinogene 
verbindingen. 
Tenslotte hebben we laten zien, dat de zuurstof radicaal productie in volbloed van patiënten 
met een geschiedenis van sporadische dikke darmkanker hoger is vergeleken met leeftijd- en 
geslacht-gematchte controles. Dit zou kunnen betekenen dat oxidatieve stress betrokken zou 
kunnen zijn bij de etiologie van sporadische dikke darmkanker. 
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